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Abstract 
 
 
Iron platinum (FePt) has attracted growing interest because of its high Curie 
temperature, magneto-crystalline anisotropy and chemical stability. Nanoparticles 
(NPs) made of this alloy are promising candidates for a wide range of biomedical 
applications including magnetic separation, magnetic targeted drug delivery, 
hyperthermia for cancer therapy and also as magnetic resonance imaging (MRI) 
contrast agents. 
 
This thesis presents the synthesis, functionalization and characterization of FePt 
NPs along with a toxicity study and an investigation into their application as MRI 
contrast agents. Regarding their synthesis, different approaches have been 
explored including the co-reduction of Fe and Pt precursors in an aqueous media, 
the thermal decomposition in a conventional high-boiling solvent such as benzyl 
ether, and in low-melting organic salts (ionic liquids). The data revealed an 
inhomogeneous composition distribution of Fe and Pt between particles obtained 
in aqueous media, due to the iron salts hydrolysis, and a mismatch in the 
co-reduction kinetic of the two metal precursors. While the iron content in the 
NPs could be increased by using more hydrolytically stable iron precursors or 
stronger reducing agents, there are remaining limiting parameters which prevent 
further Fe content increase in NPs. In contrast, by excluding the water from the 
reaction system and using a Fe2- iron precursor, homogenous 1:1 Fe to Pt ratio 
NPs can be obtained through a modified thermal decomposition pathway in 
benzyl ether. Based on the study of synthesis in this conventional chemical, the 
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potential of ionic liquids (ILs) to be used as novel solvents for FePt NPs synthesis 
was further explored. It was then demonstrated that ionic liquids (ILs) can not 
only be used as a solvent for synthesis of FePt NPs, but also can provide an 
exciting alternative pathway to direct synthesis fct-FePt NPs.  
 
In the context of the bioapplication of FePt NPs, a family of FePt NPs was 
specifically designed to enhance their MRI contrast agents properties. In contrast 
with previous reports, this thesis demonstrates that FePt NPs can be made non-toxic 
and provides the first data on their cellular uptake mechanisms. A six times increase 
in the FePt based T2 contrast properties compared to clinical iron oxide NPs is 
reported. The relationship between the MRI contrast properties and the NPs 
architecture is explored and rationalised as the basis for the design of NPs as 
enhanced MRI contrast agents. Finally, the first observations of cellular and in vivo 
MR imaging with FePt NPs is also reported. This study opens the way for several 
applications of FePt NPs such as regenerative medicine and stem cell therapy, thus 
providing a bio-platform to develop novel diagnostic and therapeutic agents. 
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Chapter 1 
 
 
Introduction 
 
 
Nanoparticles (NPs) have attracted considerable research interest as revolutionary 
diagnostic and therapeutic tools in biomedical fields. 1-3 Nanometer size materials 
can display very different chemical and physical properties compared to 
corresponding bulk materials due to their high surface to volume ratio and 
quantum confinement effects.4 Their unique properties offer tremendous 
opportunities for applications in biomedicine. For example, the surface plasmon 
resonance effect of gold NPs has led to their applications in optical imaging and 
sensing.2 The photoluminescence wavelength of Cd, Pb and Se derived 
semiconductor nanoparticles, known as quantum dots (QDs), can be controlled 
over the visible to near infrared range by adjusting their size, enabling their use as 
fluorophores in a variety of biological investigations.3 Magnetic NPs, which often 
contain magnetic elements such as iron, cobalt, and nickel, offer unique properties 
and have applications including magnetic separation, magnetic targeted drug 
delivery, hyperthermia for cancer therapy and also as MRI contrast agents.5 
 
Iron platinum (FePt) metallic alloy NPs are one of the important classes of 
magnetic materials. Their magnetic properties strongly depend on size, shape and 
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composition together with their crystalline structure. For example, depending on 
the size as well as structure, they behave as superparamagnetic when they are in 
face centred cubic (fcc) phase and ferromagnetic when they are in face centred 
tetragonal (fct) phase. FePt NPs have emerged as promising candidates for a new 
generation of magnetic nano-material thanks to their high Curie temperature and 
magneto-crystalline anisotropy.6  
 
This thesis presents synthetic pathways, characterization of FePt NPs and their 
application as MRI contrast agent. It will begin with providing an overview of the 
development of NPs, especially inorganic NPs, their features and potential for use 
in biomedicine (Chapter 2). It then focuses on introducing specific elements of 
magnetism, magnetic NPs and some of their biomedical applications (Chapter 2). 
A review of the development of chemical synthesis of FePt NPs, functionalization 
is presented in Chapter 3.  
 
In the context of this PhD study, three main different approaches have been 
applied to synthesize FePt NPs. In Chapter 4, a detailed investigation of low 
temperature aqueous solution syntheses, focusing on the stoichiometry and the 
composition of FePt NPs, is presented. A quaternary system based on water, 
isooctane, and Brij52 as nonionic surfactant and butanol as a co-surfactant was 
used. A precise composition analysis of individual NPs was carried out and 
revealed an inhomogeneous distribution of Fe and Pt between particles. The aim 
of this work is to understand the limiting parameters on individual NP 
composition and identify suitable strategies to increase the iron content of NP. The 
characterization was completed by combining a SQUID magnetometer, 
Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES), 
Wide-angle powder X-ray diffraction (XRD), Transmission Electron Microscopy 
(TEM) as well as Scanning Transmission Electron Microscope and Energy 
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Dispersive X-ray analysis (STEM-EDX). The reaction time, precursor ions and 
choice of reducing agents were used to increase the insertion of the iron in the 
FexPt100-x NPs.  
 
Based on the knowledge and experience learned from the FePt NPs synthesis in 
aqueous solution, a modified thermal decomposition method was developed for 
FePt NPs synthesis, presented in Chapter 5. In contrast to low temperature synthesis, 
uniform, well dispersed and close 1 to 1 Fe to Pt ratio fcc-FePt NP could be 
obtained, by using a high-boiling organic solvent like benzyl ether, combined with 
Na2Fe(CO)4/Pt(acac)2 in the presence of oleic acid and oleylamine. In addition, the 
potential of ionic liquids (ILs), as novel solvents for FePt NPs synthesis was 
explored. ILs are low melting organic salts many of which are liquid over a wide 
range of temperature and can be used as solvents for numerous inorganic and 
organic materials.7-11 The results indicate that ILs can not only be used as a solvent 
for high temperature synthesis of FePt NPs, but also can provide an exciting 
alternative pathway to direct synthesis fct-FePt NPs.  
 
Finally, the bioapplication of FePt NPs as MRI contrast agent was investigated and 
presented in Chapter 6. It describes the fabrication of a family of FePt NPs designed 
to explore and rationalise both toxicity and MRI contrast agent properties. In 
contrast with previous reports, this work demonstrated that FePt NPs can be made 
non-toxic and provides the first data on their cellular uptake mechanisms. A six fold 
increase in the FePt based T2 contrast properties compared to clinical iron oxide 
NPs is reported. The relationship between the MRI contrast properties and the NPs 
architecture is explored and rationalised as the basis for the design of NPs as 
enhanced MRI contrast agents. Finally, the first observations of cellular and in vivo 
MR imaging with FePt NPs are also reported. This study opens the way for several 
applications of FePt NPs such as regenerative medicine and stem cell therapy, in 
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addition to the enhanced MR diagnostic imaging, thus providing a platform to 
develop novel diagnostic and therapeutic agents. 
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Chapter 2 
 
Nanoparticles and Their Applications 
 
 
 
2.1. Nanoparticles and Their General features 
 
Nanoparticles (NPs) are part of a class of materials bridging bulk materials and 
structures with an atomic length scale. All the solid particles in the range of 1 nm 
to 1 µm in all three dimensions could be called as NPs. However, the particles 
smaller than 100 nm often show dramatical changes in their physical chemical 
properties compared to the corresponding bulk materials.1-4 
 
Over the past decades, nanomaterials have attracted tremendous attention from 
researchers from a wide range of disciplines especially in physics, chemistry, and 
biology, because of their distinct characteristics which include the ultrafine size, 
large surface to volume ratio and unique physical chemical properties.3-4 This 
dissertation focuses on biomedical applications of NPs with domain size 
comparable or smaller than the biological materials e.g. a cell (10-100 µm), a 
virus (20-450 nm), or a protein (5-50 nm). As a result the NPs operate at the same 
microscopic scale as these biological functional subjects. Thus, NPs are expected 
to be able to provide a new framework for diagnosing, treating and preventing 
disease.5-6 NP has large surface to volume ratio, which means that relatively there 
are many more atoms located on the surface of a nano-size particle than a 
micro-size particle. For example, the fraction of atoms on the surface of a 20 µm 
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cubic particle is less than 0.01%, but this increases to almost 50% for a 2 nm 
cubic particle.3 Consequently engineered NPs can have much higher chemical 
reactivity, and binding efficiency compared to bulk materials. In addition, NPs can 
display unique physical and chemical properties such as magnetic and photonic 
behaviours, which set them apart from bulk materials.  
 
Semiconductor quantum dots (QDs), non-magnetic metallic, magnetic 
nanoparticles, lipid and polymeric particles and carbon-based nanomaterials are 
major and sometimes overlapping classes of nanomaterials which have emerged 
over recent decades, and they are being exploited for a large range of applications. 
Carbons, lipid, polymeric based nanomaterials are appreciated for their high 
biocompatibility, and have been widely investigated for their drug delivery 
purposes since 1950s.7 In this thesis, this exciting aspect of nanocolloids will be 
put aside and focused on inorganic NPs. Whereas magnetic NPs, QDs, and non 
metallic NPs have attracted tremendous attention over the past three decades, due 
to their special magnetic, optical, and thermal properties, that are appealing for 
both disease diagnosis and therapy.6 Thanks to the development of various 
inorganic NPs, we are getting closer to the day when the concept of a “magic 
bullet” as a medical agent with specific biomedical functions, including targeted 
delivery and multimodal non-invasive imaging, becomes reality. A brief 
introduction on semiconductor NPs, noble metallic NPs, magnetic NPs are given 
in the following section.  
 
2.2. Non-magnetic Nanoparticles 
 
2.2.1. Semiconductor Nanoparticles 
 
QDs are defined as semiconductor structures with physical dimensions typically 
in the range of a few nanometers.8 QDs such as CdSe, CdTe, CdS, ZnSe, PbS, 
PbSe etc. can display unique photoluminescence properties including high 
emission intensity, superb photostability over conventional organic fluorophores. 
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In addition, the fluorescence emission of QDs is size and composition tunable 
therefore it is possible to fabricate QDs with fluorescence emission that ranges 
from the visible to infrared wavelengths. Furthermore, QDs have large absorption 
coefficients across a wide spectral range which allows different QD emissions to 
be excited simultaneously using a single wavelength, i.e. single excitation 
wavelength for multiple colours.6, 9 Therefore, QDs are promising biological 
optical probes to replace or complement existing organic fluorophores used 
extensively in biological research. 9-15 
 
The optical properties of QDs can be described by conventional semiconductor 
physics and quantum mechanics.9, 16-17 In these systems, characterized by valence 
and conduction bands, the energy difference between the two bands is called the 
bandgap energy. When a semiconductor is optically or electrically excited, the 
electrons located in the valence band will move into the conduction band and 
leave holes behind. After a period of time termed as the lifetime, typically around 
20 ns, the electron and hole will recombine. This recombination can be associated 
with the emission of photons with a high “quantum yield”. The QDs fluorescence 
emission is dependent upon the bandgap energy; which in turn is related to the 
QD’s size, shape, and composition due to the quantum confinement effect. Figure 
2.1A1-A3 show several vials of QDs of different size illustrating their 
fluorescence properties,9 demonstrating that as the QDs size becomes larger, their 
optical emission shifts from blue to red. This tunable fluorescence emission 
property and the microscopic size of the QDs means they play an immense role in 
the development of biomedical imaging. A typical example is the multi-colour 
labelling shown in Figure 2.1B, which presents a pseudocoloured image of fixed 
human epithelial cells stained by five-colour QDs functionalized with different 
antibodies which selectively binds to specific surface receptors inside the cells.11  
 
A new and exciting avenue of QDs research is their application as optical probes 
emitting in the near-IR (NIR) emission range (> 650 nm).18-19 650–900 and 
1025–1150 nm are typical NIR emitting windows,9, 11 which have low tissue 
absorption and scattering effects hence increase the potential of non-invasive in 
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vivo biological optical imaging as it allows deeper penetration. While there are 
only a limited amount of organic fluorophores and chemiluminescence probes 
with NIR emission, it is possible to prepare a series of NIR-emitting QDs suitable 
for animal imaging, by tuning the optical properties of QDs altering their size and 
composition. Indeed, CdTe, CdSe-ZnS, CdTeSe, InAs, PbS, and PbSe have 
already been successfully synthesized with NIR emission.19-21  
 
Figure 2.1 (A) Tunable optical properties of QDs: Schematic of the size-dependent optical 
properties of QDs (A1), their real-color emission, excited by a hand-held UV lamp (A2) and the 
corresponding bandgap energies (A3).9 (Copyright 2006, Wiley-VCH Verlag GmbH & Co. KGaA. 
Reproduced with permission.) Pseudocoloured image depicting five-colour QD staining of fixed 
human epithelial cells (B). (Courtesy of Quantum Dot Corp.) Simultaneous in vivo imaging of 
multicolour QD-encoded polymer microbeads (C).18 (Adapted by permission from Macmillan 
Publishers Ltd: [Nat. Biotechnol.] (18), copyright 2004.)  
 
 
A1 
A2 
A3 
B C
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Figure 2.1C illustrates the capability of CdSe-ZnS core-shell QD in high sensitive, 
multicolour imaging of live animals.18 An equal number of polymer beads doped 
with 3 different colour QDs emitting green, yellow and red light respectively, 
were injected into a host mouse at three adjacent locations. All three colours were 
observed simultaneously in the mouse with a single light source, thus 
demonstrating the large potential of NIR QDs as sensitive optical probes for 
non-invasive, multi-colour in vivo imaging.  
 
2.2.2. Noble Metal Nanoparticles 
 
The coherent oscillation of free electrons at metallic surfaces associated with 
electromagnetic fields is called the surface plasmon resonance (SPR).22-24 When 
metal NPs are exposed to light radiation, the electric field of the light can cause 
the collective oscillation of the free electrons at the surface of the NPs. 
Subsequently, the oscillating electrons radiate electromagnetic radiation with the 
same frequency as the oscillating electrons. Chemically stable silver and gold NPs 
have been shown to be efficient at Plasmon scatter. Their SPR-enhanced 
properties including Mie scattering, surface plasmon absorption, surface-enhanced 
luminescence and surface enhanced raman scattering (SERS) have been widely 
investigated for biomedical applications.22 
 
In this section, gold (Au) NPs are briefly introduced representing non-magnetic 
metal NPs. When compared with QDs, Au NPs have their own advantages such as 
dual scattering, fluorescence properties, easier surface functionalization, and low 
toxicity.22 Most importantly, Au NPs have photothermal property that QDs do not 
exhibit. The photothermal property of Au NPs is attributed to the strong light 
absorption as a result of the SPR. The absorbed light can be converted into heat on 
a picosecond time scale. The highly efficient and localized light-to-heat 
conversion by Au NPs makes them very promising candidates for cancer 
photothermal therapies and as a thermal sensitive drug delivery system.22 Recently, 
a controllable drug releasing system was reported based on photothermal effect of 
Au nanocages, as illustrated in Figure 2.2. Au nanocages are gold nanostructures 
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with hollow interiors and porous walls, and have strong light absorption in the 
near-infrared region, a region in which biological tissue has high transmissivity. In 
this drug delivery system, these Au nanocages are coated with thermal sensitive 
polymer which can change conformation in response to small variations in 
temperature. Therefore, when the heat is generated by Au nanocages through 
conversion of absorbed light into heat which dissipates into the surroundings, it 
will cause the polymer chains to collapse. This in turn, exposes the pores on the 
nanocages resulting in the release of preloaded drug. The drug release can then be 
stopped by turning off the laser source, reducing the temperature and returning the 
polymer to its original extended conformation therefore closing the pores of 
nanocages and stopping drug release.25  
 
 
Figure 2.2 Schematic illustration of Au nanocage-smart polymer controlled-drug system. The drug 
releasing is controlled by triggering the thermal sensitive polymer conformation change through 
the light-heat conversion by Au nanocage upon exposure to a near-infrared laser.25 (Adapted by 
permission from Macmillan Publishers Ltd: [Nat. Mater.] (25), copyright 2009.) 
 
2.3. Magnetic Nanoparticles 
 
During the course of this PhD, I have focused on iron platinum alloy magnetic 
NPs. Thus, the following section will introduce the general rules associated with 
their magnetic properties.  
Drug Realising 
Thermal Sensitive 
Polymer Collapse of Polymer 
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2.3.1. Origin of Atomic Magnetic Moment 
 
When a current passes through a length of wire, a magnetic field is generated. In 
the case of an electric current moving in a circular loop, this current loop behaves 
as a magnetic dipole,26 a schematic drawing is shown in Figure 2.3A. By invoking 
this concept of electrical charges in motion, the origins of atomic magnetic 
moment responsible for magnetism in all materials can be explained. The electron 
spin magnetic moment of an atom originates from the orbital angular momentum 
of the electrons around the nuclei (Figure 2.3B). If the atom has more than one 
electron, the total atomic magnetic moment depends on the spin orbital electron 
magnetic moment interactions, so called spin-orbit, spin-spin or orbit-orbit 
coupling between electrons of the atom.27 
 
 
Figure 2.3 Schematic drawing of a magnetic field generated by a current loop (A), an atomic 
magnetic moment produced by an electron orbiting the nucleus and the spin of the electron. 
 
2.3.2. Types of Magnetism 
 
Materials can be classified into five magnetic categories namely: diamagnetic, 
paramagnetic, ferromagnetic, ferrimagnetic and antiferromagnetic according to 
the arrangement and origin of their magnetic moment in the absence and presence 
of an external magnetic field.5, 26-30  
 
 
N
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2.3.2.1. Diamagnetism  
 
Diamagnets are materials with no permanent net atomic magnetic moment, for 
example, copper, silver and gold are typical diamagnetic materials. The 
diamagnetic atoms have filled sub-electron shells and the magnetic moments of 
those paired electrons will cancel each other in the absence of a magnetic field 
resulting in zero net atomic magnetic moment (Figure 2.4)27 When a magnetic 
field is applied, the atomic magnetic moment with a direction opposing the 
external field will be generated. This is because the orbital motion of the electrons 
in the same electron shell will be either accelerated or decelerated simultaneously 
subject to an applied magnetic field, thereby contribute to a change in the orbital 
magnetic moment in such a way that the induced moment opposing the applied 
field.26-27  
 
 
Figure 2.4 Schematic illustrating the arrangements of magnetic dipoles for Diamagnetic and 
Paramagnetic materials in the absence or presence of an external magnetic field (H).5, 28 
 
The magnetization (M) is defined as the magnetic moment per unit volume of a 
solid and is used to quantify the strength of the magnetic moment. The magnetic 
M 
H
Slope = mχ
0 
Diamagnetism 
Au (5d106s1)  
Paramagnetism 
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susceptibility ( mχ ) usually describes the magnetic response of material to an 
applied magnetic field, and can be defined as the gradient of the M-H curve 
(Figure 2.4). The mχ  of diamagnetic materials is negative with a very small 
magnitude typically of about 10-5.26-27  
 
2.3.2.2. Paramagnetism 
  
Unlike diamagnets, paramagnetic materials have permanent atomic magnetic 
moments which do not rely on the presence of an external magnetic field. 
Paramagnetic atoms, e.g. oxygen and platinum, usually have an odd number of 
electrons in the sub-electron shell, the unpaired electron spins give rise to a 
permanent net atomic magnetic moment (Figure 2.4).27 However, normally these 
atomic magnetic dipoles are not parallel but randomly oriented within a material, 
the interactions between paramagnetic atomic dipoles are much weaker than the 
thermal agitation, termed as Boltzmann energy. Under these conditions, for 
example in the absence of an external magnetic field, the macroscopic or net 
magnetic moment of the paramagnetic material is zero.  
 
Appling a strong external magnetic field has the effect of making the atomic 
dipoles line up parallel to the applied field; as a result a positive susceptibility can 
be obtained (Figure 2.4). However, the fraction of the moments that align with the 
field is usually very small subject to the thermal agitation, thus the magnitude of 
the susceptibility ( mχ ) typically ranges from 10-3 to 10-5.27, 31  
 
2.3.2.3. Ferromagnetism 
 
2.3.2.3.1. Bulk Ferromagnetic Material 
 
Similar to paramagnetic materials, ferromagenetic materials e.g. iron, cobalt, 
nickel, heavy rare earth elements have permanent atomic magnetic moments due 
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to unpaired electrons in sub-electron shell. However strong interatomic interaction, 
the so called Weiss Interaction, induces spontaneous magnetization in 
ferromagnetic materials. Thus neighbouring atomic magnetic moments tend to 
align parallel to each other to lower the energy of the system (Figure 2.5A). This 
can not be explained in classical terms but depends entirely on quantum theory. 
The overall energy of the system is further decreased in bulk ferromagnetic 
material, as it forms small magnetic domains which in the absence of an external 
magnetic field are separated by domain walls (Figure 2.5A). Within each domain, 
there is a large net magnetic moment (spontaneous magnetization), due to the 
 
 
Figure 2.5 Schematic drawing of Ferromagnetism in the bulk material. (A) Multi-domain structure 
existed in the bulk ferromagnetic material (B) important parameters obtained from a magnetic 
hysteresis loop: the magnetic saturation (Ms), the remnant magnetization (Mr). The coercivity field 
(Hc) (C) a typical plot of the Curie temperature Tc. 31  
 
parallel alignment of the large numbers of atomic magnetic dipoles, typically from 
1012 to 1015.27 The size and direction of the magnetic moments of each domain 
however varies with each other, and in the demagnetized state the net magnetic 
moment of the macroscopic ferromagnetic material is zero. However, the 
application of even a small magnetic field induces a large magnetization often in 
domain wall 
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the order of a magnitude greater than the field strength in ferromagnetic material. 
The magnitude of susceptibility is positive with typical values from about ~50 to 
103, which is much larger than in the paramagnetic materials.27  
 
The generation of large magnetization is attributed to two processes. One is the 
rotation of the direction of the domain magnetization along the applied field 
direction. This generally costs more energy than the motion of domain walls, 
because it involves rotating the magnetization away from the easy direction being 
fixed by magnetic anisotropy.31 The other is the domain wall motion involving the 
volumes of domains aligned along the field become greater than the volume of 
domains aligned against the field (Figure 2.5B).31 When these two processes are 
completed under a sufficiently strong applied magnetic field, the sample is in a 
state of magnetic saturation (Ms). The rotation of magnetization is reversible, 
therefore on the reduction of the applied magnetic field, the magnetization rotates 
back toward its easy directions. As the applied field decreases further, domain 
walls begin moving backwards. However because wall motion is an irreversible, 
lossy process, the M-H loop opens up, resulting in hysteresis. The induced 
magnetization remains in the sample even when the applied field is reduced to 
zero, this is called remnant magnetization (Mr). A reverse field called the coercive 
field (Hc) is required to completely demagnetize the remaining magnetization 
(Figure 2.5B). 
 
Ferromagnetism is highly temperature dependent, as the magnetization of 
ferromagnetic material arises from the collective net interactions of permanent 
atomic magnetic moments.28 As temperature increases, thermal energy starts to 
become large enough to break the parallel alignment of atomic magnetic moments 
of the ferromagnetic material. When it has risen to above a critical temperature, all 
the atomic magnetic moments are randomized by thermal agitation, and the 
spontaneous magnetization of ferromagnetic materials falls rapidly to zero. The 
result is the ferromagnets behave like a paramagnetic material. This transition 
temperature from ferromagnetic to paramagnetic behaviour is called the Curie 
temperature (Tc) (Figure 2.5C).27   
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In addition to ferromagnets, there are two other magnetic materials that are 
classified as ferrimagnets and antiferromagnets. They also exhibit ordered 
magnetic states in the absence of an external magnetic field. In a ferrimagnetic 
material, the magnetic dipoles have an ordered arrangement with one magnetic 
dipole aligned antiparallel to an adjacent stronger dipole resulting in a weak net 
magnetic moment (Figure 2.6A). In an antiferromagnetic material, the 
neighbouring dipoles are aligned antiparallel and of equal magnitude thus they 
cancel each other (Figure 2.6B).32-33   
 
 
Figure 2.6 Schematic drawing of atomic magnetic moments arrangement in ferrimagnetic material 
(A) and antiferromagnetic material (B).32-33  
 
2.3.2.3.2. Single Domain Magnetic Nanoparticle 
 
In addition to temperature, the magnetization of ferromagnetic material is also 
strongly related to the size of material. In large scale bulk materials, there is 
presence of magnetic domains where regions of uniform magnetization are 
separated by domain walls (Section 2.3.2.3.1). When the material size is reduced 
as in the case of NPs, there is a critical volume below which it costs more energy 
to create a domain wall than to support the external magnetostatic energy of a 
single-domain particle. This critical size is called the single-domain size (Dc). 
Inside each single-domain particle, there is a giant magnetic moment because all 
the atomic magnetic moments within this particle are aligned parallel along a 
specific direction (Figure 2.7A).  
A B
Chapter 2. Nanoparticles and Their Applications                              Shu Chen, St Andrews 
 
 
 
19
 
Figure 2.7 Schematic drawing of a single domain ferromagnetic NP, its free energy with uniaxial 
anisotropy as a function of magnetization direction (A),34 and hysteresis loop of ferromagnetic 
NPs (B). Schematic drawing of the reversals of a superparamagnetic NP magnetization subject to 
thermal agitation, ZFC-FC curve of superparamagnetic NPs (C) and hysteresis loop of 
superparamagnetic NPs (D). 
 
The macroscopic magnetic moment of magnetic NPs can be seen as a collection 
of giant magnetic dipoles, which thus depends on the directions of individual 
magnetic nanoparticle magnetization. The magnetic anisotropy is responsible for 
holding the particle magnetization along a certain direction, and the energy per 
particle can be expressed as follow:  
 
E(θ ) = KeffVsin2θ              eq.(1) 
 
where Keff  is the anisotropy constant depends on magnetocrystalline anisotropy, 
shape anisotropy, strain anisotropy and surface anisotropy,34 V is the particle 
volume and θ  is the angle between the particle’s magnetization and the 
preferential direction of magnetization known as the easy axis. The energy barrier  
 
∆E = KeffV               eq.(2) 
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corresponding to the magnetization aligned parallel or antiparallel along the easy 
axis (Figure 2.7A).34 Particles are also subjected to thermal energy, kBT, where kB 
is the Boltzmann constant, T is the temperature. When KeffV > kBT, particles 
manifest ferromagnetic properties as characterized by an irreversible hysteresis 
loop (Figure 2.7B). The magnetic moments of particles tend to align to the same 
direction as the applied external magnetic field and finally reach a saturation 
magnetic moment (Ms) with all the particular magnetic moment aligned in the 
same direction. Similar to bulk ferromagnetic magnetic material, there is a 
remnant magnetic moment (Ms) left after the disappearance of the external field, 
and a magnetic field applied in the opposite direction (Hc) is needed to 
demagnetize the sample (Figure 2.7B).  
 
The energy barrier KeffV decreases with the particle size, and below a size limit 
when the thermal energy KBT exceeds KeffV, the magnetization of particle, it 
becomes easily flipped (Figure 2.7C). These particles are said to be 
superparamagnetic particles. The critical size below which this occurs is called the 
superparamagnetic limit size (Ds). It needs to be noted that, different to a 
paramagnetic particle which has no net particulate magnetic moment itself, each 
superparamagnetic particle is still a permanent magnet because of spontaneous 
magnetization within the particle; however, the magnetization of each single 
particle is fluctuating rapidly subject to the thermal agitation (Figure 2.7C), 
resulting in zero net macroscopic magnetization for a collection of 
superparamagnetic particles. 
 
This magnetic property of superparamagnetic particles can be characterized by the 
ZFC-FC (Zero-Field Cooled and Field Cooled) curves using SQUID 
(Superconducting QuantUm Interference Devices). The ZFC curve is obtained by 
cooling down the sample without applying any magnetic field from a high 
temperature, at which all particles show superparamagnetic behaviour, to a low 
temperature whilst measuring the magnetization under a small applied field 
typically 100 Oe and increasing temperatures stepwise. The FC curve is normally 
obtained by first cooling the system from a high temperature to a low temperature 
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in the presence of the small applied magnetic field, then measuring the 
magnetization in the same small applied field while stepwise increasing 
temperatures.35 The magnetic behaviour of particles is characterized by the so 
called blocking temperature (Tb), at which the relaxation time of NPs becomes 
comparable to SQUID measurement time (tm) about 100 s (Figure 2.7C). The 
relaxation time (τ ) of the magnetic moment of a particle, is given by the 
Néel-Brown equation, where τ 0 ≈ 10-10 s is the inverse attempt frequency,34 K is 
the anisotropy constant, V is the particle volume, kB is the Boltzmann’s constant, 
 
)exp(
B
eff
0 Tk
VKττ =             eq. (3) 
 
Below Tb, the particles magnetic moments are said to be ‘blocked’, they appear 
frozen on the time scale of the measurement and therefore particles show 
ferromagnetic properties, as characterized by an open hysteresis loop. Above Tb, 
particles exhibit paramagnetic properties without any hysteresis. However, in 
contrast, the collective magnetic moment of superparamagnetic NPs can easily 
reach saturation under relatively low magnetic field (Figure 2.7D). For a specific 
sample the blocking temperature is not uniquely defined and depends on the 
characterization instrument used for the characterisation. However, the blocking 
temperature can be defined for each applied experimental technique.34  
 
2.4. Biomedical Application of Magnetic Nanoparticles 
 
Due to the unique magnetic properties and their ability to function at the cellular 
and molecular level of biological interaction, magnetic NPs have attracted 
tremendous research interest as revolutionary diagnostic and therapeutic tools in 
biomedical applications.5, 28, 33, 36 Major bioapplications of magnetic NPs 
including magnetic separation, magnetic targeting, hyperthermia, and as MRI 
contrast agent are introduced in the following sections.  
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2.4.1. Magnetic Separation 
 
In biology, it is often of interest to separate out specific biological substances from 
a heterogeneous sample matrix either to purify the sample or to concentrate the 
desired components for subsequent analysis and usage. Separation using magnetic 
NPs provides one straightforward and efficient way to achieve this purpose. In 
general, the separation involves two-steps,  
i) the tagging or labelling of the desired biological objects like bacteria or  
protein with the magnetic NPs. The labelling is normally made via a linkage 
between NPs and targeted biological materials such as ligand-receptor 
interactions.33  
ii) the magnetically labelled materials can be separated from the native solution, 
for example, passing the fluid mixture through a region where a magnetic 
field gradient can immobilize the tagged materials.5  
 
 
 
Figure 2.8 A schematic illustration of the capture of bacteria by vancomycin-conjugated FePt 
magnetic NPs, modified based on ref.37 
 
A typical example is illustrated in Figure 2.8. A broad spectrum antibiotic 
Vancomycin is attached to the surface of magnetic NPs that targets the terminal 
peptide, D-Ala-D-Ala, which is located on the cell wall of a Gram-positive 
bacterium via polyvalent ligand-receptor interaction. The nP-Van conjugates can 
selectively and efficiently bind to Gram-positive bacteria (within ~10 min), such 
as Staphylococcus aureus, S. epidermidis. The bacteria bound with NPs can then 
be separated by a point magnet (with the tip field strength at ~400 G) from the 
Ligand-receptor 
bonding 
+ 
Vancomycin D-Ala-D-Ala
Bacteria (E.Coli) 
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solution and allow subsequent identification with optical microscopy or SEM. The 
sensitivity of this bacteria assay using FePt NPs is impressive as it can purify 
bacteria at a concentration of ~10 cfu mL-1 (cfu: colony forming units), which is 
more sensitive than the best assays for bacteria detection based on luminescence 
(detection limit: 180 cfu mL-1).37-38 
 
2.4.2. Magnetic Drug Delivery and Targeting 
 
The concept of targeted drug delivery is attractive as the aim is to release the 
drugs at specific lesions sites in the body. This achieves enhanced drug delivery 
efficiency, reduces dosage and minimize undesired side effects. In cancer 
treatment, the traditional chemotherapy is non-specific and the therapeutic drugs 
are normally administered intravenously leading to general systemic distribution. 
This results in deleterious side-effects as the drug not only attacks tumour cells 
but also healthy cells. There are typically two approaches to achieve specific drug 
delivery to pathological sites. 39 The first one is called passive targeting pathway 
which takes advantages of “natural” process of the body for clearance of drugs. 
For example, particulate drug carriers tend to be phagocytosed by cells of 
mononuclear phagocyte system (MPS) sometimes also known as the 
reticuloendothelial system (RES). This results in the drug accumulation in the 
major organs such as liver and spleen which have abundance of MPS 
macrophages and a rich blood supply. This passive targeting is advantageous in a 
number of situations, e.g. the treatment of macrophage-associated microbial, viral 
or bacterial diseases and the immunopotentiation of vaccines, etc.40 Passive 
targeting can also be achieved by enhancing permeability and retention (EPR) 
effect, this will deliver drugs to the particular pathological sites e.g. tumours, 
inflammatory where the microvasculature is hyperpermeable, leaky and lack of 
lymphatic drainage system which leads to the accumulation of macromolecules 
and small particles to these sites (Figure 2.9).18, 40-41 This form of passive targeting, 
also called ‘selective targeting’, requires the size of the drug carrier system to be 
larger than the size of normal endothelial fenestrations but also small enough to go 
through the “leaky” endothelial sites. In addition, the carrier systems have to 
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“escape” from MPS clearance so they have long enough blood circulation time to 
accumulate at the desired pathological sites. To reduce the RES clearance, a 
typical approach is to increase the hydrophilicity of the particles, by for example, 
coating the particles with hydrophilic polymer like PEG (Figure 2.9).42 
 
The alternative specific drug delivery approach is called “active targeting”. This 
strategy is to attach a “homing device”, like antibodies or ligands targeting 
corresponding cell-specific receptors covalently or non-covalently, to the particles 
surface that allows the drug carriers to identify and bind to a desired target at the 
pathological sites (Figure 2.9). For example, galactose can be used to target a drug 
carrier to parenchymal liver cells.40  
 
 
Figure 2.9 Schematic drawing of drug delivery strategies.  
 
The development of magnetic NPs allows an alternative ‘active targeting’ strategy 
known as magnetic targeting, this guides magnetic drug carriers to a chosen site 
by an external magnetic force (Figure 2.9).41 The magnetic targeting strategy is 
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appealing as it complements existing passive and active drug delivery methods 
and ca improve the effectiveness of drug targeting. FeRx, Inc. produced magnetic 
particles (MTC-DOX) of size 500 nm – 5 µm consisting of metallic Fe ground 
together with activated carbon loaded with an anticancer drug Doxorubicin. 
Experiments showed that MTC-DOX NPs can be accurately targeted to the 
regions of interest e.g. liver and lung in a swine model. The development of 
MTC-DOX NPs went to the Phase II clinical study in patients with primary liver 
cancer. Although the trial was not successful, it demonstrated the promising 
capability of magnetic particles for the drug targeting application.43-44 
 
2.4.3. Hyperthermia  
 
When magnetic NPs are exposed to an alternating magnetic field, heat will be 
generated. For ferromagnetic NPs, the mechanism of heat generation is due to 
hysteresis loss, and the amount of heat generated by this mechanism is proportional 
to the frequency of the oscillating magnetic field and to the area of the magnetic 
hysteresis loop. For superparamagnetic NPs, two different mechanisms of heat 
generation are involved: (i) the rotation of magnetic moment across the NPs and (ii) 
the physical rotation of the particles themselves. The former is referred as ‘Néel 
relaxation’ and the latter is termed as the ‘Brownian relaxation’.5, 45-46 
 
Hyperthermia is an attractive cancer therapy as controlled heat release from the 
magnetic NPs produces apoptosis of cells. The tumour cells are more vulnerable 
due to the physiological difference between healthy tissues and solid tumours. The 
low oxygen and low pH environment in tumour due to the insufficient blood 
perfusion, makes tumour cells more sensitive to temperature rises than healthy 
tissues. For example, it has been demonstrated that if the temperature can be 
maintained above the therapeutic threshold of 42 ºC for half an hour or more, the 
tumour cells can be destroyed 33, 45, 47-48, while most tissues are undamaged by 
heating treatment for 1 h at the temperature up to 44 ºC.47 In addition, the 
temperature rises are easier in tumours sites because of the insufficient blood flow. 
Consequently, tumour cells can be selectively killed by hyperthermia treatment. It 
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is usually used as an additive therapy with standard treatments, such as 
radiotherapy and chemotherapy.49  
 
2.4.4. MRI Contrast Agents 
 
2.4.4.1. Introduction of Basic Principles of MRI 
 
The basic principle of nuclear magnetic resonance (NMR) that underpins 
magnetic resonance imaging (MRI) is shown in Figure 2.10.50-52 If we consider a 
hydrogen nucleus, it contains a positively charged proton. The proton has nuclear 
spin. Thus the positively charged hydrogen nucleus has a magnetic moment due to 
its self-rotation, and the direction of the magnetic moment is parallel to the axis of 
self-rotation. In the absence of a field, the protons have their magnetic moments 
oriented randomly, thus the net magnetic moment of these protons is zero (Figure 
2.10A). When an external magnetic field is applied, the spins of the protons nuclei 
have two potential energy states, which in classical terms can be thought of 
nuclear magnetic moment aligning either parallel or antiparallel to the applied 
magnetic field. During their alignment, the spins precess at a specified frequency, 
known as the Larmor frequency (ω0) or the frequency of precession, which is 
proportional to the strength external magnetic field,  
 
ω0 = γ B0              eq.(4) 
 
where γ is the magnetogyric ratio and B0 is the strength of the applied magnetic  
field (Figure 2.10B1). The magnetization of proton (M0) can be considered as two 
orthogonal components: a longitudinal component or Z component (Mz) and a 
transverse component lying on the XY plane (Mxy) (Figure 2.10B2). Under the 
external magnetic field, there are more spins aligned with the field (low energy 
state) than against the field (high energy state). Therefore, the net magnetization 
or macroscopic magnetization has a longitudinal component aligned with applied 
magnetic field (Figure 2.10B3).  
Chapter 2. Nanoparticles and Their Applications                              Shu Chen, St Andrews 
 
 
 
27
 
Figure 2.10 Principle of magnetic resonance imaging. (A) Protons have their magnetic moment 
oriented randomly in the absence of an external magnetic field. B) Proton spins align parallel or 
antiparallel to the magnetic field and precess under Larmor frequency (ω0). (C) Excitation process: 
after induction of 90º radio-frequency (RF) pulse, protons absorb energy and magnetization rotates 
into transverse plane. (D) Relaxation process: following a 90º RF pulse, excited spins release their 
energy through longitudinal and transverse relaxation process. More details are presented in the 
main text. 
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At equilibrium, the sum of transverse magnetization is zero as spins and 
magnetization of proton (M0) equals Mz (Figure 2.10B4). When a ‘resonance’ 
frequency in the radio-frequency (RF) range is introduced to the nuclei, the 
protons absorb energy at resonance frequency and are excited to the higher energy 
state, i.e. from parallel to antiparallel direction. Depending on the strength of the 
RF pulse, the magnetization of proton (M0) can rotate 90-degree into the 
transverse plane, this is termed as a 90-degree flip angle pulse (Figure 2.10C1). 
During such excitation process, the longitudinal magnetization disappears 
gradually due to the decrease of z axis component (Mz) of net magnetization, 
while transverse magnetization (MXY) increases since the spins have phase 
coherence. At the end of the 90° RF pulse, when the magnetization of proton are 
oriented in the transverse plane, the value of Mz  will be zero (Figure 2.10C2). By 
contrast, MXY reaches its maximum because each proton precesses at the same 
frequency and is synchronized at the same point or phase of its precessional cycle 
(Figure 2.10C3). 
 
After excitation, the nuclei will undergo the relaxation process, i.e. emit energy 
and return to their equilibrium state (Figure 2.10D1). There are two different 
relaxation pathways. The first is called longitudinal relaxation and involves 
energy loss so that the net magnetization (Mo) returns to its initial equilibrium 
state along Z axes (Figure 2.10D2). The longitudinal relaxation time (T1), also 
called spin-lattice relaxation time, is a consequence of energy transfer between the 
excited proton (“spin”) transfers its energy to its surroundings (“lattice”) like 
nearby molecules. It is noticeable that this type energy transfer no longer 
contributes to the spin excitation.51 The relaxation time T1 is defined as the time 
required for Mz to return to 63% of its original value following an excitation pulse 
(Figure 2.10D3).51 
 
Transverse relaxation is the other relaxation pathway and involves the induced 
magnetization in the perpendicular plane (Mxy) and involves the loss of coherence 
of the proton spins in the XY plane (Figure 2.10D4). Transverse relaxation time T2 
is defined as the time when the transverse magnetization decays to 37% of its 
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original value after an excitation RF pulse (Figure 2.10D5).51 Transverse 
relaxation is also referred as spin–spin relaxation, involving the energy transfer 
from an excited proton to another nearby proton.51 Indeed nearby proton of the 
same type having the same molecular environment and the same ω0, can readily 
absorb the energy that is being released by its neighbour, get excited and then 
transfer this energy to another neighbouring spin. In a T2 relaxation process, the 
absorbed energy remains as spin excitation rather than being transferred to the 
surroundings in contrast of a T1 relaxation process. This fluctuation produces a 
gradual, irreversible loss of phase coherence to the spins as they exchange energy 
and reduce the magnitude of the transverse magnetization. Another additional 
mechanism for the loss of phase coherence arises is called T2* arises from the fact 
that a proton never experiences a 100% homogeneous magnetic field. The 
fluctuating local magnetic field causes a change in ω0 and a loss in transverse 
phase coherence. This nonuniformity in B0 comes from three sources:  
i) main field inhomogeneity related to imperfections in magnet manufacturing.  
ii) sample-induced inhomogeneity, e.g. differences in the magnetic susceptibility 
or degree of magnetic polarization of adjacent tissues (e.g., bone, air) will 
distort the local magnetic field near the interface between the different tissues. 
iii) Imaging gradients generated by a technique used for spatial localization 
generates a magnetic field inhomogeneity that induces proton dephasing. 51  
 
In a T1-weight image, the repetition time (TR) is set short relative to T1. Under 
these conditions, the water hydrogen’s with long T1 are not given time to relax 
back to equilibrium before the next pulse of radiofrequency energy is applied, 
therefore the signal get saturated and signal observed is reduced. Thus in an image, 
water in tissues with short T1 appears brighter than water in tissues with long T1. 
In a T2-weighted image, the echo repetition time (TE) is set long relative to T2. 
Water protons with short T2 lead to signal loss and gives dark contrast image. 
Since there is often little difference in relaxation time between healthy and 
pathological tissues, additional supplements known as contrast agents are often 
necessary in order to improve the accuracy of detection and diagnosis.52  
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2.4.4.2. T1 Contrast Agent 
 
In practise, all MRI contrast agents alter both T1 and T2. However, T1 contrast 
agents alter the longitudinal relaxation rate T1-1 more than transverse relaxation 
rate T2-1. The result is that tissue containing contrast agent appears brighter than 
before (hypointensity). Most intravenous contrast agents currently in clinical use 
are T1 relaxation agents. The formulations consist of one or more paramagnetic 
metal ions, typically gadolinium.  
 
 
Figure 2.11  Exchange of water molecules in the coordination sphere of a metal ion (Mx+) 
surrounded by ligand. The chelate molecule causes steric hindrance around the metal ion, 
restricting its access. An excited water molecule is small enough to reach the inner sphere and 
transfer its energy to the metal ion and becomes unexcited. Modified from ref.51. 
 
As mentioned above, T1 relaxation depends upon the “lattice” or surroundings 
receiving the energy from the protons have absorbed from the RF excitation pulse. 
The primary mode of operation for T1 contrast agents can be seen a relaxation sink 
for the water protons. When an excited water molecule diffuses and gets close to 
the paramagnetic metal ion, it transfers energy to the metal ion and becomes 
unexcited (Figure 2.11).51 The water molecules which gave its absorbed energy to 
the contrast agent will further exchange energy with other water molecules. This 
diffusion/exchange occurs very rapidly, ~106 times per second, ideally enabling 
the bulk tissue water to relaxed back to equilibrium before the subsequent 
excitation pulse is applied. In addition, the coordinated ligands around metal ions 
are relatively large and cause a steric hindrance. For this reason, the energy 
transfer between water molecules and contrast agent occurs most efficiently when 
the protons are close to the metal ion. This is one of the factors that induce the 
O
HH
O
HH 
low energy state 
high energy state 
Mx+ 
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contrast between different tissues. For example, it is difficult for the protons of 
large molecules such as fat to get close to the metal ion for efficient energy 
transfer. In contrast, protons on water molecule are able to diffuse into the 
coordination sphere of the metal ion and transfer its energy, after which it can 
exchange energy with the bulk tissue water molecules, enabling additional water 
molecules to enter the coordination sphere. The effect is a much more efficient 
energy transfer than with large hydrocarbon molecules.  
 
 
Figure 2.12 Electron configuration and spin-only effective magneton numbers of metal ions, µB is 
the Bohr magneton, closely equal to the spin magnetic moment of a free electron.29, 50 
 
The Gadolinium (Gd3+)-based agents are most widely used T1 contrast agent 
because Gd3+ has seven unpaired electrons resulting a high magnetic moment and 
its relatively slow electronic relaxation rate (Figure 2.12). 52-53 Other transition 
metal ions are used alternatively as T1 contrast agents include manganese (Mn2+), 
iron (Fe3+), and copper (Cu2+) ions. Due to the toxicity of metal ions, the contrast 
agents are usually in the form of ionic complexes with chelating ligands. For 
example, Gd-DTPA (Magnevist) is a widely used Gd based T1 contrast agent and 
its chemical structure is displayed in Figure 2.13. It is the first contrast agent 
introduced in clinical practice in which the octa-coordinating DTPA ligand wraps 
around the Gd3+. The ligand encapsulates the gadolinium, resulting in a high 
thermodynamic stability and kinetic inertness with respect to metal loss. All 
commercialized gadolinium compounds exhibit similar features: eight coordinate 
ligands plus a single water molecule bound to gadolinium. The coordinated water 
molecule is responsible for a rapid chemical exchange with solvating water 
Ion 
64Gd3+
Electron Configuration 
3d 4f 
Magnetic 
Moment 
(µB) 
25Mn2+ 5.92 
26Fe3+ 5.92 
29Cu2+ 1.73 
7.94 
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molecules leading to a catalytic effect whereby the Gd complexes are able to 
effectively shorten the T1 relaxation times of the bulk solution.  
 
 
Figure 2.13 The chemical structure of Gd-DTPA compound.53  
 
After administration, the paramagnetic ions complexes based T1 contrast agents 
are easily excreted from the patients’ body resulting in very short life spans in the 
body after having worked in a nonspecific manner. Most T1 contrast agents reside 
within the extracellular space, and usually interact with the blood. Therefore they 
have limitations to be used as MRI probes of targeting and long time tracking 
functions.50  
 
Very recently, the nanostructured T1 contrast agents have attracted intense 
attention. They are promising candidates as they only retaining the positive 
contrast function, but have very efficient relaxivity because the surface of the NPs 
contains a large number of metal ions with high magnetic moment.54 In addition, 
nanostructured size also allows more efficient intracellular uptake and 
accumulation, as well as having longer circulation time in the body. Furthermore, 
nanostructured materials have large surface area that is suitable for surface 
modification and labelling with for example disease-specific biomarker. The 
nanostructured T1 contrast agents can be classified into two categories:54 the first 
category is nanostructured materials immobilized with a large number of 
paramagnetic ions like Gd3+. Such nanostructured materials have been 
investigated include dendrimers, liposomes, silica and carbon nanotubes, which 
act as framework to be either loaded or surface conjugated with paramagnetic ions 
or their complexes.55-56 The other class of nanostructured T1 contrast agents is 
inorganic NPs with surface functionalized with biocompatible materials. Typical 
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examples include Dextran, PEG coated Gd2O3,57 GdPO4,58 MnO,59 GdF3 NPs,60 
graphitic carbon-PEG coated FeCo NPs.61 
 
2.4.4.3. T2 Contrast Agent 
 
In contrast to T1 contrast agents, T2 contrast agents increase T2-1 dominantly. The 
reduction in the water protons T2 relaxation time is induced by the local magnetic 
inhomogenities created by the local magnetic moment of T2 contrast agents, 
leading to a rapid dephasing of proton spins in XY plane. Consequently, the 
presence of T2 contrast agents in tissues produces a reduction in signal intensity 
resulting in a dark contrast image (hyperintensity). T2 contrast agents are normally 
based on magnetic NPs.36, 45-46, 50, 62-69 Because of their particulate structure, they 
have advantages over conventional T1 paramagnetic complex contrast agent, such 
as efficient uptake by both macrophage and non-phagocytic cells, and large 
surface area ready for surface functionalization with biological probes like 
antibodies, oligonucleotides for targeted imaging purpose. Superparamagnetic 
iron oxide particles (SPIO) are classic examples of T2 contrast agents, which have 
been widely investigated as MRI molecular and cellular imaging probes since 
their first use as MRI contrast agent about 20 years ago.52 Since the size of 
particles is the main factor that controls their bio-characteristics, such as blood 
half-life and biodistribution, they can be classified by size into three categories:50, 
70  
i) micro-sized paramagnetic iron oxide NPs (MPIO, > 200 nm),  
ii) superparamagentic iron oxide NPs (SPIO, < 50 nm),  
iii) ultra small superparamagentic iron oxide NPs (USPIO, < 50 nm), 
Each of them has their main imaging applications. 
 
MPIO are iron oxide particles with a large diameter normally over 200 nm. Their 
main applications are for exploration of gastrointerinal tract due to their large size. 
70 MPIO NPs convey an amount of iron per particle that is orders of magnitude 
greater than ultrasmall iron oxide NPs. Therefore they are able to cause a local 
magnetic field inhomogeneity extending for a distance roughly 50 times their 
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physical diameter. Advantageously, MPIO NPs are less susceptible to non-specific 
uptake by endothelial cells than smaller NPs. Finally, MPIO NPs clear rapidly 
from the blood circulation which results in minimal background contrast. Due to 
these advantages, MPIO NPs have also been exploited as MRI probes conjugated 
with antibody for in vivo detection endothelial vascular cell adhesion molecule-1 
which is one of the key mediators of leukocyte recruitment associated with acute 
brain inflammation in a mouse model. 71 
 
 
Figure 2.14 MR images of liver metastases: T2-weighted MR image without Feridex (A) and with 
Feridex (B). Lesions are indicated by arrows. (Reproduced with permission from (72). Copyright 
2001, Radiological Society of North America.) 
 
The most widely used T2 contrast agent are SPIO NPs, which are 
superparamagnetic iron oxide (e.g. Feridex I.V.®, Resovist®) with diameters 
greater than 50 nm. The usual clinical targets of SPIO have been liver, spleen, 
bone marrow, because of the efficient phagocytosis of SPIO by the macrophages 
which are abundantly located in those organs.73-75 For the instance with the 
detection of liver disease, the normal liver architecture is destructed by a hepatic 
disease, such as a primary liver tumour or liver metastasis, this region lacks 
macrophages known as Kupffer cells. Consequently the pathological tissue takes 
up less SPIO and therefore in the image appears brighter compared to healthy 
liver tissues. Typical MR images of liver metastases are presented in Figure 2.14 
to illustrate the efficiency of SPIO as a contrast agent. Figure 2.14A shows 
T2-weighted MR image without contrast agent containing two mildly hyperintense 
focal liver lesions as indicated by arrows. In comparison, Figure 2.14B under the 
contrast enhancement of Feridex displays additional small metastases that are not 
A B
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apparent in Figure 2.14A as indicated by arrows. The main disadvantage of SPIO 
is their rapid clearance by the reticuloendothelial system which leads to a short 
blood circulation time and limits SPIO’s capacity to be used as molecular and 
cellular targeting MRI probes in vivo.  
 
 
Figure 2.15  Schematic drawing of mechanism of lymph nodes MRI using USPIO NPs (A). (B) 
Clinic MRI of nodal abnormalities in patients with prostate cancer: as compared with conventional 
MRI (B1), MRI obtained 24 hours after the administration of USPIO NPs shows a homogeneous 
decrease in signal intensity due to the accumulation of USPIO NPs in a normal lymph node 
indicated by arrow (B2), MRI with USPIO NPs demonstrates two hyperintense foci (B3) within 
the node, corresponding to 2-mm metastases. (Reproduced with permission from (76). Copyright 
2003 Massachusetts Medical Society.)  
 
USPIO are superparamagnetic iron oxide (e.g. Cambidex®) with size less than 50 
nm. Like SPIO, USPIO are also used for macrophage-specific MR imaging since 
they can be selectively ingested by macrophages which are located in the organs 
of the mononuclear phagocyte system, i.e. bone marrow, lymph nodes, liver and 
spleen or by migrating macrophages.76-79 However, USPIO NPs have longer blood 
circulating life than SPIO NPs, primarily because they accumulate less in the 
reticulo-endothelial system due to their smaller size than SPIO. This makes them 
very useful in lymph nodes imaging application. The resulting longer blood 
A B1
B2
B3
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circulating life allows USPIO NPs to be extravazated from the blood vessels into 
interstitial spaces, from which they are transported to lymph nodes through 
lymphatic vessels. Within normal lymph nodes tissue, USPIO NPs accumulate 
through phagocytosis by nodal macrophages and induce a reduction in signal 
intensity in T2 weighted image. However, if a lymph node contains metastases, 
there will be a limited hypointensity within metastases tissue due to the lacks of 
nodal phagocytosis of USPIO NPs. This produces contrast between normal lymph 
nodes tissue and metastases (Figure 2.15A). 
 
Weissleder et al reported a successful detection of lymph-node metastases in 
patients with prostate cancer using USPIO. As compared with conventional MRI 
(Figure 2.15B1), MRI obtained 24 hours after the administration of USPIO NPs 
shows a homogeneous decrease in signal intensity due to the accumulation of 
USPIO NPs in a normal lymph node indicated by arrow (Figure 2.15B2). MRI 
with USPIO NPs demonstrates two hyperintense foci within the node, 
corresponding to 2-mm metastases (Figure 2.15B3). 
 
2.5. Conclusion 
 
This chapter presented an overview of the general features and unique physical 
and chemical properties of inorganic nanoparticles (NPs) and their biomedical 
applications. Quantum dos (QDs) and gold NPs are introduced as representative 
examples of non-magnetic NPs in the first half of this chapter. QDs, due to their 
size and composition tunable fluoresce emission (ranging from visible to infrared 
wavelengths) have been widely investigated as fluorophore probes for optical 
biological imaging including in vivo imaging. They have great potential in 
non-invasive disease diagnosis application. Gold (Au) NPs have attracted huge 
attention as optical probes for biological imaging, due to their SPR (surface 
plasmon resonance) enhance scattering and fluorescence properties. In addition, 
the photothermal property of Au NPs attributed to the strong light absorption as a 
result of the SPR, makes them promising candidates for photothermal cancers 
treatment and as thermal sensitive drug carriers.  
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This PhD thesis focuses on the synthesis and biomedical application of iron 
platinum alloy magnetic NPs as MRI contrast agent. Therefore, the second half of 
this chapter focused on the basic principles of magnetic properties including the 
origins of magnetism, magnetic properties in the bulk materials and special 
magnetic features of magnetic NPs. Due to the unique magnetic properties of 
magnetic NPs and their ability to function at the cellular and molecular level of 
biological interaction, magnetic NPs have attracted tremendous research interest 
as revolutionary diagnostic and therapeutic tools in biomedical applications 
including magnetic separation, magnetic targeting, hyperthermia, and especially 
as contrast agents for magnetic resonance imaging. MRI contrast agents depend 
upon altering the longitudinal (T1) or transverse (T2) relaxation time of water 
protons, and can be divided into two general groups i.e. T1 or T2 contrast agent 
depending on which relaxation is the dominate effect. Magnetic NPs can 
significantly shorten the T2 relaxation time of water protons by producing local 
magnetic moment inhomogenities, resulting in hyperintensity. Magnetic NPs 
based T2 contrast agents have advantages over conventional T1 paramagnetic ionic 
contrast agent, such as efficient uptake by both macrophage and non-phagocytic 
cells, and large surface area ready for surface functionalization with biological 
probes like antibodies, oligonucleotides for targeted imaging purpose.  
 
Iron platinum (FePt) NPs have emerged as an important class of magnetic 
material with high Curie temperature, saturation magnetic moment and 
magneto-crystalline anisotropy. FePt NPs are promising candidates for a new 
generation of magnetic nano-material. Over the course of this PhD thesis, the 
synthesis, characterization and functionalization of FePt NPs and their application 
as MRI contrast agent were investigated. In next Chapter, a short literature review 
of synthesis, characterization, functionalization of FePt magnetic NPs will be 
presented.  
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Chapter 3 
 
 
Background of FePt Magnetic Nanoparticles 
 
 
 
3.1. Introduction to FePt Magnetic Nanoparticles 
 
The 2nd chapter presented the main characteristics of nanoparticles and then 
provided an introduction to magnetic nanoparticles together with their main 
properties and applications. This 3rd chapter aims at introducing the reader to FePt 
nanoparticles which, over the course of this PhD, has been the key-material used 
in view of developing a platform for biomedical applications. After having 
justified the choice of FePt as a starting material, this chapter will briefly review 
the main “wet” chemistry pathways used to synthesize FePt NPs, followed by the 
main coating options available to use FePt nanoparticles for biomedical 
applications. Advantages and drawbacks of each approach will be briefly 
discussed in each section.  
 
 
Figure 3.1 Number of publications on iron oxide and iron platinum from year 1995 to 2010. This 
search was carried out through ISI web of Science.1  
 
0
2
4
6
8
10
12
1995 2000 2005 2010
Iron oxide
Iron platinum
N
um
be
r o
f p
ap
er
s 
(X
10
2 )
Year
Chapter 3. Background of FePt                                            Shu Chen, St Andrews 
 
 
 
42
Interest in FePt nanocolloids is fairly recent as compared with iron oxide or cobalt 
for instance. Potentially more challenging to prepare than the above mentioned 
materials along with including the more expensive platinum, it has nonetheless 
seen a surge of activities over the past 10 to 15 years, which can nicely be 
illustrated by a straightforward search on ISI web of Science (Figure 3.1) with a 
simple set of keywords.1  
 
Table 3.1 Some intrinsic magnetic properties for selected materials. Tc: Curie temperature, Ms: 
saturated magnetization, K: magnetocrystalline anisotropy and Dc: estimated or reported single 
domain particle diameter, Dp is the thermally stable grain diameter over 10 years storage time at 
300 K.  
Material Crystal Symmetry 
Tc (K)  
(bulk) 
Ms 
(emu/cm3) 
bulk 
K 
(1*106 
J/m3) 
Dc (nm) 
Dp 
(nm) Ref 
Fe bcc 1043 ~ 1700  ~1 15 -- 2-3 4 
Co hcp 1390 ~ 1400  0.45 ~ 35-60 8.0 
2-3, 
5-7 4 
Ni fcc 631 ~ 510  ~ 0.08 55 -- 2-3 4 
FePt fcc, fct 585 (fcc) 750 (fct) 
-- 
1140 
-- 
6.6-10 
-- 
~340 
-- 
2.8-3.3 
2-3, 
5-6, 8 
CoPt fcc, fct 840 ~ 800  4.9 ~610 3.6 
2-3, 
5-6 
γ-Fe2O3 fcc 848 ~ 450-490 ~ 0.035 30 -- 2, 7 
Fe3O4 fcc 858 ~ 480-520 ~ 0.1 128 -- 2-3 
Fe14Nd2B tetragonal 585 1270 4.6 ~ 230 3.7 6 
SmCo5 hcp 1000 910 11-20 
~ 
710-960 2.2-2.7 
6-7 
-- Values could not be found in the literature. 
 
FePt is a bimetallic alloy material comprised of both iron and platinum. It has 
relatively high Curie temperature, Tc: 750 K (Table 3.1), which is much higher 
than room temperature. The saturated magnetization Ms is comparable to Fe and 
Co and about 3 times higher than iron oxides. The magnetocrystalline anisotropy 
K is one of the highest among hard magnetic materials of the order of ~1–10 106 
J/m3 (Table 3.1). This large K value observed for FePt alloys is explained by Fe 
and Pt interactions originating from spin-orbit coupling and the hybridization 
between Fe 3d and Pt 5d states.9 The grain diameter, Dp can go down to ~2.8 nm 
at 300 K.6 This makes FePt a promising candidate for ultra-high density recording 
media with the potential to reach an areal density as high as 10 Tbits/in2 and 
above,10 if NP magnetic interactions at such a small length scale can be controlled 
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to guarantee the integrity of the stored information. In addition, FePt is thought to 
have higher chemical stability as compared to single metallic material like Fe and 
Co, as well as the other large coercive materials like SmCo5 and Nd2Fe14B, which 
makes it attractive for biomedical applications.9 While the chemical stability will 
be discussed further in chapter 6, selected intrinsic magnetic properties of some of 
the most common magnetic materials are shown in Table 3.1 for comparison 
purposes.  
 
 
Figure 3.2 Schematic drawing of (A) face centered cubic (fcc) crystal phase FePt and face 
centered tetragonal (fct) FePt.  
 
Depending upon the Fe to Pt elemental ratio, iron-platinum materials can display 
a complex phase diagram including chemically disordered face centered cubic (fcc) 
phase or chemically ordered phases, such as L12 for Fe3Pt, face centered 
tetragonal (fct) phase (L10) for FePt and L12 for FePt3. While these crystalline 
structures can be influenced by the fabrication methods, they present dramatic 
variations in the magnetic properties of the alloys. For example, the L12 Fe3Pt 
material is ferromagnetic, the fcc FePt is superparamagnetic, the L12 FePt3 is 
antiferromagnetic, while the fct-L10 structured FePt shows strong ferromagnetic 
properties. Among these, the most investigated FePt crystal phase are fcc and fct 
phase FePt (Figure 3.2).  
 
In the fcc phase, iron and platinum atoms are chemically disordered (Figure 3.2A), 
the material is a magnetically soft alloy, which means that it has very small 
coercivity and remanence, when the size of the material is decreased it becomes 
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superparamagnetic at room temperature. In contrast, the fct-structured FePt is 
chemically ordered and can be viewed as alternating atomic layers of Fe and Pt 
stacked along the c axis direction (Figure 3.2B). The fct FePt is a hard magnetic 
material, and its coercivity can reach values as high as ~2 T.6 The fct crystalline 
structure can be obtained after annealing of fcc-FePt material and is consequently 
the thermodynamically stable phase; however both phases of FePt have great 
potential for biological applications. 
 
3.2. Review of Solution Chemical Syntheses of FePt Nanoparticles 
 
The preparation of homogenous colloidal nanoparticles with desired composition, 
size, and crystal phase is a key-concern for researchers using wet chemistry 
methods and this has consequently received tremendous attention for a wide range 
of nanocolloids. There are various techniques for producing colloidal 
nanoparticles and generally they are classified as either physical or 
chemical-synthetic methods. Larger volumes of product could potentially be 
produced by physical methods, the ball milling method11 or pulsed plasma 
chemical vapor synthesis for example,12 which would be commercially attractive. 
However, chemical routes often provide better control over the particle size, shape, 
composition and crystallinity; all of which in return impact on researchers abilities 
to tune the NP properties. In addition, surface modifications of the particles during 
or after synthesis is relatively easily achievable and provides numerous 
opportunities to combine additional but essential functionalities to fit specific 
applications.  
 
The chemical synthesis of FePt NPs can be divided into two main classes for the 
sake of argumentation. The first one normally requires the reaction to be completed 
at a high temperature of the order of ~300 ºC if not above (thermal decomposition 
pathway), while the 2nd is carried out at temperatures close to room temperature 
(amphiphilic method). It is however noticeable that these approaches generally lead 
to fcc crystalline structures; whereas the direct synthesis of well dispersed fct-FePt 
is still rather challenging at present.13-14 A compensatory protocol is to subsequently 
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anneal fcc-FePt NPs which can be obtained directly through most solution synthesis 
protocols to induce a phase transfer towards the fct crystalline phase at temperatures 
normally above 500 ºC.9, 15-17 In addition to the high temperature, the composition 
of the initial alloy is an essential factor to achieve fcc-fct phase transfer, which 
requires 40 < x < 60 in FexPt100-x.18-20 Over the past few years, the annealing 
methods of FePt nanomaterials have gone through tremendous evolution, including 
for instance the use of a salt matrix,21-24 or the use of a doping agent to reduce the 
annealing temperature.25-30 However for this review chapter to remain concise, FePt 
nanocolloids obtained after annealing will not be described in depth and the reader 
will be referred to the relevant literature.14, 18, 31-45 Instead, it will be focused on the 
nanoparticle syntheses themselves.  
 
3.2.1. High Temperature: Thermal Decomposition and Reduction  
 
3.2.1.1. “Conventional” Thermal Decomposition 
 
The first very successful synthesis of monodispersed FePt NPs was reported by 
Sun et al in 2000,46 potentially triggering further interest for this material. This 
synthesis is based on the reduction of platinum acetylacetonate Pt(acac)2 by a mild 
reducing agent 1,2-hexadecanediol and the thermal decomposition of iron 
pentacarbonyl, Fe(CO)5 in a high boiling point solvent such as benzyl ether and 
octyl ether (Figure 3.3A). The synthesis was carried out at ~300 ºC, in the 
presence of stabilizers such as oleic acid and oleylamine. To describe the interplay 
between the precursors and the ligands, the general consensus is that carboxylate 
groups tend to bind to Fe atoms as a chelate ligand via monodentate or bidentate 
configuration, whereas amine molecules interact primarily with Pt atoms (Figure 
3.3B).9 The long alkyl chains from both capping agents provide a steric blocking 
effect to stabilize FePt NPs. A typical TEM image of synthesized 6 nm FePt NPs 
is shown in Figure 3.3C. The composition of NPs is controlled by changing initial 
molar ratio of Fe to Pt precursors, e.g. a 2:1 molar ratio yielded Fe52Pt48, and a 4:1 
ratio produced Fe70Pt30.46 These parameters (precursors, ligands, solvents, 
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temperatures) have mostly become standards with little variation from one 
research group to another.41, 47-49 Oleic acid and oleylamine are now the ligands 
used as standards in several syntheses completed in non-polar, alkyl media 
including benzyl ether and octyl ether. 
 
 
Figure 3.3  Schematic illustration of FePt nanoparticle formation through the decomposition of 
Fe(CO)5 and reduction of Pt(acac)2 (A). The schematic of binding of alkyl carboxylate and 
alkylamine molecules to a FePt nanoparticle (B).9 (Copyright 2006, Wiley-VCH Verlag GmbH & 
Co. KGaA. Reproduced with permission.) TEM micrograph of a 3D assembly of 6 nm Fe50Pt50 
sample (C).16 (From (16), reprinted with permission from AAAS.) 
 
The main disadvantage of this protocol is the broad composition distribution of 
individual NPs. An EDX study on the composition of individual FePt NPs showed 
that only 29.0% of the NPs were within the composition range of 40 < x < 60 
(FexPt100-x), whereas 40.5% NPs were Pt rich, and 30.5% were Fe rich.13 The NPs 
nucleation and growth mechanism along with their broad composition distribution 
was investigated by a systematical study on this Fe(CO)5/Pt(acac)2/1,2- 
hexadecanediol system.50 It showed that Pt rich nuclei with a composition of 
~Fe4Pt96 (4% of Fe) formed as early as ~160 ºC, and their formation could have 
been assisted by 1,2-hexadecanediol acting as a reducing agent (Figure 3.4A1). In 
contrast, a significant amount of Fe(CO)5 could be found in vapor phase because 
of its low boiling point of 108 ºC. Whereas the decomposition temperature of 
 
A 
 
B 
 
C 
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Fe(CO)5 is around 298 ºC,51 the decomposition can be catalyzed by the Pt nuclei, 
as suggested by the Fe increase in NP, e.g. the iron content reached 15% (Fe15Pt85) 
at 175 ºC (Figure 3.4A2). While the temperature further increased up to 200 ºC, 
~4 nm NPs with an individual NP composition varying from ~ Fe14Pt86 to ~ 
Fe54Pt46 were formed (Figure 3.4A3). After 30 min refluxing, the composition 
distribution of individual NPs was reported to be narrowed from ~ Fe38Pt62 to ~ 
Fe66Pt34, which was concomitant with a further size increase up to ~4.5 nm 
(Figure 3.4A4). 
 
 
 
Figure 3.4 TEM images of FePt NPs withdrawn at 160 °C (A1), 175 °C (A2), 200 °C (A3), 256 
°C, 30 min (A4), and a schematic of the suggested particle growth mechanism used to explain the 
wide composition distribution from particle to particle (B). (Adapted with permission from (50), 
copyright 2007, American Institute of Physics.) 
 
The broad composition distribution from particle to particle is attributed to the 
significant size distribution of Pt rich nuclei initially formed at 160 ºC (Figure 
3.4A1). Indeed, since small Pt nuclei have a larger surface area per Pt atom 
compared to the large nuclei, the smaller Pt nuclei would become richer in Fe 
(Figure 3.4B).50 A later report provided further evidence showing that smaller NPs 
are indeed richer in Fe than larger ones.52 A later numerical study completed by 
Monte Carlo free energy perturbations pointed towards a thermodynamic 
preference for iron to be incorporated into the subsurface of a platinum rich 
A2A1 A3 A4
Fe4Pt96 Fe15Pt85 Fe14Pt86 to 
Fe54Pt4 
Fe38Pt62 to 
Fe66Pt34 
B 
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cluster,53 this work has however to be considered carefully as the ligands are not 
included in the simulation and these molecules are known to have a strong impact 
on the growth of the NPs as illustrated for instance in the QD research field.54-56 
Nonetheless as a consequence of the thermodynamic preference, the initial iron 
rich clusters could experience a restricted growth compared to Pt rich ones and 
end up as small iron rich NPs. This may explain the composition and size 
distribution of the NPs synthesized through this synthetic pathway.57 An extension 
of the refluxing time however allows the eventual narrowing of the composition 
likely resulting from the Fe rich clusters attaching to the larger Pt richer NPs 
probably via an Oswald ripening kind of growth.52  
 
By excluding the reducing agent 1,2-alkaediol from the reaction system, NPs size 
was increased to 6 nm, without compromising the low size polydispersity of the 
product.58 This can be attributed to a slower Pt rich nucleation in the absence of 
diol, which leads to a slower consumption of metal precursors at the nucleation 
stage.58 Illustrating the efforts made to control this relatively new nanomaterial, 
along with its challenges, it is noticeable that the NPs size can be further tuned by 
controlling not only the ratio of stabilizers to metal precursors and the growth 
temperature, but also the interim heating temperature steps and heating rate. High 
stabilizers to precursor’s ratio, low interim heating temperature steps or slow 
heating rate apparently slow down the nucleation rate and consequently favor the 
formation of larger size NPs.20, 58-60 For example, a molar ratio of at least 8:1, and 
a 15 ºC/min heating rate, and a 240 ºC interim heating temperature before 
reaching refluxing at 300 °C was required to make 6 nm size NPs. In contrast, a 
slower 5 ºC/min heating rate and a lower heating temperature 225 ºC lead to 9 nm 
size FePt NPs.58  
 
Noticeably, there are very few studies focusing on controlling the shape of FePt 
nanocrystals, however Fe(CO)5/Pt(acac)2/1,2-hexadecanediol system has been 
successfully used for this purpose; and by adjusting ligand concentration, or 
ligand adding sequence, nanowires, nanorods, hexagonal, oval-shaped and cubic 
NPs could then be obtained.61-67 These opportunities to control the NP 
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morphology is very exciting, howeve falls beyond the scope of the present short 
review.  
 
Due to the high toxicity and low boiling point of Fe(CO)5, less toxic and 
nonvolatile iron precursors, such as Fe(acac)3,37, 68-70 and Fe(OEt)3,20, 40, 71 were 
investigated for the synthesis of FePt NPs. When Fe(acac)3 is used as a precursor, 
~2 nm NPs can be obtained by using a similar experimental protocol as described 
with Fe(CO)5 /Pt(acac)2/1,2-hexadecanediol system,69-70 and size can be further 
increased to ~6 nm NPs in presence of a large excess of ligands,68 as very likely 
the complexes they form with the iron and platinum atoms decrease the NPs 
nucleation rate. 
 
 
Figure 3.5  Schematic drawing of the nucleation and growth of FePt NPs. (Reproduced with 
permission from (20), copyright 2005, American Chemical Society.) 
 
The Fe(OEt)3/Pt(acac)2 system received an in-depth consideration and was used to 
carry out detailed investigations of FePt NPs formation mechanism.20, 40, 71 It is to 
be noted that no 1,2-hexadecanediol was used in this system, and FePt NPs were 
obtained by heating the mixture of metal precursors, oleic acid, oleylamine and 
octyl ether to 297 ºC for 30 min. Results showed that > 70% NPs are in the range 
of 40 < x < 60 (FexPt100-x). The narrower composition distribution compared to 
Fe(CO)5 is believed to result from a better synchronization between thermal 
decomposition of Fe(OEt)3 and the reduction of Pt(acac)2.20 A detailed mechanism 
is presented in Figure 3.5: 
 
i) At an early stage of the heating, part of ethoxide ligands detaches from 
Fe(OEt)3 through β-hydride elimination at ~60 - 100 ºC. Fe atoms or more 
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likely Fe-ligands complexes are then generated with the surrounding oleic 
acid molecules.  
ii) Fe atoms or complexes are believed not to form nuclei, i.e. the core of the NPs 
but instead to catalyze the reduction of Pt(acac)2, this come in contrast with Pt 
nuclei catalyzing the highly stable Fe(CO)5 precursor used the more standard 
system. The reduction of Pt(acac)2 takes place at ~180 ºC. Formed 
Pt-oleyamine complexes (or Pt atoms) conversely would act as catalyst for the 
further decomposition of Fe(OEt)3. 
iii) The allelocatalytic thermal decomposition of Fe(OEt)3 and reduction of 
Pt(acac)2 accelerate at ~250 ºC. When the metal atoms reach a nucleation 
supersaturation concentration, FePt NPs start to form dominated by Pt 
nucleation and followed by a slow addition of Fe and Pt atoms to the Pt rich 
core. 
iv) It is then suggested that heating at 297 ºC favors the formation of fcc FePt NPs 
through atomic diffusion. 
 
It is noticeable that despite the earlier release of the Fe atoms, the FePt NPs 
formation mechanism in this system is still dominated by Pt nucleation and 
growth by a slow addition of Fe and Pt atoms to the Pt rich core. The stabilization 
of Fe and Pt atoms by the oleic acid and oleylamine, respectively, was confirmed 
by XPS.20 This would contribute to explain that even though Fe atoms are 
released earlier than their Pt counterpart, the core of the NPs is still Pt rich. The 
NPs size could be tuned by adjusting ligand to precursor ratio (Figure 3.5).20 For 
instance, the increase of [oleylamine]/[Pt(acac)2] decreases the Pt atoms 
concentration available for nucleation.20 Therefore, this simple parameter induces 
a decrease in the number density of Pt nuclei therefore leads to larger Pt rich core. 
In addition, reducing the number density of Pt nuclei also results in a slower 
catalytic activity on Fe precursor which could also explain the presence of larger 
Pt core. In contrast increasing [oleic acid]/[Fe(OEt)3] ratio which decreases the 
concentration of Fe atoms available for the NPs growth results in a smaller NPs 
size and Pt richer NPs composition. As a final comparison between the Fe(CO)5 
and Fe(OEt)3 systems, it is noticeable that the NPs nucleation and growth kinetics 
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differs not only due to 1,2-hexadecanediol acting as reducing agent, but also due 
the difference in physical chemistry property (e.g. valence and decomposition 
temperature) of the Fe precursors. In contrast to the potential for tuning the NPs 
growth, the ligands oleic acid and oleyamine seem to drive most of the NP growth 
mechanism as illustrated in Figure 3.4 and Figure 3.5.  
 
The composition is referred as a key-concern for FePt nanoparticles and to gain 
better control over the individual NP composition, one of the most noticeable step 
has relied on Na2Fe(CO)4, so called Collman’s reagent, to replace more 
conventional iron precusors.19, 72-73 The use of Na2Fe(CO)4 started about 4 years 
ago and in contrast with most Fe precursors, Collman’s reagent provides the Fe2- 
anion which can act as a reducing agent for Pt(acac)2, through the simple chemical 
reaction Fe2- + Pt2+ → FePt. This direct reduction of Pt2+ by Fe2- seems to favor 
the simultaneous presence of Fe and Pt in an equal molar ratio, which is essential 
to get stoichiometric FePt NPs. It was indeed demonstrated that the composition 
of 83% of the individual NPs prepared by this route lies in the range of 40 < x < 
60 (FexPt100-x).19 The experimental results showed partially fct FePt can be 
obtained by using tetracosane as a solvent when synthesis was carried out at 389 
ºC, as illustrated in Figure 3.6.  
 
Figure 3.6  XRD pattern and TEM image of as-synthesized fct-FePt nanoparticles in tetracosane 
at 389 ºC, using oleylamine as ligands. Hysteresis loops of directly synthesized fct-FePt NPs at 10 
and 290 K. (Reproduced with permission from (72). Copyright 2005 American Chemical Society.)  
 
20 nm 
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The NPs are aggregated and not uniform as indicated by TEM, but the fct 
formation is indicated by the (001) and (010) XRD peaks and the ferromagnetism 
observed at 290 K by measuring the sample magnetization when sweeping the 
magnetic field.72 Aiming at the direct synthesis of fct-FePt nanoparticles, further 
investigations were completed by the same research group. By focusing on the use 
of high boiling point solvents, it was argued that the fct phase could be formed at 
temperatures as low as 350 °C, even thought the authors only provide XRD data 
and that both magnetic and TEM characterisation critical to assess the overall 
quality of the material were not provided for these samples.19 It is also noticeable 
that fct formation only occurred when oleic acid had been removed from the 
synthetic media. Using oleic acid was said to lead to only small size NP, i.e. less 
than 3 nm, which is the size limit for the fct ordering formation.  
 
3.2.1.2. Co-reduction of Fe and Pt Precursors  
 
FePt alloy NPs can also be prepared with the co-reduction of both Fe and Pt 
precursors by a strong and soluble reducing agent like metal borohydrides in a 
reaction system similar to the reduction/thermal decomposition route at high 
temperature described previously.74-76 For example, the co-reduction of preheated 
FeCl2 and Pt(acac)2 mixture in diphenyl ether containing oleic acid, oleylamine 
together with 1,2-hexadecandiol was completed by the addition of LiBEt3H at 200 
ºC, and a refluxing at ~260 ºC for 30 min. The advantages are numerous i) the 
particle growth is self-limited with the size being independent of the amount of 
ligands, ii) the formation by-products such as Li salts with Cl- and acac- can be 
removed by using alcohol while BEt3 can be removed under nitrogen flow. 
Refluxing at 263 ºC from 30 min to 2 h would only improve the morphology of the 
NPs and resulted in 4 nm FePt NPs (Figure 3.7B) which can self organise on a TEM 
grid.75  
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Figure 3.7  Schematic illustration of FePt nanoparticle synthesis by co-reduction of FeCl2 and 
Pt(acac)2 by LIBEt3H at ~260 ºC, in the presence of oleic acid, oleylamine, and 
1,2-hexadecanediol (A). TEM image of a 2-D array of synthesized 4 nm FePt nanoparticles (B). 
(Reprinted with permission from (75). Copyright 2003 American Chemical Society.) 
 
As will be seen later in this thesis, in contrast to either elemental analysis or 
inductively coupled plasma-optic emission spectrometry, the most convincing 
argument regarding the NP composition was the use of Rutherford backscattering 
spectrometry leading to compositions ranging between 59:41 to 61:39 Fe:Pt.75 
 
A further study showed that NPs synthesized with this superhydride method could 
have a narrower composition distribution than observed as a result of standard 
Fe(CO)5 thermal-reduction.76 The suggested mechanism of FePt NPs formation in 
this process is again based on Pt rich nuclei formed around 160 ºC,50 and FePt NPs 
grow by the incorporation of subsequently reduced Fe atoms into Pt rich nuclei. 
After the addition of superhydride at 200 ºC the reduction of the FeCl2 would be 
more instantaneous than Fe(CO)5,76 and the formation of Pt nuclei would be more 
homogenous due to the separate Pt and Fe reduction. Alternatively, LIBEt3H is a 
fairly strong reducing agent could level off kinetic differences between the metal 
precursors and thus allow better synchronization of generation and incorporation of 
Fe and Pt atoms, an interpretation based on our study on co-reduction of Fe and Pt 
in aqueous media as presented in Chapter 4.  
 
Not only powerful reducing agent like metal borohydrides, but diol or polyol 
which are milder organic reducing agent have also been used as both reducing 
agents and high boiling point solvents to produce FePt NPs.9, 32, 77-83 In that 
context, the thermal decomposition assisted by the 1,2-hexadecanediol reducing 
 A  B
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agent discussed above does not qualify for a polyol process as the 
1,2-hexadecanediol is not used as a solvent. Nonetheless, diol and polyol, which 
typical chemical structures are given in Figure 3.8A, are mild reducing agents as 
illustrated by the fact that the reduction of Fe alone in a polyol process is rather 
difficult. However, reduced Pt atoms can act as catalysts which in turn accelerates 
the reduction of Fe ions and leads to the formation of FePt alloy NPs.14, 78-79.68  
 
 
Figure 3.8  Chemical structure of typical reducing solvents used in “polyol” process (A).TEM 
image of partially ordered fct FePt nanoparticles (B). X-ray diffraction patterns of the synthesized 
at ~ 200 (fcc) and 300 ºC (fct) in tetraethylene glycol (C). Room temperature hysteresis loop for 
FePt nanoparticles synthesized at 300 ºC (D). (Adopted from (84). Copyright 2005, with permission 
from Elsevier.)  
 
It is noticeable that without oleic acid and oleylamine, formation of partial 
fct-FePt NPs with a fct ordering parameter (S) of 0.76 was observed by direct 
heating a solution containing Fe(acac)3 and Pt(acac)2 dispersed in ethylene glycol 
or tetraethylene glycol (Figure 3.8A) at 300 ºC. The partial fct order is indicated 
by the emergence of (001) and (110) peaks on the XRD spectra (Figure 3.8C), and a 
coercivity of 2.1 kOe at room temperature (Figure 3.8D).84 Not surprisingly, the 
NPs tended to aggregate as a result of not using stabilizers (Figure 3.8B). In 
addition, the NPs display a multi-domain and polycrystalline morphology which is 
made of agglomerates consisting 3-5 FePt subgrains of 2-3 nm, a structure which 
likely results from the absence of stabilizers.14 The reason behind the fct FePt NPs 
formation was suggested to be the slow reaction kinetics of Fe and Pt salts in the 
polyol system,14 even though the mechanism associated with fct phase formation 
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well below usual annealing temperature is not fully explained and understood.14, 84 
Similar uncertainties and lack of quantifiables are noticeable regarding how/if the 
solvent viscosity, radical formation and chemical structure can impact on the 
nanoparticle growth. It will be clear to the readers that the availability of such 
information could potentially allow the synthesis of fully fct ordered NPs.   
 
 
Figure 3.9 Chemical structure of PVP (poly(N-vinyl-2-pyrrolidone) (A). TEM image (B), XRD 
pattern (C) and magnetic hysteresis loop at 300 K (D) of PVP protected FePt NPs synthesized by 
refluxing at 300 ºC for 3 h. XRD patterns of FePt NPs prepared at reaction temperature from 213 
to 293 ºC (E) and corresponding hysteresis loop at 300 K (F). (Adopted from (85). Copyright 2007, 
with permission from Elsevier.)  
 
Due to the aggregation of NPs synthesized by polyol protocol, PVP 
(poly(N-vinyl-2-pyrrolidone) (Figure 3.9A) was used as a protective agent to 
improve the dispersibility of nanomaterial.85-88 PVP is widely used for other 
metals such as silver,89-90 it has a boiling point of ~250 ºC, it is thermally stable up 
to 400 ºC as suggested by thermogravimetric analysis.85 It is also a weakly 
coordinating polymer. Taking advantage of this latter property, the synthesis 
protocol is almost identical to the standard polyol synthesis method mentioned 
above, except PVP is used as a protective polymer and mixed at ambient 
temperature with the metal precursors from the beginning of the synthesis. The 
NPs obtained after 3 hours at 300 ºC are ~5 nm in diameter, and seem to be better 
dispersed on a TEM grid than those obtained with the conventional polyol process 
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even though the NPs remain polydispersed in size and shape (Figure 3.9B).  
 
As for the conventional polyol process, formation of partially fct FePt with a fct 
ordering parameter (S) of ~0.5 is also observed as indicated by the two weak 
superlattice peaks of (001) and (110) planes at 24º and 33º respectively (Cu source) 
(Figure 3.9C). S is smaller and the coercivity is of ~750 Oe at 300 K which is 
about two thirds smaller than what has been reported for the polyol products 
(Figure 3.9D). The size of NPs could be tuned by adjusting the PVP to precursors 
molar ratio, the refluxing time and the reaction temperature. A later study showed 
that partially fct FePt can be obtained at ~260 ºC (Figure 3.9E) and small 
coercivity of ~20 Oe at room temperature (Figure 3.9F).86  
 
In that report the coordination of PVP to precursors ions was suggested to be 
responsible for the fct direct synthesis. Implicitly this would then coincidently add 
up to the previously mentioned hypothesis of slow reaction kinetics of Fe and Pt 
salts in the polyol system which did not contain any PVP. In contrast with the 
standard thermal decomposition approach and its thorough step by step aliquots 
size and composition characterization, very little information is actually available 
in polyol system to quantify and fully understand the effect of temperature on the 
nanoparticles growth. A similar statement could be made regarding the kinetics 
(Fe, Pt, Fe-Pt) in polyol system, how these kinetics would impact on the NPs 
crystal structure and much they differ from a “standard” thermal decomposition 
approach. It is also difficult to comment on the specific effect of PVP on fct FePt 
formation, as very few thorough data have been reported so far and as a 
consequence, it is difficult to make a comparison between the polyol systems, 
including PVP and excluding PVP, to assess whether PVP could contribute to 
trigger the fct FePt formation at temperatures lower than 300 ºC.  
 
To the best of our knowledge the hypotheses put forwards have not been fully 
tested but certainly call for more attention in the future. The TEM pictures of 
polyol FePt NPs certainly do not look as nice as self-assembled fcc NPs, however 
the direct formation of fct phase in the solution phase is exceptional in itself, at 
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relatively low temperature is a 2nd exception. These evidences certainly set aside 
the polyol protocols when dealing with FePt solution syntheses and once the 
direct fct growth mechanism(s) will be better understood, there will be plenty of 
opportunity to address the cosmetic appearance of the NPs.  
 
3.2.2. Low temperature: Co-reduction in Amphiphilic System 
 
Temperature is certainly an essential parameter to produce nanocolloids. As 
illustrated above, it can be used as a trigger to provide plenty of exciting results. If 
there is a chance to obtain similar or the same outcomes at room temperature, this is 
certainly worth the effort which has been developed in water based media.  
 
 
Figure 3.10  Schematic drawing of a metal reduction reaction in an amphiphilic system through 
water content exchange between water droplets stabilized by surfactants (A). Representative TEM 
image of FexPt1-x NPs as synthesized by a water/CTAB/butanol/octane system (B),91 (Reprinted 
with permission from (91). Copyright2000, American Institute of Physics) a 
water/triton/cyclohexane system (C),92 (Adopted from (92). Copyright 2007, with permission from 
Elsevier.) and water/Brij52(or Brij56)/butanol/isooctane (D),93 (Copyright 2006, Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with permission.) respectively.  
 
Briefly, an amphiphilic molecule (surfactant) is composed of two antagonist parts 
having opposite solvent affinities. For instance a polar part (ion, sugar, methyl 
oxide, etc) associated with another apolar part (alkyl chain either hydrogenated or 
fluorinated) force the surfactants to sit at the interface of two antagonist liquids. 
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Amphiphilic system is often composed of two immiscible phases, i.e. water and oil, 
stabilized by interfacial film of surfactant molecules.3 These compartments can be 
taken advantage of to control chemical reactions through the exchange of water 
content when water droplets collide, coalesce and separate again when subject to 
Brownian motion (Figure 3.10).94  
 
For instance, when a water-in-oil amphiphilic solution containing a dissolved metal 
salt is mixed with a second solution containing a reducing agent, the metal ions can 
be reduced to the metallic state and form nanoparticles. Amphiphilic systems have 
been widely and successfully applied to nanoparticles ranging from metals, such as 
silver and copper, to semiconductor and magnetic materials, such as cadmium 
sulfide and Cobalt,95-102 providing control over both size and shape of the NPs. In 
the regards to FePt NP, it is noticeable that there have been only very few reports 
published so far on the use of amphiphilic system for FePt NP synthesis,30, 91-92, 96, 
103-107 and very few of these provided insight into compositional variations between 
individual NPs which has been demonstrated to be a challenging element for FePt 
NPs synthesis through thermal decomposition methods.  
 
Among these reports, the co-redution of FeCl2 and H2PtCl6 (the specific salts are 
not stated in the publication but obtained by contacting the corresponding author) 
were carried out in a water/CTAB/butanol/octane system leading to FePt NPs of 10 
nm in diameter and with a apparent composition determined by EDX following the 
initial molar ratio of precursors in the system.91 In addition, FeCl2/H2PtCl6 
/hydrazine in a water/triton/cyclohexane system led to 3.7 nm (FePt) and 8.4 nm 
(FePt3) NPs obtained depending on the initial molar ratio of precursors. TEM 
associated with both studies show polydispersed and aggregated NPs, while no 
detailed composition data was presented in the paper.92 A potentially more 
successful study relied on FeCl3/K2PtCl4/anhydrous hydrazine mixed in 
water/Brij52(or Brij56)/butanol/isooctane solution leading to well dispersed NPs 
which size between 8 and 20 nm was apparently controlled by adjusting the 
hydration of the surfactant. While the composition appeared by EDX analysis to 
follow the initial precursors molar ratio,93 no detailed nanometer scale EDX data 
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was presented.  
In views of its potentials for room temperature FePt NPs synthesis and its flexibility, 
the water/Brij52/butanol/isooctane system was investigated as part of my PhD 
study. A detailed investigation on individual NP composition and NP formation 
mechanism in aqueous media are presented in Chapter 4.108 
 
3.3. FePt NPs Surface Functionalisation for Biomedical Purposes 
 
Due to their high surface energy, uncoated nanoparticles tend to aggregate in 
solution.3 It is then necessary to introduce a chemical coating around the NP 
surface to stabilize the colloid. For medical purpose, an ideal surface coating 
should satisfy the following basic requirements:  
i) Providing water solubility;  
ii) Preventing NPs from aggregation; 
iii) Maintaining the chemical stability of the NPs, e.g. preventing oxidation, metal 
etching in physiological environment; 
iv) Providing the biocompatibility of NPs,  
v) Allowing further bio-Functionalisation like drug or targeting ligand 
attachment.3, 109-112 
 
3.3.1. Molecular Coating 
 
Steric repulsion, electrostatic repulsion or a combination of both can be used to 
stabilize NPs,109, 113 or even extract the NPs from a liquid media.114 After synthesis, 
FePt NPs are often coated with oleic acid and oleylamine which are not soluble in 
aqueous solution. (Figure 3.11A) Using hydrophobic interaction is a common 
strategy to transfer hydrophobic NPs into water soluble colloids (Figure 3.11E).  
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Figure 3.11  Schematic drawing of typical surface Functionalisation strategies on as-synthesized 
hydrophobic magnetic nanoparticles (A) towards biomedical applications by hydrophobic 
interactions (A) and ligand exchange protocol (C-D).   
 
Water soluble FePt NPs can be prepared by adding amphiphilic phospholipids 
(DSPE-PEG(2000)carboxylic acid lipid, 1,2-distearoyl-sn-glycero-3-Phosphor 
ethanolamine-N-[carboxy(poly-ethylene glycol)-2000].115 The phospholipid forms 
a bilayer structure with the long hydrocarbon chains of both oleic acid and 
oleylamine. The poly-ethylene glycol group provides excellent water solubility 
and stability and –COOH group at the end of phospholipid allows further 
chemical conjugation. However, the potential drawback of this approach is that 
the coating can be sensitive to environmental conditions.116 The collapse of the 
bilayer might exposure potentially toxic ligands like oleic acid and oleylamine 
and the metallic core to the biological environment, which in an interesting twist 
can be used to develop targeted therapy for tumour inhibition.115, 117  
 
Ligand exchange protocol is another popular protocol, which often takes 
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advantages of the affinity of the ligand binding to the surface of the NPs. For 
instance, thiol provides stronger bonding to iron and platinum than carboxylic 
acid and amine.118-119 Therefore, original oleic acid and oleylamine coatings can 
be replaced with ligands or polymers which contain thiol in the chemical structure. 
In this context, it has been demonstrated that FePt NPs can be coated with 
carboxylic acid group terminated mercapto ligand like 11-mercaptoundecanoic 
acid (Figure 3.11B),119 N-[Nα,Nα-Bis(carboxymethyl)-L-Lysine]12-Mercaptodo- 
-decanamide,120 or amine terminated mercapto ligand like cysteamine (Figure 
3.11C).117, 121-122 These ligands not only make the FePt NPs soluble and stable in 
water solution through electrostatic repulsion but also allow further surface 
Functionalisation with either covalent or non-covalent conjugation of biological 
molecules or proteins. 116, 123-124 Alternatively, FePt NPs can also be coated with 
polyethylene glycol(PEG)-terminated thiol (Figure 3.11D) 125 the resulting NPs 
are appealing for use as long circulating drug carriers or imaging probes which 
would be able to avoid fast clearance by the Reticuloendothelial System (RES) 
due to the stealth effect provided by PEG coating, as described in Chapter 2. 
 
3.3.2. Thin Film Coating 
 
Stability is a crucial requirement for magnetic nanoparticles, especially as pure 
metals, including Fe, Co, and Ni are sensitive to oxidation. Although metal alloy 
NPs show higher stability against air exposure than pure metal NPs, surface 
oxidation of the NPs can still happen and can result in loss of magnetic 
moment.126-127 Therefore, it is of high interest to develop efficient strategies to 
improve the chemical stability of magnetic NP interfaces. The introduction of a 
protection layer which is chemically inert and impenetrable thus averting the 
contact of NPs surface with oxygen seems to be the most straightforward method. 
Various inorganic materials such as noble metals, graphite, silica, metal oxide 
have been exploited to serve this purpose, and some of them could also introduce 
special features like optical properties to create multifunctional NPs.3, 110, 116, 128 
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3.3.2.1. Carbon Coating 
 
The interest of using carbon material to protect magnetic NPs is justified by its 
higher chemical and thermal stability as compared to organic ligand coatings.3, 129 
The thermal stability of the carbon shell is then of special benefit to prepare 
fct-FePt NPs, which often requires high temperature annealing normally above 
550 ºC. alit was reported the preparation of FePt-carbon coated NPs obtained 
through the annealing of polymer encapsulated FePt NPs.130 The polymer 
poly(vinyl butral-covinyl alcohol-co-acetate) PVB as the carbon source supply 
was injected into the iron-platinum/ligands reaction system at about 220 ºC, then 
heated up to ~300 ºC for 3 h to obtain polymer encapsulated FePt NPs (Figure 
3.12A1).  
  
Figure 3.12  Synthetic procedure for the preparation of FePt-carbon NPs from polymer PVB 
(poly(vinyl butral-co-vinyl alcohol-co-acetate) encapsulated FePt NPs (A1), and corresponding 
TEM image (A2) FePt-carbon NPs prepared with different synthesis method involving glucose at 
900 ºC (A3).130 (Copyright 2007, Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with 
permission.) Low resolution TEM image of FePt-carbon NPs prepared through methane 
chemical-vapor deposition method (B1), and high resolution TEM image show FePt core 
surrounded by an amorphous carbon shell (B2).131 (Copyright 2008, Wiley-VCH Verlag GmbH & 
Co. KGaA. Reproduced with permission.)  
A1 
A2 
B1 
A3 
B2 
Chapter 3. Background of FePt                                            Shu Chen, St Andrews 
 
 
 
63
These NPs were further annealed at 700 ºC for another 2 h leading to both carbon 
shell formation by the decomposition of polymer and an fcc to fct phase 
conversion. However, a severe NPs sintering occured during the preparation 
procedure as indicated in Figure 3.12A2. Another synthetic method involves 
hydrothermal treatment of Fe and Pt precursors in glucose follow by calcination at 
900 ºC which could lead to better dispersed FePt NPs (Figure 3.12A3).130 
Alternatively, rather than a solution based synthesis pathway, carbon coated FePt 
can be obtained by heating a silica powder loaded with iron and platinum salts to 
800 ºC under H2, and then subject to methane chemical-vapor deposition for 
carbon film formation. 2-3 nm fct-FePt NPs were obtained as presented in Figure 
3.12B1 and B2.131  
 
In summary, even though very promising at first sight, one of the main obstacles 
for FePt-carbon NPs preparation is the often observed aggregation of the NPs. A 
low degree of understanding and control of the carbon shell formation mechanism 
might be to blame and consequently the preparation of individual and dispersible 
NPs with a controllable carbon-coated shell thickness remain a challenge.3 
Noticeably, a simple carbon shell also provides only two elements (iii and iv) of 
the checklist we established at the beginning of the section, which reduces its 
attractiveness.  
 
3.3.2.2. Noble Metal Coating 
 
Over the past 10 years, noble metals like platinum,132 silver,133 and gold,133-139 
have also been investigated to form a protective layer around magnetic NPs. 
Owing to their low chemical reactivity but facile surface Functionalisation, and 
together with their special physical-chemistry properties, such coatings indeed 
appear as versatile protective shells to build more complex structure onto. For 
example, a layer of Au coating can provide efficient protection for a magnetic NP 
core against oxidation; in addition, gold shell can provide magnetic NPs with 
appealing optical properties due to the surface plasmon resonance (SPR) effect. 
The popular approaches for gold coating on magnetic NPs include reactions in 
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microemulsion,140-141 redox transmetalation,142-143 iterative hydroxylamine seeding 
pathways.144 While a lot of efforts has been dedicated to iron oxide NPs,133-134, 
145-147 there are only a few reports on gold coating of FePt NPs.136-138, 148 The 
preparation of FePt-Au NPs is normally carried out by mixing pre-synthesized 
FePt NPs with a gold precursor like gold acetate at temperature as high as 265 ºC 
through thermal decomposition,138 or by reduction at a relatively low temperature 
of about 150 ºC (Figure 3.13A), when the FePt NPs are solubilised in a diol 
solvent such as hexadecanediol.138 
 
 
Figure 3.13  Schematic drawing of the preparation of FePt-Au core-shell NPs (A), corresponding 
low (B) and high (C) magnification TEM images of FePt-Au NPs, and UV-vis absorption spectra 
of FePt, Au and FePt-Au NPs (D). (Adopted with permission from (138). Copyright 2009 American 
Chemical Society.)  
 
The Au coating was confirmed by TEM images (Figure 3.13B-C), and FePt-Au 
NPs indeed shows a red-shift of UV-vis absorption as compared to pure FePt and 
Au NPs (Figure 3.13D).  
 
3.3.2.3. Silica Coating 
 
Silica coating is perhaps one of the most promising and important approaches to 
form a protective but biocompatible layer around magnetic NPs. While its high 
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thermal stability can also prevent NPs aggregation during any annealing post 
treatment, this attractiveness is certainly due to the high chemical inertness of silica 
as well as the negatively charged surface of the silica, which already have ticked 4 
elements of our check-list (i, iii, iv and v). Furthermore, the existence of silanol 
group on the silica surface also allows further versatile surface Functionalisation 
with a variety of functional groups through the rich chemistry of siloxane-based 
monolayers.2, 149 Of further interest to guaranty the integrity of the NPs properties, a 
silica shell can also prevent the direct contact of the magnetic core with additional 
agents linked to the silica surface thus avoiding unwanted interactions.  
 
Sol–gel and reverse microemulsion are the two most commonly used approaches to 
complete silica coating around a very wide range of NPs.150-154 In the sol-gel 
pathway, the silica coating process is carried out in alcohol based solvents, like 
ethanol or 2-propanol mixed with water solution. A base, like ammonia solution, is 
often added to catalyze the hydrolysis reaction of the silane precursor.149 The silica 
is then formed in situ through the hydrolysis and condensation of a sol-gel precursor, 
like triethoxysilane (TEOS). The reaction equations are briefly presented below:155 
 
Si(OR)4 + 4H2O → Si(OH)4 + 4ROH 
nSi(OH)4 → nSiO2 + 2nH2O 
 
Under basic conditions, water dissociates to produce nucleophilic hydroxyl anions 
(-OH) which attacks the silicon atom and replace the alkoxide groups (OR) 
resulting in the formation of Si(OH)4. The released alkoxide groups (OR) undergo 
hydrolysis reaction with H+ to form ROH and the condensation of Si(OH)4 leads to 
the formation of silica shells which appear to be monodisperse after fine tuning of 
the experimental conditions.155 
 
For this process, making FePt NPs water soluble and enhancing the affinity of FePt 
NPs surface towards silica are two crucial elements to obtained well isolated single 
FePt core silica shell NPs. Typical strategies include Functionalisation of the FePt 
NPs with a primer which has a silane group like aminopropoxysilane,156 or by 
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adding another layer of amphiphilic molecules such as CH3(CH2)15SO3H, 
CH3(CH2)15(CH2CH2)8OH or CH3(CH2)15N+(CH3)3Br through hydrophobic 
interactions, see Section 3.3.1.157-159  
 
Reverse micelles (see Section 3.2.2) have also been used to confine and control the 
coating of silica on magnetic NPs.38, 160 One of the advantages of the microemulsion 
protocol over the sol-gel approach is that hydrophobic FePt NPs can be directly 
coated without requiring the preparation of water soluble NPs as an intermediate 
step. Indeed, as-synthesized hydrophobic FePt NPs with oleic acid and oleylamine 
coating can be dispersed directly into a water-in-oil microemulsion together with a 
silane precursor, and the silica shell formation can start after adding a base to trigger 
the hydrolysis reaction of the silane precursor.38 A mechanism to form a silica 
coating on hydrophobic NPs in reverse microemulsion using QDs as model was 
developed.160 In that study, evidence indicated replacement of hydrophobic amine 
ligand coating on QDs by hydrolyzed TEOS molecules and surfactant, therefore 
transfer of the QDs into the hydrophilic inerior of the micelles, and also enhance the 
affinity of NPs surface to silica. This mechanism could be applied to other 
hydrophobic nanoparticles such as iron oxide, gold, or FePt nanocrystals and is 
investigated in Chapter 6. 
 
3.4. Conclusion 
 
This chapter has presented an overview of the magnetic properties of FePt NPs 
and their syntheses and Functionalisation. The high Curie temperature, saturation 
magnetic moment and magneto-crystalline anisotropy make FePt attractive 
magnetic materials compared to conventional iron, cobalt, nickel, their oxides and 
some of their alloys. Various chemical pathways have been developed for FePt 
NPs synthesis, which can be divided into two main classes. the first one normally 
requires the reaction to be completed at high temperature of the order of ~300 ºC 
if not above (the thermal decomposition pathway) while the 2nd is carried out at 
temperature close to room temperature (the amphiphilic pathway). 
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The NP composition is always a key element to be careful about when considering 
alloy NPs synthesis including FePt. The desired composition for FePt should 
contain 35 – 60% Fe to allow a crystalline structure optimization. So far there is 
no detailed individual composition analysis reported for FePt NPs obtained by 
co-reduction at low temperature. Therefore a systematic NPs composition 
investigation and NPs formation mechanism study is presented in Chapter 4.  
 
For FePt NPs synthesized at high temperature, it has been demonstrated that the 
NPs often have a broad individual NP composition distribution. This is mainly 
attributed to the low boiling point of the commonly used Fe(CO)5 iron precursor 
and to the temperature difference between reduction of Pt(acac)2 and the 
decomposition of Fe(CO)5. Thus a lot of effort has been dedicated to explore 
alternative iron precursors including Fe(acac)3, Fe(OEt)3 and Na2Fe(CO)4. 
Stoichiometry close to a 1:1 ratio of FePt NPs was obtained by using this Fe2- 
precursor (Na2Fe(CO)4) and this method was further developed as part of this PhD 
study, and the results are presented in Chapter 5.  
 
Direct synthesis of fct FePt NPs has also attracted some attention. It is noticeable 
that traditional chemistry methods often produce fcc FePt NPs. To obtain fct FePt, 
a post-treatment, such as annealing at > 550 ºC, is normally required. However, 
this process often leads to significant NPs sintering. It has been reported that 
partially fct FePt could be obtained by using Na2Fe(CO)4 when the reaction was 
carried out at 389 ºC; alternatively, the polyol process can also lead to partially 
ordered fct FePt NPs at a relatively lower temperature ~300 ºC. However, in both 
case there is very little understanding of the associated mechanisms. Over the 
course of this PhD study, a lot of effort has been dedicated to the investigation of 
new opportunities based on the use of ionic liquids for the direct fct FePt synthesis 
as presented in Chapter 5.  
 
As-synthesized FePt NPs are often coated with hydrophobic molecules, and to 
form water soluble FePt NPs suitable for biomedical applications, ligand 
exchange, and hydrophobic interaction are the most common approaches 
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providing the NPs with a protective shell against oxidation, and chemical 
degradation. These coatings are also ideal platforms for allowing further NPs 
Functionalisation and production of multifunctional NPs for biomedical 
applications. In this PhD study, cysteamine coated FePt NPs through ligand 
exchange, and silica shell coated NPs were both prepared and the results are 
presented in Chapter 6.  
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Chapter 4 
 
FePt Magnetic Nanoparticles Synthesized at Low 
Temperature in Aqueous Media 
 
 
4.1. Introduction 
 
The possibility of synthesising nanoparticles (NPs) in aqueous media is attractive 
because of the low synthesis temperature. It often relies on surfactant molecules to 
control the NPs growth and to stabilize a water phase used to dissolve both the 
precursor salts and a reducing agent. NPs can then form through the exchange 
between water phases, with a rate that is controlled by Brownian motion and the 
lability of the surfactant interface.1-2 Even though aqueous media pathway has 
been successfully used to synthesize numerous types of NPs with metal to 
semiconductor NPs,3-14 for iron platinum (FePt) NPs, low-temperature syntheses 
have attracted less interest. Indeed, as presented in Chapter 3, only a few 
publications have reported on FePt NPs formation in amphiphilic systems,15-22 and 
very few have focused specifically on the chemical composition of the NPs at a 
nanometer scale. 
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In this chapter, a detailed investigation of low temperature solution syntheses 
focusing on the stoichiometry and the composition of FePt NPs is presented. A 
quaternary system based on water, isooctane, and Brij52 as non-ionic surfactant 
and butanol as a co-surfactant was used to synthesis FePt NPs.23 By combining 
Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES), Wide-
angle powder X-ray diffraction (XRD), Transmission Electron Microscopy 
(TEM), Scanning Transmission Electron Microscope, Energy Dispersive X-ray 
analysis (STEM-EDX) and magnetometer (SQUID), a precise composition 
analysis of individual NPs was carried out and revealed an inhomogeneous 
distribution of Fe and Pt between particles. This work was aimed to understand 
the limiting parameters on NP composition and identify suitable strategies to 
increase the iron content of NPs. A number of systems including reaction time, 
precursor ions and reducing agents were investigated to gain insight into the 
mechanisms associated with the insertion of iron atoms in the FexPt1-x NPs. It was 
concluded that a degree of control is possible but that there remain substantial 
limitations. Limiting parameters including iron salts hydrolysis and a mismatch in 
the co-reduction kinetic of the two salts. These results indicate that to overcome 
these problems and obtain higher stochiometry in FePt NPs by co-reduction at low 
temperature, future investigations should focus on preventing the formation of 
hydrolytically unstable iron complexes, preferably by working in the absence of 
water.23 
 
4.2. Experimental Results  
 
4.2.1. Amphiphilic System Characterization 
 
A non-ionic surfactant, Brij52, was chosen to reduce the influence of the variation 
of the precursor ion content over the course of the synthesis of interest. Its 
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hydrophobic block is a 16 carbon long alkyl chain and its hydrophilic head 
includes 2 ethylene oxide and is terminated by a hydroxyl group (Figure 4.1A).  
 
Figure 4.1 Chemical structure of Brij52 non-ionic surfactant (A). Real impedance 'Z  (V) vs. 
imaginary impedance ''Z  (V) curve of water / isooctane / Brij52 / butanol amphiphilic system 
measured at 30°C, [Brij52] = 0.3 mol/L, [Brij52] / [butanol] = 5, hydration w = 1(○), 2 (□), 3 (◊), 
4 (Δ), 5 (×) and 6 (+) (B). Conductivity variation as a function of water content, w (C).  
 
The phase behavior of the precursor free water / isooctane / Brij52 / butanol 
amphiphilic system was characterized by impedance spectroscopy. As shown in 
Figure 4.1B, the impedance spectra, )'('' ZfZ = , are dominated by semi-circlular 
features for all the hydration values, w = [H2O] / [surfactant] = 1 to 6, defined at 
the ratio of water molecule per surfactant. The diameter of the semi-circles is 
related to the conductivity of the system and the spectra were fitted to extract the 
resistance values associated with these semi-circular features. Conductivity values 
were calculated and follow a non-monotonic behavior with the hydration, w, of 
the system (Figure 4.1C). The conductivity indeed first increases with w, reaches a 
maximum at w = 4, and then decreases at higher hydration. Up to w = 4, 
conductivity value reflects an increased salt content associated with the hydration, 
the variation of the rigidity of surfactant interface, and consequently the variation 
of the exchange rate of the water phases in the amphiphilic system. Above w = 4, 
the system becomes unstable and progressively phase separates into an upper 
phase rich in oil and a lower phase rich in water. The solution was kept under 
stirring over the 3 h duration of the syntheses which were then completed at w = 
O
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4, corresponding to the maximum of the conductivity values to optimize the 
exchange rate (Figure 4.1C). 
4.2.2.  N2H4.H2O as Reducing Agent 
 
In a typical synthesis, a surfactant solution was prepared by mixing isooctane, 
Brij52 and butanol in a surfactant to alcohol ratio of 5:1. Dissolution was obtained 
after 15 min sonication. Platinum and iron respective aqueous stock solutions 
were added to the amphiphilic system to obtain the desired [Pt2+] and [Fe3+] 
concentrations. 30 min sonication was then applied, followed by injection of the 
reducing agent to reach the targeted molar ratio of [reducing agent] to [Fe+Pt]. 
 
The final water to surfactant molar ratio, w, was reached after addition of the 
hydrated reducing agent solution. The system was stirred at 30 ºC for 3 h. 
Dodecane thiol was then injected and the solution aged for a further 15 min. The 
NPs were then precipitated by adding alcohol and next collected by 
centrifugation. This extraction step was repeated several times. A similar protocol 
was followed when the syntheses were completed with different iron and platinum 
precursors, and different reducing agents. A detailed example of NPs preparation 
protocol is given in the appendix.  
 
To tune the composition of the NPs, syntheses were completed with variation of 
the initial precursor molar ratio incrementing the concentration of FeCl3 whilst 
keeping the concentration of K2PtCl4 constant. The particles were then 
synthesized with precursor salt ratios, [Fe]:[Pt], ranging from of 0.2 to 1.8. To 
quantify the average composition of the NPs, the product of each synthesis was 
dissolved in aqua regia solution and the ratio of Fe to Pt elements in the final 
solution was determined by Inductively Coupled Plasma Optical Emission 
Spectrometry (ICP-OES, Figure 4.2A). All the results are reproducible and very 
consistent from one sample to another. 
Chapter 4. FePt Nanoparticles Synthesized in Aqueous Media                            Shu Chen, St Andrews 
 
 81
 
 
Figure 4.2 FePt NPs synthesized with varied FeCl3 concentration, [N2H4.H2O] / [Fe3++Pt2+] = 40. 
Composition analysis by ICP-OES (A) XRD patterns (B), Lattice constant (■), chemical 
composition (●) (C) and crystalline grain size in diameter (DXRD) as a function of Fe to Pt 
precursor molar ratio (D) deduced from XRD. A typical selected area electron diffraction pattern 
of FePt NPs (E), and the lattice constant (■) and chemical composition (●) as a function of Fe to Pt 
precursors molar ratio deduced from electron diffraction analysis (F). 
 
The final NP stoichiometry appears to correlate with the initial ratio of precursor 
salts, as illustrated by the linear variation of the ICP-OES composition as a 
function of the initial precursor molar ratio in the synthetic media which reveals 
an apparent ability to control the global composition of FePt NPs (Figure 4.2A). 
Wide-angle powder X-ray diffraction (XRD) spectra are characteristic of FePt 
NPs with a face centre cubic (fct) crystalline structure (Figure 4.2B). The strong 
peaks lying around 51º, 60º and 89º arise from the (111), (200) and (220) 
diffraction. It is, however, noticeable from Figure 4.2B that the position of the 
XRD peaks and the implied lattice constant remains independent of the relative 
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iron and platinum precursor concentrations. This is in contradiction to the ICP-
OES results (Figure 4.2A) since the composition change suggested by ICP-OES 
should manifest as a shift of peaks towards higher 2θ values and a simultaneous 
reduction of the lattice constant with increased Fe content (Figure 4.2C).24 In 
contrast to the known lattice-constant of Fe50Pt50 (~3.834 Å), the values for all the 
samples appear to be close to 3.910 Å. When compared with the lattice constant 
of Pt metal (~3.930 Å); this suggests a fixed Fe composition of about 15% across 
the entire set of samples (Figure 4.2C). Electron diffraction data yielded similar 
information. The electron diffraction pattern (Figure 4.2E) indicates fct-FePt 
phase. In addition, regardless of the initial Fe to Pt precursor ratio, all the FePt 
NPs samples have a lattice constant varying between 3.88 and 3.92 Å, as deduced 
from electron diffraction patterns (Figure 4.2F). The corresponding chemical 
compositions would vary from 15 to 35% with a large error bar of about 15%. In 
the present experiments, the uncertainty associated with the determination of the 
lattice constant obtained from TEM-ED (Figure 4.2F) is much larger than XRD 
(Figure 4.2C). In the context of NPs size, Figure 4.2D illustrates the increase of 
the crystalline size with the Fe to Pt precursor ratio. Table 4.1 summarizes all 
these results. 
 
Table 4.1 X-ray diffraction data of FePt NPs synthesized with [N2H4.H2O] / [Fe3++Pt2+] = 40. a is 
the lattice constant deduced from the (111), (200) and (220) peak positions, x is the iron content in 
FexPt1-x, the diameter DXRD is the crystalline grain size calculated based on FWHM of 3 different 
XRD peaks.25 
Fe/Pt  a x DXRD  
salt ratio  (Å) (%) (nm) 
0.2  3.906 ± 0.006 17.4 ± 4.3 6.2 ± 1.2 
0.6 3.908 ± 0.006 15.6 ± 4.4 6.4 ± 0.8 
1.0  3.911 ± 0.005 13.2 ± 3.6 7.3 ± 0.5 
1.4  3.911 ± 0.002 13.0 ± 1.2 8.5 ± 1.0 
1.8 3.910 ± 0.004 14.0 ± 3.1 9.2 ± 1.4 
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Figure 4.3 TEM images of FePt NPs synthesized with [N2H4.H2O] / [Fe3++Pt2+] = 40, [K2PtCl4] is 
controlled as a constant equal to 2.5 mmol/L, and [FeCl3] to [K2PtCl4] molar ratio is varied from 
from 0.2 (A), 0.6 (B), 1.0 (C), 1.4 (D) to 1.8 (E).  
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The apparent contradiction between ICP-OES and XRD data sets can be resolved 
by TEM analysis (Figure 4.3) which reveals that the reaction products are 
inhomogeneous and comprise well defined, Pt-rich NPs together with larger 
fragments of Fe-rich materials. In Figure 4.3, the first two columns on the left-
hand side show large length scale NPs landscape, while the two columns on the 
right-hand side display higher magnification TEM images. The FeCl3 to K2PtCl4 
molar ratio is tuned from 0.2 (Figure 4.3A), 0.6 (Figure 4.3B), 1.0 (Figure 4.3C) 
and 1.4 (Figure 4.3D) to 1.8 (Figure 4.3E). 
 
Figure 4.3A presents TEM characterization of FePt synthesized with an initial 
[FeCl3] to [K2PtCl4] ratio of 0.2. Individual NPs are associated with a film-like 
material (Figure 4.3A1), while two distinct populations of NPs appears in Figure 
4.3B. Small size NPs are smaller than 10 nm in diameter which is close to the 
XRD size of 6.2 nm in diameter. NPs larger than 10 nm appear to be NPs 
aggregated and fused together (Figure 4.3A2). Figure 4.3A3 and A4 show higher 
magnification TEM of the NPs and the film material, respectively. All the samples 
presented in Figure 4.3 agree well with such description and the common features 
in all samples can be summarized as follow:  
 
i) The NPs of darker contrast are fairly well dispersed and are mixed with a film-
like material of weaker contrast, which could also be amorphous. The darker 
regions in bright field TEM arise from the average atomic number (Z) 
dependent scattering and the darker the material, typically the denser or 
heavier it is. The NPs are polydisperse in size and shape, with a similar 
structure and morphology regardless of the Fe to Pt precursor ratio (1st and 2nd 
columns).  
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ii) The NPs have knobby like morphology and appear to be polydomain, 
probably resulting from the coalescence of smaller NPs during synthesis (3rd 
column). 
iii) The particles increase in TEM size with increasing initial [FeCl3] 
concentration while the size distributions broaden (Figure 4.4). This trend is 
consistent with the XRD data presented in Table 4.1 (3rd column). 
iv) High magnification TEM images illustrate the formation of the film-like 
material of lower electronic contrast (4th column). 
 
 
 
Figure 4.4 TEM size distribution in radius of FePt NPs synthesized with [N2H4.H2O] / [Fe3++Pt2+] 
= 40, [K2PtCl4] = 2.5 mmol/L and. [FeCl3] to [K2PtCl4] molar ratio is varied from from 0.2 to 1.8.   
 
Elemental analysis by False-coloured Energy Filtered TEM (EF-TEM) image and 
nanometer scale Scanning Transmission Electron Microscopy and Energy 
Dispersive X-ray analysis (nanoSTEM-EDX) were completed to complement 
both ICP-OES and XRD data, by providing the composition of the FexPt1-x NPs at 
a nanometer scale, as presented in Figure 4.5. 
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Figure 4.5 Bright field TEM picture (A1), corresponding EFTEM image showing Pt in blue and 
Fe in red (A2) and dark field nanoSTEM-EDX data (B1-B2) of FePt NPs synthesized with 
[N2H4.H2O] / [Fe3+ + Pt2+] = 40. [FeCl3] / [K2PtCl4] = 1.0.  
 
Figure 4.5A1 corresponds to a regular bright field TEM image and displays the 
same duality as reported in Figure 4.3 with a coexistence of higher contrast NPs 
and a lower contrast film-like material, while Figure 4.5A2 is the EF-TEM image 
of the same area, showing Pt in blue and Fe in red. The dark discrete particles of 
Figure 4.5A1 are Pt-rich whilst the lighter material is Fe-rich. Figure 4.5B1 and 
B2 are nanoSTEM-EDX analysis from a large set of NPs and single NPs, 
respectively. The red squares in Figure 4.5B indicate the areas where nanoSTEM-
EDX was completed to extract the composition at a nanometer scale. The general 
trend of the nanoSTEM-EDX spectra is similar for all samples, displaying a large 
composition inhomogeneity, and more nanoSTEM-EDX data are presented as 
below.  
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Figure 4.6 Bright field STEM picture (A), corresponding high angle annular dark filed (HAADF) 
STEM image with red squares indicating areas analyzed by nanoSTEM-EDX (B) and EDX spectra 
(C) of FePt NPs synthesized with [N2H4.H2O] / [Fe3++Pt2+] = 40 and [FeCl3] / [K2PtCl4] = 0.2.  
 
Figure 4.6 shows nanoSTEM-EDX data of FePt NPs synthesized with initial 0.2:1 
molar ratio of Fe to Pt precursor. Figure 4.6A1 and A2 are bright field STEM 
images showing separated and dispersed NPs and film-like matrix, respectively. 
Corresponding high angle annular dark field (HAADF) STEM image are 
presented in Figure 4.6B1 and B2. HAADF-STEM is an incoherent imaging 
technique that collects electrons scattered through a relatively wide angle in the 
electron microscope, beyond the usual Bragg scattering angles. Thus, HAADF 
images show little or no diffraction effects and the scattering process is found to 
be approximately proportional to the square of atomic number, i.e. proportional to 
Z2. The technique is therefore ideal for elemental-specific imaging and for 
revealing thickness variations that may be obscured in conventional TEM 
imaging. HAADF can reveal the features which sometimes are difficult to be 
viewed in bright field imaging. For instance, Figure 4.6B2 shows the area labelled 
with red square comprised of both NPs and film materials. With regard to the 
composition, the NPs appear to be Pt rich in composition (Figure 4.6C1) and the 
Fe is found in the film-like material (Figure 4.6C2).  
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Figure 4.7 Bright field STEM picture (A), corresponding high angle annular dark filed (HAADF) 
STEM image with red squares indicating areas analyzed by nanoSTEM-EDX (B) and EDX spectra 
(B) of FePt NPs synthesized with [N2H4.H2O] / [Fe3++Pt2+] = 40 and [FeCl3] / [K2PtCl4] = 0.6. 
 
Figure 4.7 displays nanoSTEM-EDX data of FePt NPs synthesized with initial 
0.6:1 molar ratio of Fe to Pt precursor. Well dispersed NPs as well as film-like 
materials are also shown in Figure 4.7A-B. The NPs are relatively polydisperse in 
size (Figure 4.7A-B), Pt rich (Figure 4.7C) and apparently inhomogeneous in 
composition (Figure 4.7C). Film-like material is Fe rich and traces of oxygen and 
chlorine may suggest the incomplete reduction of Fe precursor, or the hydrolysis 
product of Fe salt β-FeOOH (Figure 4.7C). 
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Figure 4.8 Bright field STEM picture (A), corresponding high angle annular dark filed (HAADF) 
STEM image with red squares indicating areas analyzed by nanoSTEM-EDX (B) and EDX spectra 
(C) of FePt NPs synthesized with [N2H4.H2O] / [Fe3++Pt2+] = 40. [FeCl3] to [K2PtCl4] molar ratios 
are equal to 1.0 (A1 to C1), and 1.4 (A2 to C2) respectively. 
 
Figure 4.8 presents nanoSTEM-EDX data of FePt NPs synthesized with initial 1:1 
and 1.4:1 molar ratio of Fe to Pt precursor. NP contain 17 to 22% of Fe (Figure 
4.8A1-C1 and A2-C2, Area 1). Again the samples appear inhomogeneous in 
composition. Fe was found in film material, as shown in Figure 4.8A1-C1 and 
A2-C2, Area 2. 
 
Figure 4.9 shows show similar results even though the synthesis was carried out 
with a much larger initial Fe to Pt precursor ratio, i.e. 1.8. Again Fe can be found 
in the film-like material which also contains trace of oxygen and chlorine (Figure 
4.9C2), this is consistent with the other samples.  
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Figure 4.9 Bright field STEM picture (1), corresponding high angle annular dark filed (HAADF) 
STEM image with red squares indicating areas analyzed by nanoSTEM-EDX (2) and EDX spectra 
(3) of FePt NPs synthesized with [N2H4.H2O] / [Fe3++Pt2+] = 40, and [FeCl3] / [K2PtCl4] = 1.8.  
 
In summary, while NPs appear systematically to be Pt rich, the film like material 
is consistently characterized as Fe rich regardless of the initial iron to platinum 
salt ratio used for the syntheses.  
 
4.3. Discussion 
 
Homogeneous chemical composition is a key requirement for both basic and 
technological investigations to be completed with alloyed NPs. For low 
temperature syntheses of FePt NPs to be used, this major challenge needs to be 
addressed. To summarize the data presented so far, FePt NPs syntheses were 
carried out with FeCl3 / K2PtCl4 / hydrazine monohydrate in water / isooctane / 
Brij52 / butanol amphiphilic system. The hydration of 4 molecules of water per 
molecule of surfactant was chosen to have maximum conductivity, i.e. higher 
exchange rate, throughout the system. The knobby appearance of the NPs suggests 
that their formation follows a two-stage growth mechanism in which nanocrystals 
first nucleate in a supersaturated solution and next grow by both aggregating and 
fusing to form larger particles. The size of NPs increases with the Fe to Pt 
precursor ratio in the synthesis media. 
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While ICP-OES shows the linear trend of composition with initial iron to 
platinum precursors ratio (Figure 4.2A), XRD indicates a constant composition, 
i.e. ~15% Fe, independent of the variation of precursors ratio (Figure 4.2B and C). 
This indicates the limitation of ICP-OES, which provides only global composition 
information of final reaction product. Compared to ICP-OES, XRD can provide 
nanocrystal information including composition based on lattice constant. 
However, it may not pick the core-shell structure when it is in the nanoscale or 
other amorphous inhomogeneties.26 Therefore, other techniques including TEM 
(Figure 4.3), EF-TEM (Figure 4.5A) and nanoSTEM-EDX (Figure 4.5 to Figure 
4.9) which can provide nanoscale composition information were employed in this 
study. The nanoscale composition data confirms XRD results that NPs are Pt rich, 
and further reveals that the NPs composition is inhomogeneous, and could not be 
tuned by changing the initial Fe to Pt precursor ratio.  
 
Chlorine and oxygen found in the iron rich materials (Figure 4.6 to Figure 4.9) 
suggest incomplete FeCl3 reduction or formation of akaganeite (β-FeOOH). The 
formation of β-FeOOH from the hydrolysis of Fe3+ in aqueous solution favored by 
the presence of chloride ion.27-28 It is known that FeCl3 hydrolyses to [Fe(OH2)6]3+ 
in the presence of water, but that the high charge to radius ratio in Fe3+ induces 
deprotonation leading via olation and oxolation to oxobriged iron species which 
precipitate as 2-4 nm spheres containing ~102 FeIII ions, most likely in octahedral 
Fe(O,OH,H2O)6 coordination.27 It would be tempting to associate such material 
with the small (ca. 2 nm) NPs of light contrast, observed in larger amounts in the 
HR-TEM image of the molar ratio 1.8 sample (Figure 4.3E4). This would have 
provided further evidence to indicate that it is the hydrolysis of FeCl3 which leads 
to the film-like material. However, the small size of these 2 nm light contrast NPs 
would only provide broad XRD peaks, which would be undiscernable from the 
background in the present situation. In addition, the reduction strength of 
hydrazine is weakened by the decreasing pH afforded by the deprotonation of the 
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[Fe(OH2)6]3+.29 Indeed, such a pH decrease down to 1.2 was observed when the 
FeCl3 concentration was increased. Thus the hydrolysis of FeCl3 in the presence 
of base (hydrazine) leads to insoluble ion salts which prevents the Fe ions from 
reacting with the platinum salts or the initially formed Pt clusters, and may also at 
a later stage prevent the formation an Fe rich shell surrounding Pt rich NPs. The 
validity of this hypothesis is explored in the following section.  
 
In contrast, two [PtCl2(H2O)2] complexes can be formed through hydrolysis of 
[PtCl4]2- but precipitation of platinum does not occur. The hydrolysis reaction of 
[PtCl4]2- is shown in Equation (1) and (2).30  
 
[PtCl4]2- + H2O → [PtCl3(H2O)]- + Cl-      eq.(1) 
[PtCl3(H2O)]- + H2O → [PtCl2(H2O)2] + Cl-     eq.(2) 
 
The formed complexes can be reduced to a PtII–PtI dimer stabilized with Cl-.30-32 
A PtI–PtI dimer can be formed through the addition of another electron to PtI–PtII 
dimer. Both the PtII–PtI and PtI–PtI dimers can react with a third [PtCl2(H2O)2] 
complex to form a trimer. These partially reduced dimers and trimers probably 
represent early intermediates toward the formation of larger clusters or nuclei 
from which the NPs grow. Dimers and trimers have higher electron affinities than 
the original Pt precursor due to orbital delocalization. Reduction is then expected 
to occur preferentially via electron transfer from the reductant to these dimeric 
and trimeric units.31-32  
 
4.3.1. Hypotheses and Strategy Development 
 
Assuming that FeCl3 and K2PtCl4 could be reduced at very different rates or that 
FeCl3 could hydrolyze to insoluble and unreactive oxohydroxo species and that 
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consequently the iron cannot be incorporated into the NPs, a number of strategies 
was explored with the aim of increasing the iron content: 
 
i) Reaction time: the potential formation of an iron ‘richer’ shell is investigated 
in Section 4.3.2 by considering the effect of the reaction time on the NPs.  
ii) Fe and Pt salts: more hydrolytically stable iron precursors should give higher 
incorporation of iron into the NPs. The effect of this parameter on the NPs 
composition is investigated in Section 4.3.3. 
iii) Reducing agent strength: hydrazine monohydrate is known as having moderate 
efficiency in reducing FeCl3.29, 33 A faster reducing agent might compete with 
hydrolysis of the iron precursor and allow greater Fe incorporation into the 
NPs. The use of sodium borohydride is discussed in Section 4.3.4.29, 33 
 
4.3.2. Reaction Time 
 
Reaction time was varied from 0.25 h to 16 h to assess the effect of time on the Fe 
incorporation in the NPs. The XRD patterns are presented in Figure 4.10, and the 
results are summarized in Table 4.2. There is no significant variation of the XRD 
peaks positions (Figure 4.10) hence the lattice constant and implied composition, 
regardless of the time scale of the synthesis (Table 4.2). 
 
Table 4.2 XRD data of FePt NPs synthesized with varied reaction time, [N2H4.H2O] / [Fe3++Pt2+] 
= 40. tr is the reaction time, a is the lattice constant calculated based on (111), (200) and (220) 
peaks, x is the iron content in FexPt1-x, DXRD is the crystalline grain size in diameter calculated 
based on FWHM of 3 different XRD peaks. 
 
tr a x DXRD  
(h)  (Å) (%) (nm) 
0.25 3.909 ± 0.004 14.6 ± 3.5 7.4 ± 1.4 
3.00 3.910 ± 0.004 13.2 ± 3.6 7.3 ± 0.5 
16.00 3.906 ± 0.001 15.3 ± 3.1 9.2 ± 1.0 
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Figure 4.10 XRD patterns of FePt NPs synthesized with varied reaction time, [N2H4.H2O] / 
[Fe3++Pt2+] = 40. 
 
The only effect is that the NPs become slightly larger at longer times as indicated 
by TEM (Figure 4.11A1 vs. B1). After 0.25 h reaction, NPs of ~5 - 10 nm have 
already formed (Figure 4.11A1). By increasing the reaction time to 16 h, the 
population of NPs larger than 10 nm with knobbly appearance is increased (Figure 
4.11B1), but without a significant crystalline grain size variation within 
experimental uncertainties (Table 4.2). This suggests that Pt rich NPs grow 
mainly through an aggregation manner. 
 
Figure 4.11 TEM images (1-2) and bright field STEM pictures (3) with red squares indicating the 
areas analyzed by nanoSTEM-EDX. FePt NPs were synthesized with varied reaction time, 0.25 h 
(A) and 16 h (B), [N2H4.H2O] / [Fe3++Pt2+] = 40. 
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There is no TEM evidence of formation of core shell type structure supporting the 
hypothesis that Fe is reduced gradually and forms a Fe rich shell on Pt rich core 
NPs with longer reaction times. Fe was still found in separate film material 
coexisting with NPs regardless of reaction time, as shown in Figure 4.11A2 and 
B2. The compositions of these two types of materials were characterized by 
nanoSTEM-EDX (Figure 4.11A3 and B3). The NPs formed within 15 mins are 
indeed Pt rich (Figure 4.11A3, Area 1). It is noticeable that the Fe content is 
slightly high, this is attributed to small amounts of film material included in the 
analyzed area. More Fe was found in the film material, as shown in Figure 
4.11A3, Area 2. NPs synthesized with a 16 h reaction show similar composition 
results as a 0.25 h sample. Film materials are rich in Fe (Figure 4.11B3, Area 1), 
and NPs show no obvious increase in the Fe content (Figure 4.11B3, Area 1 and 
3). nanoSTEM-EDX data demonstrated that there was very little change in the 
composition of the NPs and the only slight effect is for the Pt rich NPs to become 
slightly larger at longer reaction times, growing by aggregation type processes.  
In summary, these results revealed that Pt rich NPs have formed within 15 min 
and grow through an aggregation manner with no significant change of 
composition, whereas FeCl3 is unreduced or hydrolyzed and appears as a film like 
material regardless of longer reaction time.  
 
4.3.3. Impact of Pt and Fe precursors 
 
While synthesizing alloyed nanoparticles, the effects of mixing the salt precursors 
also need to be considered. Indeed, K2PtCl6 can form when mixing FeCl3 and 
K2PtCl4 salts in aqueous solution, leading to insoluble yellow crystals as 
characterized by XRD (Figure 4.12A). Whereas K2PtCl6 precipitates are dissolved 
when hydrazine is added to the aqueous solution, their formation could contribute  
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Figure 4.12 XRD patterns of yellow precipitates formed by mixing of FeCl3 and K2PtCl4 aqueous 
solution directly at 30 ºC, [Fe3+] = [Pt2+] = 0.14 M (A); FePt NPs synthesized with different 
precursors, [N2H4.H2O]/[Fe3++Pt2+]=40 (B).  
 
to the observed inhomogeneous nucleation of Pt and Fe materials. This was 
investigated by using Na2PtCl6 as a Pt source. In addition and as indicated above, 
a major problem with the use of aqueous systems is that FeCl3 hydrolyses rapidly 
to insoluble oxyhydroxide species, but it is well known that FeII is less 
hydrolytically unstable because of the lower charge to radius ratio. In addition FeII 
salts will not react with K2PtCl4 to give K2PtCl6. Therefore, the effect of FeII 
precursors, Fe(acetate)2 and FeCl2 as well as FeIII salts free of chlorine atoms like 
Fe(NO3)3 were investigated. The XRD characterization of the products is 
presented in Figure 4.12B, and summarized in Table 4.3.  
 
Table 4.3 X-ray diffraction data of FePt NPs synthesized with different Fe and Pt precursors, 
[N2H4.H2O] / [Fe2+/3++Pt2+] = 40. a is the lattice constant, x is the iron content in FexPt1-x, the 
diameter DXRD is the crystalline grain size. 
 
Precursors a  (Å) 
x  
(%) 
DXRD 
(nm) 
FeCl3 / K2PtCl4 3.911 ± 0.005 13.2 ± 3.6 7.3 ± 0.5 
FeCl3 / Na2PtCl6 3.910 ± 0.006 15.0 ± 1.3 8.8 ± 1.4 
Fe(NO3)3 / K2PtCl4 3.911 ± 0.005 13.3 ± 3.6 7.4 ± 1.8 
Fe(acetate)2 / K2PtCl4 3.899 ± 0.003 21.5 ± 2.2 5.8 ± 1.1 
FeCl2 / K2PtCl4 3.882 ± 0.005 33.9 ± 3.4 2.6 ± 0.5 
 
The data shows that the platinum precursor does not have much impact on the 
composition of NPs (Figure 4.12B and Table 4.3). Similarly, all Fe3+ precursor 
based samples regardless of the Pt precursors, have a similar lattice constant, 
corresponding to ~15% Fe composition. Strikingly though, Fe2+ precursors are 
associated with an increase of the Fe insertion in the NPs by more than 60% and 
(A) 
30 50 (deg)2θ
X
R
D
 In
t. 
(a
u)
 
30 50 70
XR
D
 In
t. 
(a
u)
(deg)2θ
Fe(NO3)3/K2PtCl4
FeCl2/K2PtCl4
FeCl3/Na2PtCl6
Fe (II) acetate/K2PtCl4
FeCl3/K2PtCl4
(111)
(200) (220)
B 
Chapter 4. FePt Nanoparticles Synthesized in Aqueous Media                            Shu Chen, St Andrews 
 
 97
150% for Fe(acetate)2 and FeCl2, respectively. The difference between 
Fe(acetate)2 and FeCl2 between could result from the different dissociation 
constant associated with the acetate and the chlorine salts. The general trend of 
increased iron insertion in the NPs can be explained by greater hydrolytic stability 
of Fe2+ precursors, but may also be influenced by the lower reduction potential of 
FeII/0 compared with FeIII/0 (Table 4.4).  
 
Table 4.4 Decreasing Standard redox potentials.34 
 
Chemical Reaction  E° (V) 
[PtCl4]2-+ 2e- ↔ Pt0 + 4Cl- 0.755 
[PtCl6]2-+ 2e- ↔ Pt0 + 6Cl- 0.68 
Fe3+ + 3e- ↔ Fe0 -0.037 
N2H4·H2O ↔ N2 + 5H+ + 4e- + OH- -0.23 
Fe2++2e-↔ Fe0 -0.447 
Fe3+ + e- ↔ Fe2+ -0.771 
BH4- + 3H2O ↔ B(OH)3 + 7H+ + 8e- -1.73 
 
For all precursors, TEM reveals similar typical features as previously highlighted 
including the presence of both NPs which show a multidomain structure and film 
like materials (Figure 4.13), while slight variations of the NPs size can be 
observed (Table 4.3). The multidomain feature is stronger for the synthesis 
completed with FeCl2 and K2PtCl4 (Figure 4.13D1), which is also associated with 
the smallest crystalline grain size of about 2.5 nm in diameter. Larger length scale 
TEM images and nanoSTEM-EDX results are presented in the 2nd row of Figure 
4.13, with the main features being the large inhomogeneous distribution of Fe and 
Pt materials together with the coexistence of Pt rich NPs with Fe rich film-like 
material. This can be observed regardless of the precursor set.  
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Figure 4.13 TEM images of FePt NPs with different precursors FeCl3 and Na2PtCl6 (A), Fe(NO3)3 
and K2PtCl4 (B), Fe(acetate)2 and K2PtCl4 (C), FeCl2 and K2PtCl4 (D), [N2H4.H2O] / [Fe3+/2+ + Pt2+] 
= 40.  
 
While the formation of K2PtCl6 could be avoided by changing Pt and Fe 
precursors, the most important parameter for increasing the iron content in the 
alloyed FePt NPs appears to be the oxidation state of the Fe ions. Fe2+ ions are 
more stable to hydrolysis and hence remain available for reduction to Fe0 and 
incorporation into the NPs increasing the iron content up to ~34% (Table 4.3). 
4.3.4. NaBH4 as reducing agent 
 
NaBH4 which is commonly used for the synthesis of nanomaterials, is a much 
stronger reducing agent than hydrazine monohydrate (Table 4.4).25, 35 Marcus 
theory and experimental results for a large range of nanoparticles36-41 suggest that 
it is also a faster reducing agent implying that the reduction to Fe0 may then 
become competitive with the hydrolysis reaction.  
 
Compared to when using hydrazine, the XRD peak positions are shifted towards 
higher 2θ values (Figure 4.14), corresponding to a decrease of the lattice spacing 
and a concomitant higher Fe content, up to 35% (Table 4.5). This value is similar 
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to the 34% value obtained with FeCl2 / K2PtCl4 / N2H4.H2O, supporting a kinetic 
related strategy is appropriate to co-reduce Fe and Pt precursors simultaneously, 
but also implying that a limit to Fe insertion may have been reached. 
 
Table 4.5 XRD data of FePt NPs synthesized with [NaBH4] / [Fe3+/2+ + Pt2+] = 2.5, 5 and 10. a is 
the lattice constant, x is the iron content in FexPt1-x, the diameter DXRD is the crystalline grain size. 
 
 Ratio a (Å) x (%) DXRD (nm) 
2.5 3.887 ± 0.005 30.2 ± 3.3 4.0 ± 0.7 
5.0 3.881 ± 0.002 34.6 ± 1.3 3.5 ± 0.5 (a) 
10.0 3.880 ± 0.005 35.6 ± 3.4 3.2 ± 0.7 
(b) 5.0 3.882 ± 0.003 34.4 ± 2.1 3.8 ± 0.8 
(a) FeCl3/K2PtCl4 / NaBH4, (b) FeCl2/K2PtCl4 / NaBH4 
 
 
Figure 4.14 XRD patterns of FePt NPs synthesized with NaBH4as a reducing agent with varied 
reducing regent to precursors ratio compared to N2H4.H2O.  
 
 
Figure 4.15A1 and B1 are typical TEM images and fully consistent with the data 
previously presented showing both knobbly NPs and thin-film like material. 
nanoTEM-EDX demonstrates once again inhomogeneous distribution of Fe and 
Pt regardless of the iron precursor being used (Figure 4.15A2-B2). 
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Figure 4.15 TEM images of FePt NPs synthesized with NaBH4 as reducing agent with [NaBH4] / 
[Fe3+/2++Pt2+] = 5: FeCl3 and K2PtCl4 (A), FeCl2 and K2PtCl4 (B).  
 
The increase of Fe content in NPs was further confirmed by magnetic 
characterization by SQUID magnetometer (Figure 4.16). Despite the smaller size 
compared to NPs synthesized with hydrazine, NPs with higher Fe content reduced 
with NaBH4 show stronger magnetic properties. The ZFC-FC curves indicate a 
low blocking temperature of 30 K and 25 K for both NPs obtained with hydrazine 
and sodium borohydrate respectively (Figure 4.16A1 and B1). However, it is 
noticeable that in contrast to the NPs obtained with NaBH4 (Figure 4.16B1), the 
FC magnetization curve of the NPs synthesized with N2H4.H2O does not reach 
saturation at temperatures below Tb (Figure 4.16A1). In addition, the hysteresis 
loop of NPs of ~15% Fe synthesized by hydrazine showed similar to 
paramagnetic material behaviour, without reaching saturation even at 5.0 T 
(Figure 4.16A2). Whereas NPs of ~35% Fe synthesized by NaBH4, showed 
superparamagnetic properties (Figure 4.16B2), the magnetic moment of NPs were 
saturated at a much smaller external magnetic field. This is attributed the higher 
Fe content in NPs synthesized with NaBH4.  
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Figure 4.16 Magnetic characterization of FePt NPs synthesized with hydrazine as reducting agent 
at [N2H4.H2O] / [Fe3++Pt2+] = 40 (A1-2) and sodium borohydride at [NaBH4] / [Fe3++Pt2+] = 5 (B1-
2). ZFC-FC magnetization curves were obtained in a field of 100 Oe (1) and hysteresis loops were 
measured at 5 K (2).  
 
Consequently, we have demonstrated not only that it is possible to increase the 
iron content in the NPs, but also that aqueous media induced a limit to the Fe 
content which could insert into the alloyed iron-platinum magnetic nanoparticles 
synthesized. This was demonstrated by focusing on both increasing the reduction 
rate of the iron ions and decreasing the hydrolysis of the Fe precursor. This 
investigation was deliberately undertaken using a non-ionic surfactant in order to 
limit its interactions with the ionic precursors and reduce its potential impact on 
the alloy. Rather than a limitation of amphiphilic systems, our results highlight 
what appears to be a limitation of the co-reduction method to form alloyed NPs 
when water is present. These results then imply that future attempts to synthesize 
should focus on overcoming the formation of hydrolytically unstable iron 
complexes to develop room temperature co-reduction syntheses of FePt NPs with 
homogenous chemical composition. This would best be achieved by eliminating 
water entirely from the system. Tuning the size of the product obtained in non-
aqueous media and more specifically increasing the size of the NPs might then 
later be achieved by decreasing the reduction rate difference between the two 
precursors.  
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4.4. Conclusion 
 
FexPt1-x alloy NPs were synthesized at low temperature in non-ionic amphiphilic 
systems made of water, isooctane, Brij52, butanol, for which the conductivity was 
measured to identify the hydration providing the highest conductivity. By 
combining characterization techniques including ICP-OES, XRD, EFTEM and 
nanoSTEM-EDX, this investigation highlights a two-stage growth mechanism of 
the NPs. Primary Pt rich nanocrystals first nucleate in a supersaturated solution 
and then keep on growing and coalescing into larger knobbly particles. 
Polydomain Pt rich NPs are already formed after 15 min of synthesis. While 
excess of Fe is found in film-like material, extending reaction time up to 16 h 
leads to larger NPs but does not alter the NPs Fe to Pt ratio because the 
competitive hydrolysis of the iron precursors is completed within 15 min. This 
was confirmed by using the faster reducing agent, NaBH4 and the less 
hydrolytically unstable FeII precursors which both increased the iron content of 
the nanoparticles from 15% to ~34%.  
 
To obtain stochiometric FePt NPs by co-reduction at room temperature, future 
investigations should first focus on overcoming the formation of hydrolytically 
unstable iron complexes, preferably by working in the absence of water. Due to 
limitations of co-reduction synthesis in aqueous media, future synthesis was 
focused on a modified thermal decomposition method, and the results are 
presented in the following Chapter 5.   
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Chapter 5 
 
 
FePt Magnetic Nanoparticles Synthesized through 
Thermal Decomposition 
 
 
5.1. Introduction 
 
In Chapter 4, the synthesis of FePt NPs in aqueous media at low temperature was 
investigated. This work focused on the composition issue. The iron salts 
hydrolysis and the mismatch in the co-reduction kinetic of the iron and platinum 
salts were identified to be the limiting parameters preventing the formation of 1:1 
stoichiometry FePt NPs. Those results indicate that to obtain higher stochiometry 
in FePt NPs, investigation should focus on preventing the formation of 
hydrolytically unstable iron complexes, preferably by working in the absence of 
water.  
 
This chapter focuses on FePt NPs synthesis completed in organic media, hence 
avoiding the hydrolysis reaction of iron salts in aqueous solution. The FePt 
synthesis in a conventional high-boiling solvent, i.e. benzyl ether is first 
investigated. Next the potentials of ionic liquids (ILs) are further explored to be 
used as novel solvents for NPs synthesis.  
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5.2. Reminder of the Mechanism of NPs Nucleation and Growth 
 
In order to understand the work herein, a brief description of the NPs nucleation 
and growth mechanism based on the classic LaMer Mechanism is presented.1 For 
the thermal decomposition route, the precursor compounds are either decomposed 
or reduced to generate zero-valent metal atoms, which are the building blocks of 
the nanocrystals. The nucleation and growth mechanism of the NPs is illustrated 
in Figure 5.1.  
 
 
Figure 5.1 Plot of atomic concentration against time, illustrating the NPs nucleation and growth 
mechanism.2 (Copyright 2008, Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced in part with 
permission.) 
 
As the precursors are reduced or decomposed, the concentration of metal atoms 
steadily increases with time and reaches the supersaturation point (Cs). Once the 
degree of supersaturation is high enough to overcome the energy barrier for 
self-nucleation, the atoms start to form small clusters, i.e. nuclei. The minimum 
supersaturation point required for nucleation is defined as numinC which varies with 
every system. The nuclei then increase in an accelerated manner, therefore the 
concentration of metal atoms in solution drops. Once the concentration of atoms 
drops below the level of numinC , no additional nuclei will be generated. With a 
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continuous supply of metal atoms via ongoing precursor decomposition or 
reduction, the nuclei will grow into larger nanocrystals until an equilibrium state 
between the atoms on the surface of the nanocrystals and the atoms in the solution 
is reached. Besides growth via atom addition, the nuclei and nanocrystals can also 
directly merge into larger objects via agglomeration. In addition, a process known 
as Ostwald ripening takes place if the supersaturation is too low for all the 
particles to keep growing. In this process, particle of a size smaller than the 
minimum radius of a nucleus that can grow spontaneously in the supersaturated 
solution dissolves and generates metal atoms. The reprecipitation of these atoms 
on larger NPs leads to a continuous growth of NPs but generally broadens the 
particles size distribution.2-3  
 
5.3. Conventional High-boiling Chemical as a Solvent 
 
Benzyl ether has been widely used as a solvent for inorganic NPs synthesis 
including FePt NPs,4-5 a choice justified by its relative chemical inertness and a 
high boiling point of ~298 ºC.6 In this study, FePt NPs are synthesized through a 
modified thermal decomposition approach in benzyl ether, with Na2Fe(CO)4 and 
Pt(acac)2 as precursors and oleyl amine and oleic acid as ligands.7-8  
 
5.3.1. Experiment Protocol  
 
In a standard synthesis protocol, a mixture of Pt(acac)2 (1 mmol), oleyl amine (8 
mmol) and oleic acid (4 mmol) in 10 mL of benzyl ether was placed in a 50 mL 
round bottom flask connected to a condenser. Under stirring, the mixture was 
heated up to 100 °C for 1 h to remove oxygen and moisture. Then Na2Fe(CO)4 (1 
mmol) in 10 mL benzyl ether mixture was added and heated up to 150 °C for 1 h. 
The mixture was further heated up to reflux for 3 h. The dark solution was left to 
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cool down to room temperature and the NPs were collected by centrifugation after 
washing with hexane and ethanol.  
5.3.2. Experiment Results  
 
After synthesis, the dark colour product was characterized by powder X-ray 
diffraction (XRD). The XRD pattern shows peaks around 51º, 60º and 89º which 
are characteristic of fcc-FePt (111), (200) and (220) peaks, respectively (Figure 
5.2A). It is noticeable that the (200) and (220) peaks are very weak. This is 
attributed to the small NP size. Therefore the composition and crystalline size of 
FePt NPs was calculated based on the (111) peak which gives the strongest signal 
to noise ratio. It suggests a composition of 43.8 ± 1.3% in Fe,9 and a crystalline 
size about 3.6 ± 0.1 nm in diameter.  
 
Transmission electron microscopy (TEM) images (Figure 5.2B1-B2) display a 
single layer of well dispersed FePt NPs coating on the carbon film on the TEM 
grid. The TEM size of NPs is 4.8 ± 0.8 nm in diameter, which is close to the XRD 
crystalline size. To characterize individual NP composition, nanometer scale 
scanning transmission electron microscopy and energy dispersive X-ray 
(STEM-EDX) composition analysis was completed on different nanoscale areas 
including single or several NPs and the representative data are shown in Figure 
5.2C-D. The peak ratio of Fe Kα at ~6.4 keV and Pt Lα at ~9.4 keV (Figure 5.2C3 
and D3) implies a ~1:1 ratio of Fe to Pt in composition, which agrees with XRD 
composition value. It is noticeable that there are no significant composition 
variations between different regions of the TEM grid holding the NPs, which 
support a homogenous composition distribution of the FePt NPs.  
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Figure 5.2 XRD pattern (A), TEM images (B1-2) and nanoSTEM-EDX data (C, D) of FePt NPs 
synthesized in benzyl ether at under reflux. [Na2Fe(CO)4] = [Pt(acac)2] = 0.05 M, 
[oleylamine]/[Pt(acac)2] = 8, [oleic acid]/[Na2Fe(CO)4] = 4, heat rate 15 °C/min. The 
nanoSTEM-EDX data include bright field STEM pictures (C1 and D1), corresponding high angle 
annular dark filed (HAADF) STEM images (C2 and D2) with red squares indicating analyzed 
areas and EDX spectra (C3 and D3).  
 
The magnetic properties of the NPs were characterized by a superconducting 
quantum interference device (SQUID) as shown in Figure 5.3. The zero field 
cooling/field cooling (ZFC/FC) measurement presents a peak on the ZFC curve 
known as the blocking temperature (Tb). At Tb the relaxation time of NPs becomes 
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comparable to SQUID measurement time (Tm) which is about 100 s.10 If the NPs 
have a broad size distribution, there will be a mismatch between Tb and the 
temperature Tirr at which the ZFC and FC curves coincide. At Tirr the remanence 
and the coercivity of the largest NPs vanish.11  
 
  
Figure 5.3 SQUID data of FePt NPs synthesized in benzyl ether at ~300 ºC: ZFC-FC (A) under a 
magnetic field of 100 Oe and hysteresis loops (B) at 2 K and 100 K, the insert shows hysteresis 
ranging from -2 to 2 kOe.  
 
As shown in Figure 5.3A, the as-synthesized FePt NPs have a Tb of ~95 K and a 
Tirr ~150 K. At 2 K, i.e. lower than Tb, FePt hysteresis loop displays a 
ferromagnetic behaviour with a coercivity value of 980 Oe and a saturation 
moment (Ms) of ~30 emu/g. At 100 K, FePt NPs do not display coercivity as 
expected for superparamagnetic NPs. They also have a smaller Ms of ~27 emu/g 
(Figure 5.3B).  
 
5.3.3. Discussion and Comparison with Literature  
 
As discussed in Chapter 3, using conventional iron precursors, such as Fe(CO)5, 
Fe(acac)3, Fe(OEt)3, FeCl2, often lead to a broad individual NP composition 
distribution, due to the kinetic difference between the decomposition and 
reduction of iron and platinum precursors. Therefore, Na2Fe(CO)4 is selected in 
this study as a Fe precursor based on the litterature.8, 12 Na2Fe(CO)4 is a Fe2- 
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precursor, which can act as a reducing agent itself to react with Pt(acac)2 through 
the reaction: Fe2-+Pt2+→Fe + Pt.8, 12 Consequently Fe and Pt atoms are expected 
to be generated simultaneously, which leads to formation of FePt NPs of better 
stoichiometry.  
 
In this work, the synthesis protocol was modified to target larger size NPs with a 
narrow composition distribution. The two main modifications are:   
i) In contrast to heating the mixture of iron and platinum precursors straight up 
to reflux (~300 ºC) as reported,8, 12 a step allowing the reaction mixture to be 
heated at 150 ºC for 1 h is inserted before heating the system to the refluxing 
point in our synthesis protocol. This is expected to favor the interaction of 
Fe2- and Pt2+ by suppressing or avoiding the self reduction of Pt(acac)2 
which occurs above 200 ºC.4, 13 In addition, Fe-oleic acid has a larger 
coordination strength than that of Pt-oleylamine, because oleic acid is a 
bidentate ligand while oleylamine is a monodentate ligand.13 In order to 
compensate the binding difference, the amine to Pt molar ratio used in this 
study was 2 times larger than the acid to Fe molar ratio. These changes are 
expected to be beneficial to obtain a narrow NP composition distribution. 
ii) When compared with the literature, the ligand to precursor ratios were 
increased by a factor of ~4 in this study. The higher ligand concentration 
stabilizing Fe and Pt atoms by forming metal-ligand complexes should lead 
to a slower nucleation rate and thus larger NPs. Indeed, FePt NP of TEM 
size ~5 nm were produced based on this modified protocol, which is two 
times larger than what was reported.8, 12 Besides the higher ligand 
concentration, the heating step at 150 ºC could also contribute to the 
formation of larger size NPs, as it allows a slower nucleation rate.  
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5.4. Ionic Liquids as Solvents 
 
The results of the study of FePt NPs synthesis in benzyl ether opens up the 
possibility of using ionic liquids (ILs) as novel solvents for FePt NPs synthesis. 
ILs are low-melting organic salts many of which are liquid over a wide range of 
temperature.14-18 While ILs can be designed to be environmentally friendly and 
have negligible vapor pressure, a variety of physico-chemical properties such as 
melting point, solvation, polarity, viscosity, and hydrophobicity can all be 
achieved through appropriate choice of ions. Besides the potential of being made 
recyclable, ILs are also easier to handle than other high-boiling organic solvents 
like nonadecane (mp 32-34 ºC, bp 330 ºC). In addition, ILs are promising 
alternatives to replace the conventional organic solvents used for material 
fabrications including both organic and inorganic materials.14-18 ILs have been 
presented as attractive tools for creating new synthetic opportunities in material 
science including the fabrication of inorganic nanomaterials such as metals,19-22 
metal oxide,23-25 and alloys.26-27 Studies have shown that nanostructures with new 
features, which are difficult to be fabricated via conventional approaches, can be 
accomplished by using ILs.15, 28 A typical example is the fabrication of ZnO, 
morphologies of which are strongly dependent on the nature of ILs.24, 29-30 
However, very few investigations have been completed on alloy NPs, especially 
for magnetic NPs such as CoPt,26 and FePt NPs.27 This chapter will demonstrate 
that ILs can not only be used as a solvents for FePt NPs synthesis, but can also 
provide an exciting alternative pathway leading to direct synthesis of fct FePt 
NPs.  
 
In this study, FePt NPs syntheses in two ILs with a same anion were investigated 
(Figure 5.4A-B). The synthesis was first carried out in [P66614][NTf2] as a solvent. 
This IL is comprised with a phosphonic cation bonding to long alkyl chains, 
associated with a fluoro-amide anion (Figure 5.4A). Due to the negative charge, 
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the anion is expected to link strongly to NPs surface and the bonding strength is 
much stronger than the dative bond formed between oleylamine and FePt.31 The 
synthesis protocol of FePt NPs in [P66614][NTf2] is similar to the synthesis 
completed in benzyl ether, but with IL replacing benzyl ether as a solvent.9 The 
following sections focus on the synthesis results, first by considering the NPs 
evolutions as a function of the heating time and next by investigating the impact 
of ILs on FePt NPs synthesis.  
 
 
 
Figure 5.4 Chemical structure: [P66614][NTf2], tri-n-hexyl-n-tetradecylphosphonium bis(trifluoro- 
-methylsulfonyl)imide (A), [HMI][NTf2], 1-hexyl-3-methylimidazilium bis(trifluoromethylsulfo- 
-nyl)imide (B), tetracosane (C), butyl sulfone (D) and LiNTf2, Lithium 
bis(trifluoromethylsulfonyl)imide (E). 
 
5.4.1. Reaction Time Investigation 
 
The formation mechanism of FePt NPs in [P66614][NTf2] was investigated by 
extracting aliquots at different reaction temperatures and times following a pattern 
as illustrated in Figure 5.5A. XRD, TEM and SQUID were then systematically 
used to gain insight into the formation mechanism of FePt NPs in this IL. 
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Table 5.1 XRD data of FePt NPs synthesized in [P66614][NTf2] as a solvent. [Na2Fe(CO)4]= 
[Pt(acac)2] = 0.05 M, [oleylamine]/[Pt(acac)2] = 8, [oleic acid]/[ Na2Fe(CO)4] = 4. Heat rate 15 °
C/min. Aliquots were collected at 300 °C 0.5 h, 1.0 h, 2.0 h and 3.0 h. 2θ is the position of the (111) 
peak, a is the lattice constant, DXRD is the crystalline grain size, DTEM is the TEM size in diameter 
and x is the iron content in FexPt1-x.  
Reaction 
time 
(111) a 
x in 
FexPt1-x 
DXRD DTEM* 
h 2θ (degree) (Å) (%) (nm) (nm) 
0.5 51.40±0.04 3.866±0.003 42.1±2.1 2.3±0.1 2.6±2.2 
1.0 51.34±0.04 3.871±0.003 41.2±2.0 2.2±0.1 2.8±2.4 
2.0 51.45±0.04 3.863±0.003 42.9±2.3 2.7±0.1 4.1±4.6 
3.0 51.37±0.03 3.868±0.002 41.7±1.5 2.8±0.1 3.9±4.7 
* TEM size distribution was quantified with Image J software by counting over 100 NPs as shown in 
corresponding TEM images (Figure 5.6C-F). 
  
Figure 5.5 A schematic drawing (A) displays the reaction time investigation. The temperatures 
and reaction times at which aliquots are extracted for investigation are labeled with “●”, their 
corresponding TEM images are presented in Figure 5.6. XRD patterns (B) of FePt NPs 
synthesized at ~ 300 °C in [P66614][NTf2] with varied reaction times.  
 
Simultaneous monitoring of the NPs crystallinity above 300 ºC was characterized 
by XRD (Figure 5.5 and Table 5.1). The formation fcc-FePt is confirmed by the 
peaks lying around ~51º, 60º and 89º corresponding to fcc-FePt (111), (200) and 
(220) diffractions, respectively (Figure 5.5B). The (200), (220) peaks of 0.5 and 
1.0 h samples are too weak to be identified, due to the small NPs size. The data 
indicate that within experimental uncertainties the NPs composition remains 
constant at ~40% Fe through out the whole synthesis. DXRD shows size increases 
after 1 h reaction time at 300 ºC (Table 5.1). 
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To gain more insight into the FePt NPs formation in ILs, the evolution of NPs at 
temperatures starting from 200 ºC was analyzed by TEM as presented in Figure 
5.6.  
 
Figure 5.6 TEM images of samples were collected during FePt NPs synthesis in [P66614][NTf2] as 
a solvent at 250 °C, 0.0 h (A), 300 °C, 0.0 h (B), 300 °C, 0.5 h (C), 300 °C, 1h (D), 300 °C, 2 h (E), 
and 300 °C, 3 h (F), as illustrated in Figure 5.5A. [Na2Fe(CO)4]= [Pt(acac)2] = 0.05 M, 
[oleylamine]/[ Pt(acac)2] = 8, [oleic acid]/[ Na2Fe(CO)4] = 4, heat rate 15 °C/min. 
 
At the 200 °C step, TEM shows mainly the formation of nuclei (data is not 
shown). The presence of well dispersed NPs begun to be observed at 250 °C 
(Figure 5.6A). Once the temperature reaches 300 °C, NPs apparently fuse with 
one another and longer reaction time leads to increased population of fused NPs. 
At 300 ºC, 0.0 h (Figure 5.6B), 0.5 h (Figure 5.6C) and 1.0 h (Figure 5.6D), the 
majority of NPs are well dispersed, accompanied with a small population of fused 
NPs. However, significant amounts of sintered NPs started to be observed when 
the reaction time is longer than 1.0 h (Figure 5.6E and F), as illustrated by the 
significantly increased TEM size of NPs (DTEM) and polydispersity index (i.e. 
deviation from the average diameter value) as shown in Table 5.1. DTEM was 
determined with the assistance of Image J software. This size analysis method is 
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mostly suitable for spherical shaped NPs, while the NPs fusion and aggregation 
can still be observed in the change of polydispersity index, which was increased 
from 2.2 to 4.7 nm when the reaction was extended from 30 min to 3 h (Table 
5.1).  
 
The evolution of the magnetic properties above 300 ºC are presented in Figure 5.7 
with the top row displaying ZFC-FC curves while the bottom row shows 
hysteresis curves obtained at 2 K. The magnetic characterization is summarized in 
Table 5.2. 
 
Table 5.2 Magnetic properties of the FePt NPs synthesized in [P66614][NTf2] as a solvent. Tb is the 
blocking temperature, Tirr is the temperature when the remanence and the coercivity of the largest 
NPs vanish, Hc is the coercivity, Ms the magnetization at saturation and Mr the remanent 
magnetization.  
Reaction time Tb (Tirr) Hc Ms Mr 
h K kOe emu/g emu/g 
0.5 20 (185) 3.2 12.2 ± 1.2 5.5 ± 0.6 
1.0 20 (185) 3.3 13.2 ± 1.3 5.9 ± 0.6 
2.0 20 (256) 2.4 14.2 ± 1.4 6.0 ± 0.6 
3.0 120 (275) 1.4 11.6 ± 1.2 5.2 ± 0.5 
 
Figure 5.7 SQUID characterization of FePt NPs synthesized in [P66614][NTf2] as a solvent, at 300 
°C 0.5 h (A1-2), 1.0 h (B1-2), 2 h (C1-2) and 3 h (D1-2). ZFC-FC magnetization curves obtained 
in a magnetic field of 100 Oe (top row), and hysteresis loops at 2 K (bottom row). The inserts 
zoom in the hysteresis loops between -4 to 4 kOe.  
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There is no variation of Tb values from the 0.5 h sample to the 2.0 h sample 
(Figure 5.7A1-C1). The Tb is small, ~20 K, which is consistent with the small size 
of NPs ~2 nm. In contrast, the 3.0 h sample has a higher Tb of 120 K (Figure 
5.7D1), which could be attributed to better NPs crystallinity because of the longer 
heating time or an increased population of the large size NPs. All the samples 
have a much larger Tirr than Tb which suggests a broad size distribution. Moreover, 
Tirr increases with increasing heating time which also suggests larger size NPs.  
 
The 0.5 and the 1.0 h samples have Hc of ~3.3 kOe, which are close to the 
literature values.8  Compared to NPs synthesized within 1.0 h, the Hc of the 2.0 h 
and 3.0 h samples tend to decrease. This behavior of the coercivity may be caused 
by a multidomain structure of those fused NPs which was also observed on the 2.0 
h sample (Figure 5.7C2), as intergranular exchange couple leads to a reduction of 
magnetocrystalline anisotropy.32 This would be consistent with DXRD which shows 
no variation with synthetic time. The reduced coercivity may also be attributed to 
the magnetic dipole coupling between nanocrystals.33-35 When preparing NPs 
samples for the SQUID measurements, the NPs were dispersed in Poly(methyl 
methacrylate) (PMMA) matrix to reduce to the magnetic dipole coupling as much 
as possible. However, the fused NPs obtained after 3 h synthesis may still induce 
some the magnetic dipole coupling, which could reduce the coercivity and also 
lead to the constricted hysteresis loops, see inserts in Figure 5.7A2 vs. Figure 
5.7D2. 
 
In summary, the reaction time investigation experiment suggests a FePt NPs 
growth mechanism in ILs, which can be summarized as follows:  
i) The nucleation starts at ~200 ºC. 
ii) NPs form rapidly at ~200 - 250ºC. Approximately 2 nm crystallite size NPs 
without significant fusion were obtained at 300 ºC within 1.0 h. 
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iii) NPs grow in a diffusion manner at 300 ºC. Significant aggregation can be 
observed after 1 h reaction time at 300 ºC.  
 
The nucleation temperature in Na2Fe(CO)4 / Pt(acac)2 / [P66614][NTf2] system is 
lower than Fe(OEt)3 / Pt(acac)2 / octyl ether system,13 in which the nucleation 
takes place at 250 to 297 ºC. The fast nucleation contributes to relative small NPs 
size obtained in [P66614][NTf2]. The fast nucleation rate maybe attributed to three 
factors: 
i) The relatively low solubility of Fe, Pt/ligands complexes in ILs may lead to a 
faster nucleation rate. Though the four long alkyl chains on [P66614] ion 
would be expected to provide enough hydrophobicity, after all [P66614][NTf2] 
is a salt, its polarity may cause lower solvation of Fe, Pt/ligands complexes 
than in other organic solvents like benzyl ether. As a consequence, it would 
lead to a higher degree of supersaturation of complexes in ILs, therefore 
faster nucleation of FePt NPs, thus smaller NPs size.  
ii) In contrast to Fe(OEt)3 / Pt(acac)2 system,13 the reaction of Na2Fe(CO)4  
with Pt(acac)2 may accelerate the generation of zero-valent metal atoms 
which consequently leads to faster nucleation rate.  
iii) It was also claimed that low surface tension of ILs could lead to high 
nucleation rate, therefore very small NPs are generated.36 However, it is 
noticeable that the authors did not provide information such as in which 
system small NPs generation was observed. There is also very limited ILs 
surface tension information has been reported in the literature, making it 
difficult to draw a solid conclusion when commenting on the surface tension 
of ILs. 
 
After nucleation, the NPs appear to grow in a diffusion manner above 300 ºC with 
increasing reaction time. In order to obtain well dispersed NPs, it is crucial to 
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confine the heat time within 1 h above 300 ºC. 
 
5.4.2. NPs Size Tuning 
 
Based on the NPs nucleation and growth mechanism as presented in Section 5.2, 
two strategies are often applied to obtain larger size NPs: 
i) Reduce the number of nuclei at the nucleation stage. When the total amount 
of precursors is certain, fewer nuclei will lead to larger size NPs. By 
applying a slower heating rate or increasing the ligand to precursor ratio, a 
slower nucleation rate can be expected.5 In addition, using a smaller 
precursor concentration can also lead to a slower nucleation rate.5, 13, 37 
However, when adjusting the concentration of precursors, it should be noted 
that if the precursors concentration is too low, there will be not enough 
precursors to allow NPs to grow to large.  
ii) Feed the NPs with more building monomers while they are at the growth 
stage. This can be achieved by an injection of additional precursors into NPs 
seeds. 
In this study, reaction parameters such as heating rate, ligands to precursors ratio 
and additional precursors injection were investigated to further explore this IL 
based system and identify differences with more traditional solvents. In addition, 
all the syntheses were carried out at 300 °C for a 1 h time period to reduce the risk 
of NPs aggregation. 
 
In contrast to benzyl ether as a solvent,5 XRD and TEM results that the heating 
rate only has a small impact on NPs size in [P66614][NTf2] system. By decreasing 
the heating rate from 15 to 5 ºC/min, the XRD size was increased by ~20% 
(Figure 5.8 and Table 5.3). This is shown in the increase of average TEM size 
from 2.8 nm to 3.2 nm (Figure 5.8A2-3 and Table 5.3).  
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Table 5.3 FePt NPs synthesized in [P66614][NTf2] as a solvent with a heat rate of 5 °C/min. 
Na2Fe(CO)4/Pt(acac)2 oleylamine (OAM)/oleic acid (OA) were used as precursors and ligands 
respectively. 2θ, a, DXRD, DXRD and x are defined in Table 5.1.  
[Fe]=[Pt] [OAM]/[Pt] [OA]/[Fe] 2θ of (111) a 
x in 
FexPt1-x 
DXRD DTEM 
Sample 
M   (degree) (Å) (%) (nm) (nm) 
A 0.05 8 4 51.30±0.04 3.873±0.003 40.5±2.0 2.5±0.1 3.2±3.8 
B 0.05 24 12 51.55±0.01 3.856±0.001 44.7±0.6 4.0±0.1 -- 
C 0.025 16 8 51.36±0.04 3.870±0.003 41.2±2.2 2.7±0.1 3.3±2.9 
D‡ injection 8 4 51.26±0.03 3.876±0.002 39.7±1.6 3.2±0.1 4.4±4.8 
‡Sample D: Injection of Fe and Pt precursor at 300 °C.  
 
 
Figure 5.8 XRD patterns (1) and TEM images (2-3) of FePt NPs obtained with the eexperimental 
parameters presented in Table 5.3. 
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Slower than 5 ºC/min heating rate was not applied, because competition between 
the nucleation and the growth may take place which would lead to smaller NPs. 
For instance, it is reported that the size of NPs was decreased from 8 to 5 nm 
when the heating rate decreased from 5 to 1 ºC/min in a system composed of 
Fe(CO)5/Pt(acac)2/benzyl ether.5 In addition, while the size of NPs is increased, 
the slower heating rate induces aggregation and fusion of the NPs (Figure 
5.8A2-A3), because of the relative extended heating time. 
 
While the heating rate is shown to have only a small impact on NPs size, adjusting 
the ligand to precursor molar ratio was demonstrated to be a more efficient way to 
tune the NPs size in the present reaction system. Indeed, the XRD crystal size was 
increased by 85% to 4.0 nm, when the ligand to precursor molar ratio was 
increased by a factor of 4. However, the trace of Fe3O4 was also detected by XRD. 
This is suggested by the 3 peaks lying at ~45º, ~55º and ~82º corresponding to 
Fe3O4 (311), (400) and (440) diffraction, as indicated by arrows in Figure 5.8A2. 
Fe3O4 species are present as triangular, lozenge shapes as indicated by TEM 
(Figure 5.8B2). Because of the aggregation of NPs, a TEM size distribution could 
not be calculated (Figure 5.8B2 and B3). 
 
Decreasing the precursor concentration did not lead to larger size NPs. To have a 
constant ligand concentration to compare with the initial experiments, the molar 
ratio of oleyl amine to Pt(acac)2 and of oleic acid to Na2Fe(CO)4 were multiplied 
by two, leaded to 16 and 8 respectively. XRD (Table 5.3) and TEM (Figure 5.8C) 
data suggest NPs size constant within the experimental uncertainty.  
 
Injection of additional precursors was also applied while monitoring the size of 
the NPs. This was carried out after the synthetic solution remained at 300 ºC for 
0.5 h and by using the NPs as nuclei while feeding their growth with additional 
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drop-wise injection of precursors. XRD showed an average crystal size about 3.2 
nm, increased by ~45% (Table 5.3). The average TEM size is also increased by 
~42% up to 4.4 nm (Table 5.3 and Figure 5.8D2-D3). This is demonstrated to be 
the most efficient way to increase NPs size in present reaction system, even 
though there is also presence of small size NPs which could be attributed to the 
competition between the nucleation and growth.  
 
Comparing to the literature, tuning the NPs size through heating rate and ligand to 
precursor ratio in Fe(CO)5/Pt(acac)2/benzyl ether system seems to be more 
efficient than with ILs. It was reported that the NPs size was increased from 6 to 8 
nm, as heating rate was decreased from 15 to 5 ºC/min. The size of NPs was also 
increased from 5 to 9 nm, when the ligand to precursor ratio increased from 5 to 
10.5 In this study, it seems more difficult to achieve efficient size control over 
Na2Fe(CO)4/ Pt(acac)2 / [P66614][NTf2] system, as compared to the 
Fe(CO)5/Pt(acac)2/benzyl ether system. It could probably be due to a fast 
nucleation rate attributed to the reactivity of Fe2- with Pt2+ precursors and a 
relatively low solubility of metal-ligand complexes in ILs. In addition, the ILs 
anions [NTf2]- which bond to NPs surface strongly could also prevent further 
growth of FePt NPs.  
 
5.4.3. Direct fct-FePt Synthesis 
 
After the study of fcc-FePt synthesis in ILs at 300 ºC, the possibility of direct 
fct-FePt synthesis by using ILs at 340 ºC is further demonstrated. The formation 
of fcc-FePt in [P66614][NTf2] is indicated by the presence of two peaks in XRD, at 
around 29º and 41º corresponding to fct-FePt (001) and (110) diffractions, 
respectively (Table 5.4 and Figure 5.9A1).  
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Table 5.4 XRD data of FePt NPs at 340 ºC for 1 h, with [OAM]/[Pt] = 8 and [OA]/[Fe] = 4, 
heating rate 15 ºC/min. DXRD is the crystalline grain size, x is the iron content in FexPt1-x and S is 
the fct crystalline order parameter.  
(001) (110) (111) DXRD S 
Sample Fe precursor/Solvent 
2θ (deg.) 2θ (deg.) 2θ (deg.) (nm) (-) 
A Na2Fe(CO)4 /[P66614][NTf2] 29.2±0.8 42.2±0.8 51.48±0.02 7.0±0.2 0.59 
B Fe(CO)5 /[P66614][NTf2] 29.0±0.5 41.7±0.5 51.41±0.01 10.3±0.2 0.50 
C Na2Fe(CO)4 /[HMI][NTf2] 29.5±0.5 41.5±0.5 51.44±0.01 11.9±0.6 0.63 
 
 
Figure 5.9 XRD patterns (1) and TEM images (2-3) of FePt NPs synthesized with the 
experimental parameters described in Table 5.4.  
 
The fct order parameter (S) was found to be ~0.59 (Table 5.4).9 It is noticeable that 
similar results were obtained with different iron precursors and ILs. For instance, 
fct-FePt is also formed when using the conventional iron precursor Fe(CO)5 
(Figure 5.9B1 and Table 5.4), and a different IL i.e. [HMI][NTf2] comprised by a 
same anion as [P66614][NTf2] (Table 5.4 and Figure 5.9B2). It is noticeable NPs are 
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agglomerated when syntheses were carried out at 340 ºC as indicated by TEM 
(Figure 5.9 Column 2 and 3). In addition, XRD indicated there is formation of 
Fe7S8 in the [HMI][NTf2] sample (Figure 5.9C1), the diffraction peaks are labelled 
with stars.  
 
Table 5.5 Magnetic characterization of FePt NPs with the experimental parameters described in 
Figure 5.10: Tb is the blocking temperature, Tirr is the temperature when the remanence and the 
coercivity of the largest NPs vanish, Hc is the coercivity, Ms is the magnetization at saturation and 
Mr is the remanent magnetization.  
Hc Ms Mr 
Tb (Tirr) 
2K 300K 2K 300K 2K 300K Sample Fe precursor/Solvent 
(K) (kOe) (emu/g) (emu/g) 
A Na2Fe(CO)4 /[P66614][NTf2] 165 (270) 2.1 0 16.9 5.9 6.2 0 
B Fe(CO)5 /[P66614][NTf2] 162 (202) 1.9 0 14.7 7.6 7.4 0 
C Na2Fe(CO)4 /[HMI][NTf2] 260 (320) 1.8 0.06 21.5 12.3 11.6 0.71 
 
 
Figure 5.10 SQUID characterization of FePt NPs synthesized with 
Na2Fe(CO)4/Pt(acac)2/[P66614][NTf2] (A), Fe(CO)5/Pt(acac)2/[P66614][NTf2] (B) and 
Na2Fe(CO)4/Pt(acac)2/[HMI][ NTf2] (C). ZFC-FC curves obtained in a field 100 Oe (1), and 
hysteresis loop at 2 K (2). 
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(Figure 5.7). Especially for the [HMI][NTf2] sample, Tb is ~260 K which is close 
to room temperature (Figure 5.10C3). Additionally, a Hc of ~60 Oe was observed 
at 300 K (Figure 5.10C4). Tb was found to be lower than room temperature and 
could be attributed to four factors: 
i) Surface effects induced by the IL and the ligands lead to the formation of a 
non-magnetic shell by electron transfer.38-41 
ii) The fct phase of the nanocolloids may be too small to provide large enough 
magneto anisotropy to compensate the thermal agitation at ambient 
conditions. 
iii) It may be attributed to the NP multidomain structure, as intergranular 
exchange couple leads to a reduction of magnetocrystalline anisotropy.32  
iv) The reduced coercivity may also be attributed to the magnetic dipole 
coupling between nanocrystals.33-35 
 
As discussed in Chapter 3, there are very few examples in the literature of direct 
fct FePt synthesis in solution. It is reported the direct synthesis of FePt NPs that 
contain a fraction of fct phase by preparing the particles in the high-boiling 
chemical hexadecylamine at ~360 °C with Fe(CO)5 and Pt(acac)2.42 The formation 
of fct-FePt NPs was also observed by the direct heating of a solution containing 
Fe(acac)3 and Pt(acac)2 dispersed in ethyl glycol or tetraethylene glycol with or 
without PVP at ~260-300 ºC.43-45 In addition, Howard et al. also reported the 
possibility of the direct synthesis of partially fct-FePt NPs using Na2Fe(CO)4 at 
~350-389 ºC.8, 12 Even though the direct synthesis of fct-FePt have been reported, 
it is noticeable that the origin of fct-FePt formation is still poorly understood in all 
these systems.  
 
In this study, we propose that the formation of fct-FePt phase may be attributed to 
special chemical structure of the anion, i.e. [NTf2]- which exists both in 
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[P66614][NTf2] and [HMI][NTf2] ILs (Figure 5.7A and B). The current hypothesis 
is that the nitrogen and four oxygens in sulfite could bind to Fe and Pt atoms and 
hold them together like a claw, thus favoring the formation of fct-FePt phase, 
where the alternating Fe and Pt atom planes stacked along the (001) direction.  
 
To investigate the role of the anion [NTf2]- for the formation of fct-FePt, a 
reference synthesis was first completed under the same experimental conditions, 
but replacing the IL with a conventional high-boiling chemical tetracosane (Figure 
5.4C). Figure 5.11A2 and A3 show that the NPs are fused to form worm like 
nanomaterials as indicated by TEM. With regard to the crystal structure, XRD 
data indicate that within the experimental uncertainty there is no fct FePt presence. 
The (110) peak which is supposed to lay at ~42º is not visible, while the very 
weak (001) peak could be guessed at ~29º but with a signal to noise ratio of ~1 
making it impossible quantify a potential ordering parameter.  
 
As a next step, a synthesis was carried out in tetracosane at 340 ºC with the 
presence of butyl sulfone (Figure 5.4D). Its chemical structure has two oxgens 
connected by a sulfite, chosen to mimic half NTf2 molecule. A molar ratio of butyl 
sulfone to precursors of 13.5 was used, based on the NTf2 to precursors molar 
ratio in the standard synthesis in ILs. TEM shows that the NPs are aggregated and 
about ~10 nm in diameter (Figure 5.11B1 to B2). XRD indicates only formation 
of fcc FePt together with other impurities which could not be matched with any 
material in the PDF library. This however may underline the crucial role of the 
nitrogen in the NTf2 structure, which acts as a bridge connecting two sulfone 
groups. To further explore this system, LiNTf2 (Figure 5.4E), which has the same 
anion as [P66614][NTf2] and [HMI][NTf2], was selected to be added into the 
reaction system. Again, the data indicates no fct-FePt formation, as implied by the 
absence of two superlattice peaks at ~29º and ~42º (Figure 5.11C1). This could be 
Chapter 5. Thermal Decomposition Pathway                                  Shu Chen, St Andrews 
 
 
 
127
attributed to the relatively poor thermal stability of LiNTf2, due to the formation of 
LiF as detected by XRD (Figure 5.11C1). 
 
Table 5.6 XRD data of FePt NPs synthesized using tetracosane at 340 ºC for 1 h with [OAM]/[Pt] 
= 8 and [OA]/[Fe] = 4, heating rate 15 ºC/min. For Sample A, no other additives were added, 
Sample B: butyl sulfone was introduced at [butyl sulfone]/[Fe+Pt]=13.5 and Sample C: LiNTF2 
was added at [NTF2]-/[Fe+Pt]=13.5. DXRD is the crystalline grain size.  
(111) DXRD 
Sample Solvent / Additives 
2θ (deg.) (nm) 
A Tetracosane / none 51.78±0.04 4.9±0.2 
B Tetracosane / Butyl sulfone 51.39±0.02 12.2±0.6 
C Tetracosane / LiNTf2 51.20±0.02 8.5±0.2 
  
Figure 5.11 XRD patterns (1) and TEM images (2-3) of FePt NPs at 340 ºC for 1 h with 
[OAM]/[Pt] = 8 and [OA]/[Fe] = 4, heating rate 15 ºC/min. Experiment parameters are described 
in Table 5.6.  
In addition, the limited solubility of LiNTf2 in the hydrophobic solvent, which 
likely hinders the interaction between [NTf2]- with metal atoms, could also 
A2 
20 nm 
A3 
5 nm
20 nm 
C2 C3 
5 nm
20 30 40 50
XR
D 
In
t. 
(a
u)
(deg)2θ
x xx LiF
(1
11
)
(2
00
)
C1 
B2
20 nm 5 nm
B3 B1 
20 30 40 50 (deg)2θ
XR
D
 In
t. 
(a
u)
(1
11
)
(2
00
)
A1 
20 30 40 50
XR
D
 In
t. 
(a
u)
(deg)2θ
(1
11
)
(2
00
)
Chapter 5. Thermal Decomposition Pathway                                  Shu Chen, St Andrews 
 
 
 
128
contribute to the absence of fct FePt. These results cold be used to emphasize that 
each part of the ILs is important. For instance, the presence of an organic counter 
ion in ILs will provide a better solubility and thermal stability to the NTf2 anion as 
compared a more conventional Li based salt. As a consequence, it will be easier 
for the [NTf2]- to coordinate with Fe and Pt atoms in ILs and lead to formation of 
fct-FePt. 
 
5.5. Conclusion 
 
This chapter presents the development of a modified thermal decomposition 
method for FePt NPs synthesis. In contrast to the synthesis carried out in aqueous 
media as presented in the Chapter 4, the synthesis was carried out in an organic 
solvent, benzyl ether, therefore the hydrolysis reaction of iron salt was avoided. In 
addition, Na2Fe(CO)4/Pt(acac)2 were used as precursors, through the reaction 
Fe2-+Pt2+→Fe + Pt, close to 1:1 ratio stoichiometry fcc-FePt NPs can be obtained. 
 
Based on the study of FePt NPs synthesis in benzyl ether, the potential of 
[P66614][NTf2] as a solvent for FePt NPs synthesis was investigated. Experimental 
results indicate a faster NPs nucleation in [P66614][NTf2] as compared to 
conventional organic solvents. Small crystallite size NPs of ~2 nm were obtained 
at 300 ºC, which is smaller than ~5 nm NPs synthesized in benzyl ether. This 
could be attributed to the lower solubility of metal-ligand complexes in ILs due to 
the polarity of ILs, which induces a higher supersaturation of metal complexes. 
Another possibility is that ILs anions which bond strongly on NPs surface could 
prevent the growth of NPs. In addition, NPs grow in a diffusion manner above 
300 ºC with increasing reaction time. In order to obtain well dispersed NPs, 
results suggested it is crucial to confine the heat time to be within 1 h above 300 
ºC.  
Chapter 5. Thermal Decomposition Pathway                                  Shu Chen, St Andrews 
 
 
 
129
To explore further the IL based synthesis and using the size of the NPs as a 
reference, reaction parameters such as tuning heating rate, ligand to precursor 
ratio, precursor concentration, additional precursors injection were investigated. It 
was demonstrated that ~4.0 nm NPs could be obtained by using higher ligand to 
precursors ratio and additional precursor injection. However, further size 
increasing was found rather difficult due to the high reactivity of iron precursor, 
the fast NP nucleation rate in ILs. To obtain larger size NPs, future synthesis 
should overcome the fast NPs nucleation issue in ILs. Potentially, designing ILs 
comprised with functional groups capable to bind to metal atoms. 
 
More importantly, this study demonstrates the formation of fct-FePt NPs in 
[P66614][NTf2] at 340 ºC, highlighting the essential role played by the combination 
of temperature and IL structure. Further study shows that the formation of fct-FePt 
can also be obtained by using a different precursor Fe(CO)5, or ILs with same 
anion like [HMI][NTf2]. These results lead to the hypothesis that the [NTf2]- anion 
triggers the formation of fct-FePt, because of its chemical structure comprised by 
one nitrogen and four oxygens in a sulfite each of them could bind to Fe and Pt 
atoms thus holding them together like a claw. Further work is currently carried out 
in collaboration with computational chemists at the School of Chemistry at St 
Andrews to gain further insight into fct-FePt formation mechanism in ILs.  
 
These results are very exciting when only very few systems have shown the 
ability of allowing direct fct formation in solution. However, further work is 
obviously needed both to obtain well dispersed nanocolloids with controlled 
morphology and trigger fct-FePt formation in solution synthesis at even lower 
temperature. This could be achieved by identifying appropriate stabilizers, but 
primarily the fct-phase formation would need to fully understood and controlled, a 
challenge which will require significant experimental work to be combined with 
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extensive numerical simulations to gain further insight into the interplay between 
the Fe/Pt precursors, the components of the ILs and the ligands aimed preventing 
the NPs aggregation. To the best of our knowledge, this ability of ILs to alter NPs 
crystallinity has not been demonstrated before this work and opens up exciting 
perspectives as the direct synthesis of fct-FePt nanocolloids will find a broad 
range of applications including data storage, sensors and biomedicine.  
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Chapter 6 
 
Biomedical Applications of FePt Nanoparticles 
 
 
6.1. Introduction 
 
Magnetic resonance imaging (MRI) is widely regarded as a powerful and 
non-invasive medical imaging tool capable of identifying disease pathways and 
physiology at the organ, cellular and sub-cellular levels. It relies upon the 
interaction of the nuclear spin of the hydrogen nucleus in water with an external 
magnetic field. Spatial information can be obtained by applying additional 
magnetic field gradients. The signal in an image originates predominately from 
water, lipids and a number of parameters contribute to image contrast. In medical 
diagnosis, differentiation between normal and pathological tissue is often 
desireable, but with the introduction of exogenous contrast agents, this can 
successfully be achieved. According to their effects on the relaxation rate of water 
protons in tissue, MRI contrast agents are typically categorized as either 
longitudinal relaxation time (T1) agents or transverse relaxation time (T2) agents. 
The T1-agents (e.g. gadolinium (III) complexes, manganese (II) complexes) 
accelerate the longitudinal relaxation rates (1/T1) of water protons more than the 
transverse relaxation rates (1/T2), resulting in an increase of signal intensity 
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(hyperintensity) on T1 weighted images thereby exhibiting bright contrast. The 
T2-agents (e.g. superparamagnetic NPs such as Fe3O4, γ-Fe2O3, MnFe2O4, FeCo 
NPs) increase the transverse relaxation rates (1/T2) of water in surrounding tissue 
resulting in dark contrast (hypointensity) in T2 weighted images.1-3 A more 
detailed introduction of the basic principle of MRI and contrast agents is 
presented in Chapter 2.  
 
Superparamagnetic iron oxide (SPIO) nanoparticles have become an important 
class of contrast agent since their development and application to the liver almost 
twenty years ago.2, 4 However, they have some limitations which originate from 
their synthetic processes. They are generally synthesized by a coprecipitation 
reaction in water at a relatively low temperature, resulting in the formation of 
polydispersed and poorly crystallined nanoparticles with inferior magnetic 
properties.2, 5-6 Additional disadvantages of SPIO NPs include fast clearance rate 
by phagocytic cells and hence limited transendothelia passage and tissue 
penetration.7 There is therefore a continuing need to develop clinically viable and 
targeted MRI contrast agents with improved retention properties. The design and 
syntheses objectives of new generation of MRI contrast agents will likely focus on 
strengthening the MRI contrast effect, prolonging intravascular retention, 
improving tissue delineation.  
 
FePt metallic alloy nanoparticles have emerged as promising candidates for a new 
generation of magnetic nano-material, thanks to their high Curie temperature and 
magneto-crystalline anisotropy.8 Studies have demonstrated the biomedical 
potential of FePt NPs, such as magnetic separation,9-10 hyperthermic ablation11-12 
and as T2 MRI contrast agents. 11, 13-15 However, toxicity remains a major concern 
preventing their use as a bioplatform for diagnosis and therapy.15-17 
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Figure 6.1 Schematic drawing of preparation of fcc-FePt-A NPs (A), fcc-FePt-silica-A NPs (B), 
and fct-FePt-A NPs (C).  
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In this study, three biocompatible FePt NPs are designed and fabricated for 
biomedical applications. Figure 6.1 displays the schematic drawing and 
preparation of face centered cubic (fcc) FePt NPs with cysteamine coating, 
fcc-FePt-A NPs (Figure 6.1A), silica coated fcc FePt NPs with further surface 
functionalization with (3-aminopropyl) triethoxysilane, fcc-FePt-silica-A NPs 
(Figure 6.1B) and face centered tetragonal (fct) FePt NPs functionalized with 
cysteamine, fct-FePt-A NPs (Figure 6.1C).  
 
After synthesis, FePt NPs are coated with oleylamine and oleic acid, thus are 
soluble in organic solvents like hexane and chloroform. Through ligand exchange 
process, the original oleylamine and oleic acid coating is replaced with 
cysteamine, due to two aspects: 1) thiol-Pt bond is much stronger than amine-Pt 
bond;18 2) the bonding between ligand and NP is a dynamic process.19 When a 
large excess of cysteamine is available, oleic acid can be replaced, even though 
thiol is known to form wearker bonds with iron than carboxylic acid.18 Silica 
coated FePt NPs were produced in a reverse microemulsion through the 
hydrolysis reaction of saline precursor in a base environment. FePt-silica NPs 
were further functionalized with (3-aminopropyl) triethoxysilane to obtain 
fcc-FePt-silica-A NPs. fct phase FePt NPs were prepared through annealing of 
silica coated fcc-FePt NPs. The fct-FePt NP silica coating was removed and 
cysteamine was utilized to functionalize the NPs to obtain fct-FePt-A NPs. The 
detailed preparation methods are presented in appendix. 
 
Each type of FePt NPs has their own advantages for biomedical applications: 
i) fcc-FePt-A NPs: the diameter of the NPs is ~5 nm, which gives them a longer 
blood half-life since fast uptake by the liver and spleen is avoided, 
consequently their chances of reaching other targets can be improved.2, 6 The 
positive charges on the NPs surface provided by amine groups is used to 
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develop sufficient electrostatic repulsion to increase water solubility.18 In 
addition, the positively charged surface allows increased cell internalization 
efficiency, and will bind biomedical materials such as DNA and proteins 
through electrostatic attraction. In addition, amine terminated surface is an 
ideal platform for conjugation with a large range of biomolecules, including 
antibodies, proteins, peptides, polysaccharides, and aptamers.2, 20-21  
ii) fcc-FePt-silica-A NPs: in addition to organic coating, utilizing biocompatible 
and inert silica shell is commonly considered as the most attractive approach 
for engineered NPs. Not only does silica shell serve as protective layer against 
chemical degradation of the metal core but it also allows easy surface 
functionalization through the use of alkoxysilanes such as those containing 
amine or acid groups.  
iii) fct-FePt-A NPs: fct FePt NPs have stronger magnetic properties and higher 
chemical stability than fcc phase FePt making them attractive for medical 
applications.22  
 
While it was reported that FePt NPs were able to induce severe cell damage using 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay,15-16, 
22e.g. phospholipids coated fcc-FePt NPs showed 50% cell death at ~7,8 µg/mL;22 
no significant fcc-FePt-A NPs cytotoxicity was detected at concentrations lower 
than 30 µg/mL by using MTS ((3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymeth- 
-oxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)) assay in the work presented in 
this chapter. MTS assay is an updated version of MTT assay and has the 
advantage of being soluble hence no solubilisation step is required. Furthermore, 
the first data on cysteamine functionalized FePt NPs cellular uptake mechanisms 
and a 6-fold increase in the FePt-based T2 contrast properties compared to those of 
clinical iron oxide NPs were reported in this study. The relationship between the 
MRI contrast properties and the NPs’ architecture was explored and rationalized 
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as the basis for the design of NPs as enhanced MRI contrast agents. Finally, the 
first observations of cellular and in vivo MR imaging with FePt NPs was 
presented.23 These results open the way for several applications of FePt NPs, such 
as regenerative medicine and stem cell therapy, in addition to enhanced MR 
diagnostic imaging, thus providing a platform to develop novel diagnostic and 
therapeutic agents. 
 
6.2. Experimental Results and Discussion 
6.2.1. FePt NPs Characterization 
6.2.1.1. FTIR 
 
After synthesis, FePt NPs are capped with oleic acid and oleylamine ligands and are 
only soluble in organic solvents like hexane. Through ligand exchange process,24 
oleic acid and oleylamine are replaced by cysteamine and FePt NPs bound with 
cysteamine become water soluble. Figure 6.2 provides a straightforward illustration 
of the effectiveness of the ligand exchange protocol. 
 
 
Figure 6.2 Chemical structure of the ligands and photographs (A) of FePt NPs dispersions in 
hexane or water phase: oleic acid and oleylamine capped FePt NPs (i), and cysteamine capped 
FePt (ii). FTIR spectra (B) of as-synthesized NPs coated with oleic acid and oleylamine (top) and 
cysteamine (bottom) after ligand exchange. (Reprinted with permission from (23). Copyright 2010 
American Chemical Society.) 
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Hexane and water are not miscible, and water which is denser (1.0 g/mL vs 0.7 
g/mL) lies beneath the hexane phase. FePt NPs with oleic acid and oleylamine 
coating are soluble in hexane therefore manifest a black colour to the upper phase 
while the deionized water remains colourless (Figure 6.2A-i). Figure 6.2A-ii 
presents the cysteamine capped FePt NPs which are soluble in deionized water 
leading the lower phase to be black whilst the upper hexane phase remains 
transparent. After having replaced oleic acid and oleylamine with cysteamine, the 
NPs are soluble in water solution and stable for more than 8 months.  
 
The efficiency of ligand exchange was further confirmed by Fourier transform 
infrared spectroscopy (FTIR). The FTIR spectra of NPs before and after ligand 
exchange are shown in Figure 6.2B, with all characteristic transmission peaks 
labelled and matching the literature values.25 The upper spectra in Figure 6.2B is 
characteristic of the NPs coated with oleic acid and oleylamine. The peaks at 1552 
and 1713 cm-1 can be assigned to the bidendate (-COO-) and monodendate (-CO-) 
modes of oleic acid binding. The shoulder at 1595 cm-1 is due to the scissoring 
mode of the molecularly bonded oleylamine. The two peaks at 2854 and 2924 cm-1 
correspond to the symmetric and asymmetric C-H stretching modes of the oleyl 
group. The peak at 3005 cm-1 is characteristic of the stretching of =C-H.25  
 
The original oleic acid and oleylamine coating of the FePt NPs surface was 
replaced by cysteamine through the ligand exchange protocol and demonstrated by 
the bottom FTIR spectra in Figure 6.2B characterised by  
i) the absence of -COO- and -CO-, =C-H peaks, and 
ii) the dramatic decrease of the C-H stretching transmission mode. The shoulder 
at 2560 cm-1 is associated with –SH,26 while the peaks at 3350 and 3448 cm-1 
are consistent with the –NH2 end group of the cysteamine.27 
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6.2.1.2. TEM  
 
Figure 6.3 shows schematic structure and TEM, XRD and SQUID 
characterization of Feridex NPs (Column A), face centered cubic (fcc) FePt NPs 
coated with cysteamine (fcc-FePt-A) (Column B), silica coated fcc-FePt NPs 
further surface functionalized with (3-aminopropyl) triethoxysilane 
(fcc-FePt-silica-A) (Column C) and face centered tetragonal FePt NPs 
functionalized with cysteamine (fct-FePt-A) (Column D). 
 
Feridex is a clinical iron oxide NP coated with dextran (Figure 6.3A1). In 
agreement with published literature,5 TEM revealed that the commercial iron 
oxide NP samples (Figure 6.3A2) are composed of aggregated crystals of 
approximately 5 nm in diameter, embedded in an organic coating. These 
aggregates have a size distribution ranging from 20 nm to over 50 nm. In contrast, 
the fcc-FePt-A NPs (Figure 6.3B1) are well dispersed with diameters of ~5 nm 
(Figure 6.3B2). The fcc-FePt-silica-A (Figure 6.3C1) NPs are coated with a silica 
shell of ~17 nm in thickness (Figure 6.3C2). It should be noted that, careful 
control of the experimental parameters such as NP and TEOS concentrations   
prevented the formation of blank silica NPs without any FePt. Such silica shell 
prevented sintering of the NPs during the annealing process allowing fcc to fct 
phase transition. The size of fct-FePt-A (Figure 6.3D1) is ~10 nm, slightly larger 
than fcc-FePt-A NPs (Figure 6.3D2). 
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Figure 6.3 Schematic representation, TEM images, XRD pattern, ZFC-FC and hysteresis curves 
of Feridex (A1-5), fcc-FePt-A NPs (B1-5), fcc-FePt-silica-A NPs (C1-5), fct-FePt-A NPs (D1-5). 
(Reprinted in part with permission from (23). Copyright 2010 American Chemical Society.) 
 
6.2.1.3. XRD 
 
XRD pattern of the Feridex iron oxide confirms the presence of magnetite (Fe3O4), 
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the broad peaks at 38°, 45º, 55º corresponding to (220), (311), (400) peaks, 
respectively (Figure 6.3A3). Figure 6.3B3-C3 show peaks around 51º and 60º 
characteristic of fcc-FePt (111) and (200) peaks, respectively. The (111) peak 
position suggests a NP composition of 40 - 45% of Fe (Table 6.1).24 For the silica 
coated NPs, SiO2 is observed at ~28º (Figure 6.3C3). The crystal size is ~3.6 nm 
in diameter for fcc-FePt-A and fcc-FePt-silica-A NPs (Table 6.1). After annealing, 
fct crystal phase is observed around 29º, 41º and 68º corresponding to (001), (110) 
and (201) fct-FePt peaks, respectively (Figure 6.3D3). The resulting size and fct 
order parameter are 6 nm in diameter and ~0.7 respectively (Table 6.1).24  
 
6.2.1.4. SQUID 
 
Zero field cooling and field cooling (ZFC-FC) of Feridex samples highlight a 45 
K blocking temperature (Tb, Figure 6.3A4). At 2 K, i.e. lower than Tb, Feridex 
hysteresis loop measurements display ferrimagnetic behaviour with a small 
coercivity value of 300 Oe and a saturation moment (Ms) of 101 emu/g of Fe. At 
300 K, Feridex is superparamagnetic with no coercivity (Figure 6.3A5). The Ms is 
82 emu/g of Fe, in agreement with literature values.5-6  The fcc-FePt-A NPs have 
a higher Tb ~90 K (Figure 6.3B4). More importantly, when compared to Feridex, 
the Ms of fcc-FePt-A NPs is ~2 times larger at 2 K and 35% stronger at 300 K 
(Figure 6.3B5 vs. Figure 6.3A5 and Table 6.1). After silica coating, the blocking 
temperature is reduced to 50 K, and the ZFC slope below Tb is steeper (Figure 
6.3C4). At 2 K and 5 T, the magnetization of fcc-FePt-silica-A NPs is ~5% lower 
than fcc-FePt-A and 2 times larger than Feridex. At 300 K and 5 T, the 
magnetization of fcc-FePt-silica-A NPs is ~36% lower than fcc-FePt-A NPs and 
similar to Feridex (Figure 6.3C5, Table 6.1) The alteration of the magnetic 
properties of the NPs after the silica coating is attributed to partial oxidization the 
FePt surface resulting in a thin layer of softer magnetic material like iron oxide in 
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the strong base environment associated with the silica coating, the thickness of 
which is not visible by XRD or TEM.28-29 
 
Table 6.1 XRD and SQUID data of various FePt NPs compared to Feridex. Grain size DXRD of 
FePt NPs or Feridex is calculated according to Scherrer’s formula,30 DXRD = 0.9λ/(B cos θ) where 
DXRD is the “ average” dimension of the crystallites, λ is the wavelength of the X-ray source (for 
Fe source is equal to 0.1936 nm), B is the full width at half maximum of the peak intensity of FePt 
(111) or Feridex (311) peak, and θ is the corresponding glancing angle. FexPt1-x is obtained based 
on FePt lattice constant vs. composition curve reported by Bonakdarkpour et al.24, 31 Tb is blocking 
temperature obtained from FC-ZFC curves, Ms is the saturation moment. Hc is coercivity obtained 
from hysteresis loop. 
D XRD FexPt1-x Tb Ms at 2 K Ms at 300 K Hc at 2K 
Sample 
(nm) % (K) emu per g Fe emu per g Fe kOe 
fcc FePt-A 3.6±0.1 42.7±0.7 90 201 112 0.7 
fcc FePt-silica-A 3.6±0.1 43.8±1.4 50 191 83 1.3 
fct FePt-A 6.1±0.1 ~ 43  80 125 22 2.5 
Feridex I.V.® 
(EndoremTM) 
5.3±0.1 - 45 101 82 0.3 
 
fct-FePt-A NPs displayed a Tb of 80 K (Figure 6.3D4). At 2 K, the NPs 
magnetization was reduced by 38% but the coercivity was increased by a factor 3.5 
up to 2.5 kOe when compared with fcc-FePt-A NPs (Figure 6.3D5). This confirms 
the fcc to fct crystal phase conversion. However, annealing also induced a dramatic 
drop in both magnetization and coercivity attributed to silicide formation.29 It was 
reported by Thomson et al. 29 that annealing FePt NPs on a Si substrate induced 
formation of silicides leading to a strong reduction of the NPs magnetic moment, a 
schematic drawing of which is shown in Figure 6.4. A Long annealing of FePt at 
725 ºC resulted in increasing the fct ordered fraction compared to the fcc crystalline 
structure (Figure 6.4B). This is associated with a larger coercivity (Figure 6.4C) 
which could be observed below Tb (20 K). However, annealing longer than 20 min 
induced a drop of the coercivity leading to a non-monotonous behaviour of the 
coercivity variation with the annealing time (Figure 6.4C). Furthermore, a 
continuous drop in magnetization (Figure 6.4D) was observed at 9 T. This can be 
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attributed to the formation of FexSiy. The crystalline fraction of FePt was calculated 
to include both fcc and fct structures with ΦFePt + ΦFe silicide = 1 and only 40% of FePt 
remained fraction after annealing at 725 ºC for 2 h (Figure 6.4E) which reduced the 
magnetization by about 35% (Figure 6.4D).29 
 
 
Figure 6.4 Schematic drawing of silicides formation (A) as annealing of FePt NPs on Si substrate. 
Curves of fct-FePt fraction (B), coercivity at 20 K (C), magnetization at 9 T (D) and fraction of 
FePt relative to Fe silicide (E) as a function of annealing time at 725 °C. The lines are included as 
a guide to the eye. Data extracted from Thomson et al.29  
 
In Thomson et al’s work,29 NPs were annealed on a silicon substrate, such that 
atoms could only diffuse from the contact point between NPs and substrate. In 
contrast, our FePt NPs were coated with a silica shell so that annealing could be 
expected to form silicides all around the NPs. A 40 min annealing time was chosen 
to balance 
i) an increase of the fct ordered fraction, and  
ii) a potential reduction of the magnetic properties. 
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Figure 6.5 SQUID data of fct-FePt-silica NPs annealed at 700 ºC for 40 min. ZFC-FC under a 100 
Oe magnetic field (A) and hysteresis curves at 2 K and 300 K (B).  
Figure 6.5 presents the characterisation of the magnetic properties of fct-FePt-silica 
NPs which were annealed for 40 min. The fct phase formation was confirmed by the 
increased blocking temperature (Figure 6.5B and Table 6.2) by 20% and coercivity 
by 31% respectively, as compared to prior annealing fcc-FePt-silica-A NPs (Figure 
6.5 A-B and Table 6.2)  
 
Table 6.2 SQUID data of the FePt NPs. Tb is the blocking temperature, Ms is the saturation 
moment and Hc is the magnetic coercivity of the NPs.  
Tb Ms (2 K) Ms (300 K) Hc 
Sample 
(K) emu per g of Fe kOe 
fcc-FePt-A 90 201 112 0.7 
fcc-FePt-silica-A 50 191 83 1.3 
fct-FePt-silica 
(40 min, 700°C) 
60 111 13 1.7 
 
The formation of silicides induced by the annealing process, however reduced the 
magnetization measured at 5 T by 42% and 84% at 2 K and 300 K respectively 
(Figure 6.5 B and Table 6.2). In our study, the 40 min annealing time scale 
confirmed the formation of silicide at the periphery of the NPs, similar to the 
observations at 4 h annealing.  
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Figure 6.6 TEM and EDX data: as synthesized fcc-FePt-A NPs (A1-3), fct-FePt-A NPs annealed 
at 700 °C for 4 h (B1-3).  
 
It was difficult to detect the presence of thin layer of metal silicide formation on 
NPs surface by XRD (Figure 6.3D3), however,  the presence of Si in fct FePt NPs 
was confirmed by TEM-EDX analysis. Figure 6.6 presents a typical TEM-EDX 
characterization of two sets of FePt NPs. fcc-FePt-A NPs do not present any trace of 
silicon atoms (Figure 6.6A), but fct-FePt-A NPs annealed at 700 °C for 4 h do 
present a strong EDX peak at 1.7474 keV (Si Kα1) which is a characteristic of 
silicon. The composition characterization of each sample was carried out by 
TEM-EDX analysis on three different areas, the composition results of which are 
presented in Table 6.3. 
 
Table 6.3 TEM-EDX data of the FePt NPs. 
Sample Fe Pt Si 
 (%) (%) (%) 
fcc-FePt-A (as prepared) 43.1± 0.7 51.5 ± 1.0 5.4 ± 1.5 
fct-FePt-A (4h, 700°C) 20.6± 0.7 25.4 ± 3.6 54.0 ± 3.0 
 
In contrast with the Fe/Pt ratio which remained constant at Fe0.43Pt0.57, the silicon 
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ratio increased from a nominal background signal of 5.4% up to 54.0% 
corresponding to a signal to noise ratio of about 10. Due to the weakened magnetic 
moment of the fct-FePt-A NPs, the remainder of this study focuses on fcc-FePt-A 
and fcc-FePt-silica-A NPs.  
 
6.2.2. Biomedical Applications 
 
6.2.2.1. Cell Toxicity 
 
A major hurdle preventing wide use of FePt NPs in biomedicine is their potential 
toxicity. Toxicity studies of FePt NPs are currently being performed in vitro, and 
no in vivo studies have been reported to date. Since the first reliable cytotoxicity 
study on FePt NPs reported in 2007,16 very few publications have thereafter 
developed the cytotoxicity of FePt NPs.15, 17, 22  A summary of the cytotoxicity 
data of FePt NPs is presented in Table 6.4. It is noticeable that there is little 
consistent literature on FePt NPs cytotoxicity, leaving the subject rather unclear. It 
was reported that whilst FePt-cysteine NPs had no significant toxicity at 
concentrations below 5 µg/mL, 50% cell damage was observed at 15.5 µg/mL 
after incubation.16 Additionally, FePt-Fe3O4 NPs showed no significant cell 
viability damage up to 3 days at 10 µg/mL,15 but FePt-Fe2O3 and FePt-CoS2 were 
reported to induce significant, ~50% cell viability damage even at concentrations 
as low as 1.5 µg/mL and 8.5 µg/mL of NPs, respectively.15-16 A hypothesis of 
mechanism of cytotoxicty of FePt NPs was proposed by Gao. et al where FePt 
cores are oxidized and destroyed to release platinum ions (Pt2+) under the acidic 
cellular environment like lysosomes. Pt2+ can enter into the nucleus and 
mitochondria, and has the ability to damage the DNA double-helix chains leading 
to cell apoptosis.28 
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Table 6.4 Summary of FePt NP cytotoxicity studies reported in the literature: Cells stands for the 
cell line, [NPs] is the nanoparticle concentration, tinc. is the incubation time. (Reprinted with 
permission from (23). Copyright 2010 American Chemical Society.)   
   Cytotoxicity  
Material 
Fe 
Precursors§ 
Coating Cells 
[NPs] 
(µg/mL) 
[Fe] 
(µg/mL) 
tinc.  
(h) 
Cell 
Damage 
(%) 
Ref. 
FePt-CoS2 Fe(CO)5 CoS2 shell Hela 1.5 ~0.007 24 50 16 
FePt-Cys Fe(CO)5 Cysteine Hela 
5 
15.5 
~0.7 
~2.5 
24 
24 
~10 
50 
16 
FePt-Fe2O3 Fe(CO)5 
Fe2O3 shell, 
L-dopa coating 
Hela ~8.3 
~0.045† 
~3.8 ‡ 
24 50 15 
FePt-Fe3O4 Fe(CO)5 Fe3O4 shell Hela 
40 
10 
20 
# 
# 
# 
24 
72 
72 
~10 
~10 
~30 
15 
FePt-COOH Fe(CO)5 
Bilayer of 
phospholipid 
(DSPE-PEG-2
000 carboxylic 
acid lipid) and 
oleic acid / 
oleylamine 
Hela 
A431 
SK-BR3 
HEK-293 
A2780 
~10.7 
~10.7 
~10.7 
~10.7 
~7.8 
1.72 
1.72 
1.72 
1.72 
1.25 
24 
24 
24 
24 
24 
~40 
~40 
~20 
~30 
50 
22 
FePt-SiO2-A Na2Fe(CO)4 SiO2 shell 
A375M, 
MCF, 
U2OS 
200 ~2 168 0 * 
FePt-A Na2Fe(CO)4 Cysteamine 
A375M, 
MCF, 
U2OS 
30 
60 
~5.3 
~10.5 
168 
72 
0 
~10 
* 
§ Pt precursor always Pt(acac)2, † Fe contribution from Fe2O3 shell not included, ‡ Fe from Fe2O3 shell 
included, # [Fe] can not be calculated * Data presented in this work.  
 
A later toxicity study with phospholipids coated fcc-FePt NPs showed 50% cell 
viability damage at only 1.25 µg/mL Fe concentration (~7.8 µg/mL Fe40Pt60 NPs).22 
In this study, high toxicity was attributed to the fast Fe release rather than Pt release 
from phospholipids coated fcc-FePt NPs. It was reported that whereas no Pt ion 
releasing was detectable, ~6% Fe was already released after 6 h incubation, and the 
percentage of Fe was further increased to ~20% after 24 h incubation in pH 4.8 
PBS.22 Whilst iron is essential for almost all living organism, it is still toxic and can 
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for instance act as a catalyst in the Fenton reaction which generates a wide range of 
free radical species including hydroxyl radicals, i.e. ·OH.32 
 
Fe2+ + H2O2 → Fe3+ + OH- + ·OH         eq. (1) 
 
These are among the most reactive free radical species known and have the ability 
both to react with a wide range of cellular constituents including pyrimidine bases 
of DNA and trigger lipid peroxidation in cellular membranes leading to cell death.32   
 
 
Figure 6.7 Viability of A375M cells incubated with fcc-FePt-silica-A NPs (A) at different 
FePt-silica-A concentrations (25, 50, 100, 200 µg/mL) up to 7 days, and A375M cells (B) MCF7 
cells (C) and U2OS cells (D) incubated with fcc FePt-A NPs at different FePt metal core 
concentrations (15, 30, 60, 120 µg/mL). (Reprinted with permission from (23). Copyright 2010 
American Chemical Society.) 
 
In this study, cytotoxicity of the NPs was evaluated by MTS assay on an A375M 
cell line treated with fcc-FePt-silica-A and fcc-FePt-A NPs with various 
concentrations and incubation times.33 fcc-FePt-silica-A NPs have good 
biocompatibility as expected (Figure 6.7A). There is no cell viability damage at 
incubation concentrations of fcc-FePt-silica-A up to 200 µg/mL even after 7 days 
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of incubation. One likely explanation is due to the protection of the inert silica 
shell.  
 
Both dose responses and time course studies on fcc-FePt-A NPs were also 
performed (Figure 6.7B). At 120 µg/mL, fcc-FePt-A NPs exhibited cytotoxicity 
which increases with incubation time. At concentration of 60 µg/mL, fcc-FePt-A 
NPs incubated with cells for 7 days showed a ~15% loss of cell viability. 
Significantly, there is no loss of cell viability at concentrations of 30 µg/mL and 
below, even after prolonged incubation periods of up to 7 days. Similar results 
were obtained with fcc-FePt-A NPs and both MCF7 and U2OS tumour cell lines 
(Figure 6.7C and D). 
 
To confirm these results, the chemical stability of fcc-FePt-A NPs in acidic 
environment of similar pH to lysosomal environment was investigated by 
incubation of fcc-FePt-A in pH 4.8 buffer solutions.17 The concentration of FePt 
NPs incubated in buffer solution is ~120 µg/mL to match the highest NP 
concentration used in the cytotoxicity study (Figure 6.7B-C). In a pH 4.8 
phosphate buffered saline (PBS), cysteamine coated FePt NPs show excellent 
chemical stability with only ~0.7% Fe, i.e. less than 0.1 µg/mL of iron was 
released after 7 days of incubation (Figure 6.8A1). As suggested by the recent 
literature,34-35 an in vitro lysosomal model, i.e. RPMI-1640 cell media containing 
20 mM sodium citrate (pH 4.8) was also used to better match the metabolic 
conditions in lysosome. In these more extreme conditions, more Fe was released, 
0.3 µg/mL (2.2%) after 6 h and up to ~2.4 µg/mL (19.4%) after 7 days, but 
importantly it remained at a level comparable to the release observed with Feridex 
(Figure 6.8A2).  
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The Pt release is insignificant in both buffer solutions, and the level of released Pt 
is between ~0.04% - 0.45% corresponding to ~0.04 - 0.45 µg/mL from 6 h to 7 
days at 120 µg/mL incubation concentration (Figure 6.8A1 and 2). The small 
amount of Pt release might be partially responsible for cell damage observed at 
very high dosage treatment, e.g. above 60 µg/mL (Figure 6.7B-C).  
 
 
Figure 6.8 Fe released from fcc-FePt-A NPs (♦) in pH 4.8 PBS (A1). Fe Released from fcc-FePt-A 
NPs (♦) and from Feridex (∆)35 in solutions at pH ~4.8 of RPMI-1640 cell media containing 20 
mM sodium citrate. The incubation concentrations for FePt and Feridex35 are 120 µg/mL and 25 
µg/mL respectively (A2). Photomicrographs (magnification x40) of Prussian blue-stained A375M 
cells cultured on cover slips in cell media (B1), media containing 30 µg/mL of fcc-FePt-A NPs (B2) 
and media containing 30 µg/mL of Feridex (B3) after overnight incubation. (Reprinted in part with 
permission from (23). Copyright 2010 American Chemical Society.) 
 
In contrast to the above mentioned results found in the literature, our study reveals 
that cysteamine coated fcc-FePt NPs have a very high chemical stability in pH 4.8 
PBS. Fe released after 24 h incubation is ~0.3%, with only a slight increase to 
~0.7% after 7 days of incubation (Figure 6.8A1). In an in vitro model, i.e. cell 
media containing sodium citrate,34-35 fcc-FePt-A NPs were found to release as 
little Fe as Feridex (Figure 6.8A2), with ~5.2% Fe found to be released after 24 h 
and ~19.4% after 7 days. On the one hand, this confirms that the low pH in 
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endosome/lysosome environment is not enough to dissolve the NPs, and that the 
presence of endogenous citrate or similar metallic chelates which can promote the 
dissolution of the iron by binding to solubilised Fe atoms is also necessary.34-35 On 
the other hand, such outcome is very important, because it suggests when 
considering the Fe release the safety of fcc-FePt-A NPs can be comparable to 
Feridex under similar experimental condition. While emphasising further the 
importance of the NPs environment, the chemical stability of the fcc-FePt-A NPs 
is further supported by the Prussian blue-stained experiments (Figure 6.8B). 
Indeed, photomicrographs obtained after overnight incubation show no stain for 
both blank control sample (Figure 6.8B1) and fcc-FePt-A NPs labeled cells 
(Figure 6.8B2). In contrast, Feridex labeled cells show significantly stainings 
(Figure 6.8B3) characteristic of the release of Fe3+ in the cells. These results 
confirm that the cystamine coating provides fcc- FePt-A NPs with high chemical 
stability. 
 
The high chemical stability of cysteamine coated FePt NPs certainly contributes to 
the NPs’ low cytotoxicity, and metal release is only one parameter that contributes 
to this. It is quite possible that differences in the NPs preparation, surface coating, 
ligand exchange, and extraction protocols could account for the spread of the 
cytotoxicity data reported in the literature. The toxicity may not necessarily be due 
to material itself through the release of its constituent. In the present study, we 
used the Collman’s reagent, Na2Fe(CO)4, to control the FePt NP stoichiometry 
and to ensure the simultaneous presence of Fe and Pt species during the formation 
of FePt alloy NPs, while the use of Fe(CO)5 has been shown to form NP with a 
core and a shell rich in platinum and iron, respectively.36 Furthermore, after ligand 
exchange, the extraction process was repeated up to 6 times to ensure removal of 
hazardous chemicals such as chloroform, oleic acid and oleylamine, while the 
thiol group provides a strong bonding between the cysteamine and the NP surface 
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preventing the ligands becoming lethal. While this publication was submitted, 
cysteamine coated FePt NPs were reported to induce very low cell damage on 
Veron cells after 24 h.14 However it is noticeable that a strong bonding to the 
surface of the nanoparticles protecting them from the cell’s environment comes in 
contrast with, for instance, a coating made with a bilayer structure of 
phospholipids, carboxylic acid and oleic acid/oleylamine.22 Indeed, even though 
this phospholipid approach provides aqueous solubility, it is also characterised by 
a weaker bonding strength and a more dynamic behaviour allowing the coating to 
slowly disperse in the cell. By doing so, the “free” ligands can alter the cell 
viability as well as the release of the NP constituents, since the surface of the 
particle is exposed to the cell. The NP chemical integrity can thus be further 
compromised. Such outcomes have been reported by Xu et al. although the 
authors focused on the opportunity this provided to use the NPs as a metal 
reservoir to kill cancerous cells.22 
 
While the very high chemical stability of fcc-FePt-A NPs was demonstrated in this 
report, cytotoxicity was observed at high concentrations above 30 µg/mL FePt and 
with long incubation times. This could be explained by contributions from i) the 
very small release of Fe and Pt, and ii) the high concentration of positive surface 
charges which could also interact with the more negatively charged cell 
membranes and induce membrane disruption.37 In addition, ligands with strong 
anchoring groups can reduce the toxicity, as illustrated in this publication, and it is 
noticeable that the present results were obtained with commercially available 
ligands (i.e. cysteamine); such that one should expect enhanced viability from, for 
instance, custom made bidentate thiol as developed recently for quantum dots.38-39 
These could provide cell viability at higher NP concentrations than 30 µg/mL. 
 
In this context, the little consistency observed when considering FePt NPs 
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cytotoxicity data available in the literature, stresses that the measured toxicity 
should always be associated to the nanocolloids, i.e. inorganic NPs plus organic 
stabilisers. The interplay between each component will indeed contribute to the 
cytotoxicity results with for instance a weak bonding to the NP surface increasing 
the probability of the nanocolloid to be toxic. It then appears that to be able to 
compare cytotoxicity data in a meaningful way, one needs to develop and use 
standardised approaches including the correlation between i) the evolution of the 
nanocolloids integrity, relying on both the inorganic NPs and the organic 
stabilisers, and ii) the cell viability. It should be noticed that in the context of 
apparently toxic NPs, the nanocolloid solution stability could easily be measured 
by time resolved transmission monitored sedimentation experiments. As the 
ligands come off the NPs surface the NPs tend to aggregate and fall out of 
solution. 
 
6.2.2.2. Cellular Uptake 
 
The cell plasma membrane is a dynamic structure that functions to segregate the 
chemically distinct intracellular milieu from the extracellular environment by 
regulating and coordinating the entry and exit of small and large molecules. Small 
molecules, such as amino acids, sugars and ions, can traverse the plasma 
membrane through the action of integral membrane protein pumps or channels. 
The cellular entry of macromolecules and particles involves various mechanisms 
that are used by cells to internalize macromolecules and particles within 
membrane bound vesicles derived by the invagination and pinching-off of pieces 
of the plasma membrane in a process termed endocytosis. Endocytosis is a global 
term and is divided into two broad categories, phagocytosis or cell eating (the 
uptake of large particles) and pinocytosis or cell drinking (the uptake of fluid and 
solutes). The phagocytosis process starts by the formation of membrane protrusion 
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triggered by the binding of phagocyte surface receptors to the ligands on the 
surface of a particle like a bacterium. The protrusion will engulf the ligand coated 
particles and will form an internal vesicle called phagosome (Figure 6.9A). 
Whereas the phagocytosis is typically only conducted by specialized mammalian 
cells, such as monocytes, macrophages, neutrophils, and microglia; the 
pinocytosis occurs in all cells by mainly four basic mechanisms: macropinocytosis, 
clathrin-mediated endocytosis, caveolae-mediated endocytosis, and clathrin- and 
caveolae- independent endocytosis (Figure 6.9B to F). 
 
 
Figure 6.9 Multiple portals of entry into the mammalian cell. The endocytic pathways differ with 
regard to the size of the endocytic vesicle, the nature of the cargo (ligands, receptors and lipids) 
and the mechanism of vesicle formation. (Reprinted by permission from Macmillan Publishers Ltd: 
[Nature] (40), copyright 2003.)  
 
The pinocytosis pathways differ with regard to endocytic vesicles and 
mechanisms of vesicles formation which can be viewed directly under TEM. One 
of the pinocytosis mechanisms is called macropinocytosis which accompanies the 
actin-driven formation of membrane protrusions upon stimulation by growth 
factors or other signals. These protrusions then collapse into the plasma 
membrane and fuse back with the plasma membrane, forming normally larger 
than 1 µm irregular-sized vesicles called macropinsomes (Figure 6.9B). Another 
pinocytic pathway is clathrin mediated (Figure 6.9C). Clathrin is a three legged 
structured protein, which has the ability to self-assemble into cages and curve 
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lattices under the director of the assembly proteins. The clathrin cages are 
typically about 120 nm in diameter and are responsible for driving membrane 
invagination and vesicle formation. Another class of coated vesicles are called 
caveolae which are flask-shaped invaginations of the lipid rafts which are 
cholesterol and sphingolipid-enriched microdomains found in cell plasma 
membranes. The caveolae are coated with caveolin, which is a dimeric protein and 
has ability to self-associate to form a striated caveolin coat on the surface of the 
membrane invaginations (Figure 6.9D). Caveolae are relatively smaller in 
diameter (50 to 60 nm) as compared to clathrin-coated pits. The last class of 
endocytic pathway is called clathrin- and caveolin- independent endocytosis, 
which are lipid rafts mediated invagination of cell membranes which are about 90 
nm in diameter and able to diffuse freely on the cell surface (Figure 6.9E and F). 
In addition, dynamine which is a multidomain GTPase that can assemble into a 
spiral or ‘collar’ recruited to the necks of vesicles, is required for clathrin-, 
caveolae- mediated and some clathrin- and caveolae- independent endocytosis 
pathways (Figure 6.9C, D and E).6, 40-44 
 
A TEM study was carried out in order to investigate the internalization of 
cysteamine coated FePt NPs into non-phagocytic tumour cells. Figure 6.10A 
illustrates that cysteamine modified fcc-FePt NPs can efficiently enter A375M 
non-phagocytic human cells without any external allied force such as transfection 
agents or electroporation. This can be attributed to the electrostatic attraction of 
cationic NPs to the negatively charged cell membrane. TEM analysis also 
demonstrated efficient cell internalization of fcc-FePt-A NPs into MCF7 and 
U2OS cells, as shown in Figure 6.10B-C. In contrast, the internalization of 
Feridex into non-phagocytic cell is poor. This is due to the lack of efficient 
binding of non-charged hydrophilic dextran coating to the plasma membrane, 
which limits the capability of cell internalization to the fluid phase endocytosis 
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pathway.45-46 To enhance the cellular uptake of dextran coated NPs, transfection 
agents or further surface functionalization are necessary.47 
 
  
Figure 6.10 TEM images of A375M (A) MCF7 (B) and U2SO (C) cells after 16 h incubation in 
media containing 30 µg /mL of fcc-FePt-A NPs. The cell uptake mechanism of fcc-FePt-A NPs 
through macropinocytosis in A375M cells as revealed by TEM images (D1-3) and a schematic 
drawing (D4). Cell internalization of fcc-FePt-silica-A NPs by A375M cells (E1), incubated at a 
NP concentration of 50 µg/mL after 16 h, and the zoomed in area (E2) of the cellular internalized 
fcc-FePt-silica-A NPs as labeled by the orange circle in (E1). (Reprinted in part with permission 
from (23). Copyright 2010 American Chemical Society.) 
 
With regard to the cellular uptake mechanism of fcc-FePt-A NPs, we often 
observed protrusions of the plasma membrane surrounding a cluster of NPs 
providing strong evidence for macropinocytosis, a non-specific endocytic process 
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that involves the internalization of large areas of plasma membrane together with 
significant amounts of fluid. A series of typical TEM images of this phenomenon 
are presented in Figure 6.10D1-3. An early stage of macropinocytosis 
phenomenon, cell membrane protrusion formed and surrounded FePt NPs 
including large amount of fluid is indicated by Figure 6.10D1. The protrusion 
collapsed together with the NPs and tended to fuse back with the cell membrane 
to form large irregular vesicles called macropinosomes with sizes larger than 1 
µm (Figure 6.10D2). Macropinosomes moved towards the centre of the cell 
shrank by losing water, changed from early-endosome-like organelle to a 
late-endosome-like organelle then merge completely into the lysosomal 
compartment (Figure 6.10D3).43 A schematic drawing of this type of cellular 
uptake is shown in Figure 6.10D4. The intercellular presence of fcc-FePt-silica-A 
NPs is shown in Figure 6.10E1 and E2. fcc-FePt-silica-A NPs also demonstrated 
efficient non-phagocytic human cell internalization by straightforward incubation, 
without any external allied force such as transfection agents or electroporation. 
 
There was no evidence in our study to support the involvement of the other 
pathways of endocytosis, the clathrin- and caveolae- dependent and independent 
pathways.42, 44 Further study will be needed to clarify the mechanism associated 
with cellular internalization and subsequent intracellular trafficking of cysteamine 
functionalized and silica coated FePt NPs.  
 
6.2.2.3.  In vitro MRI 
 
The effectiveness of fcc-FePt-A and fcc-FePt-silica-A as MRI contrast agents was 
investigated by measuring the dependence of the longitudinal T1 and transverse T2 
relaxation rates of water in 1% agarose gel on the Fe concentration of the NPs. 
The results are presented in Figure 6.11A-B respectively. Relaxivity ri is the 
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effectiveness of a contrast agent to enhance the relaxation of the water protons and 
is used to measure the efficiency of the NPs as MRI contrast agents. ri is defined 
as longitudinal relaxivity (i = 1) or transverse relaxivity (i = 2).6, 24 
 
Figure 6.11  T1-1 (s-1) (A) and T2-1 (s-1) (B) vs. [Fe] (mM) of the water in 1 % w/v agarose gel 
containing (●) fcc FePt-A, (▲) fcc FePt-silica-A and (♦) Feridex. Hysteresis curves (C) of fcc- 
FePt-A NPs (●), fcc-FePt-silica-A NPs (▲), and Feridex (♦) measured by SQUID from -5.0 T to 
5.0 T at 300 K. Data points are extrapolated to ± 7.1 T and labeled as hollow markers. 1H 
longitudinal relaxation rate of T2-weighted MRI images (D) of 1 % agarose gel water solution 
containing FePt-A NPs with (i) [Fe]= 0 mM, (ii) 0.02 mM (CFePt=6 µg/mL), (iii) 0.04 mM 
(CFePt=12 µg/mL). T2-weighted cellular imaging (E) of A375M cells loaded with FePt-A NPs with 
a cell density of (i) 10x103 cells/mL, (ii) 100x103 cells/mL, (iii) 1000x103 cells/mL. All 
measurements were completed by MRI (3D Spin Echo, TE = 30 ms, TR = 1 s) at 7.1 T. (Reprinted 
in part with permission from (23). Copyright 2010 American Chemical Society.) 
 
The r1 and r2 values of two FePt NPs and Feridex, a commercial MRI contrast 
agent are shown in Table 6.5. At 7.1 T, the FePt NPs and Feridex only have a 
weak influence on the T1 relaxation rate of water protons.6 In contrast, the 
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presence of FePt NPs has significant effect upon water T2 relaxation rate of the 
gels (Figure 6.11B). At 7.1 T, the r2 relaxivity of the Feridex is about 148 s-1mM-1 
which agrees with the literature value (Table 6.5). The fcc-FePt-silica-A NPs have 
a 40% larger r2 than Feridex. This is attributed to higher magnetization of 
fcc-FePt-silica-A NPs than Feridex at 7 T. By design, the commercial SQUID 
magnetometer’s highest external magnetic field is 5 T, whilst MRI experiments 
were performed at 7.1 T. However, a higher magnetization of fcc-FePt-silica-A 
NPs compared to Feridex can be expected by extrapolating the magnetization 
curves from 5 T to 7.1 T (Figure 6.11C). It is indeed noticeable that Feridex has 
already saturated at 5 T, while the silica coated FePt NPs had yet to reach 
saturation magnetization. The extrapolation to 7.1 T implies that under MRI 
magnetic field, the magnetic response of fcc-FePt-silica-A NPs is larger than that 
of Feridex. 
 
Table 6.5 1H relaxivity values (r1 and r2) for agarose gel solution containing Feridex I.V.® , 
fcc-FePt-A and fcc-FePt-silica-A NPs,23 (Reprinted with permission from (23). Copyright 2010 
American Chemical Society.) compared to values of some commercial contrast agents base on the 
current literature (7.1 T, 300 MHz MRI).6  
Sample r1 (s-1mM-1) r2 (s-1mM-1) 
fcc FePt-A 2.5 ± 1.0 887 ± 32 
fcc FePt-silica-A 0.3 ± 0.1 210 ± 3 
Feridex I.V.® (Ferumoxides) 0.9 ± 0.1 148 ± 1 
Feridex I.V.® as reported 1.8* 132* 
Ferucarbotran. A® 1.6* 205* 
Ferumoxtran-10® 1.4* 71* 
Ferumoxytol® 2* 95* 
*Experimental uncertainties are not reported. 
The main result is that the r2 relaxivity of the fcc-FePt-A NPs is 6 times larger 
than that of Feridex (Figure 6.11C and Table 6.5). For example, the 1H T2 
relaxation rate of water in gels with no contrast agent was ~10 s-1, but when the 
fcc-FePt-A NPs at [Fe] = 0.04 mM was present, the T2 relaxation rate increased 
approximately four times (43.5 s-1). The presence of Feridex at twice the iron 
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concentration ([Fe] = 0.16 mM) only increased the relaxation rate of water by 
about two times (34.1 s-1). Typical T2 weighted MRI images of fcc-FePt-A NPs in 
gel as shown in Figure 6.11D; the signal intensity deceases in the T2-weighted MR 
thus appearing darker as the concentration of NPs increases. The FePt NPs 
produce distinct image contrast within gels at concentrations as low as 6 µg/mL. 
This is well within the safety range as supported by our cytotoxicity data (Figure 
6.7A). The high MRI relaxivity r2 of fcc-FePt-A NPs is attributed to a 
combination of i) high FePt magnetization (Figure 6.11C), ii) a thin organic 
coating, and iii) their small size resulting in effective dispersion across a sample. 
This combination creates a very effective T2 MRI contrast agents even at µg/mL 
concentrations. Our results underline the importance of engineering the interface 
of NPs and demonstrate that a strong magnetic moment such as FePt’s combined 
with a thin coating layer which has an open molecular structure allowing very 
close aqueous proximity, are essential parameters for the design of new 
generations of diagnostic and therapeutic MRI contrast agents. 
 
Cellular imaging is a technique that is able to visualize specific cells in an intact 
animal. MR cellular imaging is a powerful non-invasive technique therefore is 
able to detect specific cells of interest in living organisms over time, which 
distinguishes conventional cellular imaging from histology and molecular biology 
protocols which typically require a disintegration of the organisms.6 For MR 
cellular imaging, a MRI contrast agent is normally required in order to gain 
enough sensitivity and selectivity to distinguish cells of interest from other 
biological subjects. A good contrast agent should be able to selectively and 
efficiently enter cells of interest. Magnetic NPs are T2 contrast agents and have 
been applied to monitor the migration, biodistribution, and behaviour of cells in 
vivo by MRI with a typical spatial resolution of the order of tens of microns.  
 
fcc-FePt-A NPs have shown great potential to be used as a new highly sensitive 
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MRI probe for cellular imaging, as it has demonstrated a much stronger T2 effect 
than iron oxide NPs. Furthermore, efficient cellular uptake of fcc-FePt-A NPs by 
non-phagocytic tumour cells during incubation without transfection agent 
assistance or electroporation treatment has been revealed by TEM (Figure 
6.10A-C). In this study, we further demonstrate the capability of fcc-FePt-A NPs 
to be used as MRI probes for cellular imaging by analyzing labelled cells in vitro 
in agarose gels.  
 
Typically the limit of spatial resolution of μ-MRI scanners is of the order of tens 
of microns. However cells can be studied by MRI by labelling the cells with MRI 
contrast agents and their presence detected by observing their effect upon image 
contrast. Indeed, MR imaging on FePt labelled A375M cell shows significant 
signal intensity loss induced by the effect of FePt NPs and this signal loss is 
proportional to cell density in agarose gel (Figure 6.11E). The signal intensity loss 
could be observed with cell densities as low as 10-100 cells/µL. In addition to the 
stronger T2 effect of FePt NPs, it should be noticed that they also provided higher 
chemical stability than iron oxide NPs, as observed in the Prussian blue-stained 
experiments (Figure 6.8B). This is a very promising indication that fcc-FePt-A 
NPs will demonstrate enhanced stability in biological environments including for 
example lysosomes where the pH is below 5.5. This makes fcc-FePt-A NPs an 
appealing platform for cell tracking investigations. 
 
6.2.2.4. In vivo MRI 
 
To investigate the in vivo potential of the FePt NPs as MRI contrast agents, cell 
media containing varying concentrations of fcc-FePt-A NPs were injected into the 
eyes of in ovo Day 4 quail embryos. The purpose of this experiment is to 
investigate the concentration of FePt NPs required to produce hypointensities in 
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an in vivo environment. 3D MRI images were acquired of the embryos in-ovo 
after injection. The eye injected with FePt NPs in cell media was compared to the 
other eye without injection. Moreover, injection of blank cell media solution was 
used as a control.  
 
Figure 6.12 Embryo injected in ovo with cell culture media (1 µL) containing no NPs (A) and 20 
µg/mL fcc-FePt-A (B). 3D surface reconstruction of embryo eyes (blue) and blood vessels (red) 
showing the position (yellow) of the transverse and coronal images (A1-B1); Dorsal view of 
transverse image of the embryo’s head aligned through the eyes (A2-B2); Anterior view of coronal 
image of the embryo’s head aligned through the eyes (A3-B3). 2D slices from 128x128x128 3D 
Rare-8 MRI data set of Day 4 quail embryo egg (TR⁄TE = 250 ⁄ 25 ms), field of view of 30 mm and 
pixel dimensions of 0.234mm/pixel. Label: y= yolk, a= albumen, b= brain, in-e= injected eye, 
un-e= un-injected eye, h= heart; scale bar indicates 1mm. All the MRI measurements were 
completed at 7.1 T. (Reprinted with permission from (23). Copyright 2010 American Chemical 
Society.) 
 
Figure 6.12A and B display 3D MRI image data sets after injection which have 
been processed to highlight embryo eyes in blue, the blood vessels in red, and the 
NPs in green. The transverse and coronal images through the embryo’s head are 
presented. The un-injected eye (un-e) acts as an internal control. There is no 
difference in the contrast between the un-injected and the uppermost eye which 
had been injected with a 1 µL of culture media only (Figure 6.12A2-A3). 
However, when the injection media contained 20 μg/mL of fcc-FePt-A NPs, a very 
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distinct hypointensity appears in the injected eye (Figure 6.12B2-B3). This was 
consistently observed when varying the NP concentration.  
 
 
Figure 6.13 Embryo injected in-ovo with cell culture media (1 µL) containing fcc-FePt-silica-A 
NPs at FePt core concentration 27 µg/mL. 3D surface reconstruction of embryo eyes (blue), blood 
vessels (red) and NPs (green) of the transverse image (A). Dorsal view of transverse image of the 
embryo’s head aligned through the eyes (B). 2D slices from 128x128x128 3D Rare-8 MRI data set 
of Day 4 quail embryo egg (TR⁄TE = 250 ⁄ 25 ms), field of view of 30 mm and pixel dimensions of 
0.234mm/pixel. Label: y = yolk, b = brain, in-e = injected eye, un-e = un-injected eye; scale bar 
indicates 1mm. (Reprinted with permission from (23). Copyright 2010 American Chemical 
Society.) 
 
Figure 6.13 also illustrates the effect of injecting embryo with fcc-FePt-silica-A 
NPs (27 µg/mL FePt core concentration). Figure 6.13A is the 3D surface 
reconstruction of the transverse image shown in Figure 6.13 B, with the green 
colour indicating the position of the injected contrast agents. Figure 6.13B 
illustrate the presence of the NPs solution produced a strong hypointensity in the 
images clearly visible because of the darker contrast when comparing with the eye 
which has not been injected.  
 
In summary, we have demonstrated that FePt NPs can be successfully used as 
cellular and in vivo MRI probes. This is illustrated both by cell MRI (Figure 
6.11E) and distinct hypointensity of ~1 mm in size observed in in vivo 
environment the FePt NPs were injected into (Figure 6.12 and Figure 6.13). Their 
high transverse relaxivity r2 allows using less NPs than with iron oxide contrast 
A B 
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agents such as Feridex which makes FePt NPs very promising contrast agent to 
identify small lesions such as lymphnode metastases. In addition, FePt NPs can be 
used as potent MRI probes for cellular imaging, even at very low NP 
concentrations. This will allow, for instance, cell biodistribution, migration and 
behaviour to be monitored in vivo.  
 
6.3. Conclusion 
 
In conclusion, this chapter has presented the synthesis and characterization of a 
family of FePt NPs: fcc-, fct-FePt-A NPs, and fcc-FePt-silica-A NPs. The reduction 
of magnetic properties observed with both SQUID and MRI relaxivity of 
fct-FePt-A NPs prepared via annealing of silica coated NPs, is attributed to the 
formation of silicides. Although widely used, we have shown that this approach can 
be extremely detrimental to the targeted biomedical applications. Thus, research 
should focus on both direct fct-FePt synthesis and buffer layers engineering to 
prevent atomic diffusion.  
 
In sharp contrast with some previous reports, our biocompatibility studies clearly 
demonstrate the absence of cytotoxicity at concentrations below 30 µg/mL, even 
after 7 days incubation. The biocompatibility is mainly attributed to the strong 
surface coating and the extraction protocols. Another striking feature for cellular 
imaging is the ability we have shown for FePt NPs to efficiently enter tumour cells 
without requiring any external mediation; the cellular uptake by non-phagocytic 
tumour cells occurs via an apparent macropinocytosis mechanism. The 7.1 T MRI 
studies, in vitro and in vivo, have confirmed that both fcc-FePt-A and 
fcc-FePt-silica-A NPs are stronger T2 contrast agents than commercial Feridex, 
with fcc-FePt-A T2 relaxivity (r2) being more than six times larger. The superior 
capability of MRI contrast enhancement of FePt NPs makes them an ideal platform 
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for the design of diagnostic and therapeutic agents for image-guided magnetic drug 
delivery and hyperthermic tumour ablation. The findings of this study underline the 
importance of engineering magnetic NP interfaces combining intrinsically strong 
magnetizations with coating layers. Finally, our studies have also demonstrated that 
FePt NPs can be used successfully for cellular and in vivo imaging, thus confirming 
the potential of FePt NPs in regenerative medicine and stem cell therapy. 
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Chapter 7 
 
 
Conclusion 
 
Due to their unique magnetic and thermal properties, magnetic NPs offer unique 
opportunities for magnetic separation, targeted drug delivery, and hyperthermic 
ablation of cancer and as contrast agents in magnetic resonance imaging (MRI). 
While iron oxide NPs have been explored as important nano-magnetic materials for 
a wide range of biomedical applications over the past two decades, iron platinum 
(FePt) metallic alloy NPs have recently emerged as promising candidates for a new 
generation of magnetic nano-medicine. Control of composition and crystalline 
structure are among the main challenges faced by scientists working at synthesizing 
FePt NPs. In the context of this PhD study, three main approaches have been 
applied to synthesize FePt NPs before focusing on their toxicity and properties as 
MRI contrast agent.  
 
In Chapter 4, a systematic investigation of low temperature aqueous solution 
syntheses focusing on the stoichiometry and the composition of FePt NPs was 
presented. A quaternary system based on water, isooctane, and Brij52 as non-ionic 
surfactant and butanol as a co-surfactant was used. A precise composition analysis 
Chapter 7.Conclusion                                                    Shu Chen, St Andrews 
 
 
 
172
of individual NPs was carried out and revealed an inhomogeneous distribution of 
Fe and Pt between particles. By combining characterization techniques including 
ICP-OES, XRD, EFTEM and nanoSTEM-EDX, this investigation revealed a 
two-stage growth mechanism of the NPs. Primary Pt rich nanocrystals first 
nucleate in a supersaturated solution and then keep on growing and coalescing 
into larger knobbly particles. Polydomain Pt rich NPs are already formed after 15 
min of synthesis. While excess of Fe is found in film-like material. Extending 
reaction time up to 16 h lead to larger NPs but did not alter the Fe to Pt ratio 
because the competitive hydrolysis of the iron precursors is completed within 15 
min. The major limiting parameters are iron salts hydrolysis and a mismatch in the 
co-reduction kinetic of the two salts used to form the alloy. This was confirmed by 
using the less hydrolytically unstable FeII precursors and the faster reducing agent, 
NaBH4 which could level off part of the reaction kinetic difference between Pt 
and Fe precursors. Both approaches increased the iron content of the nanoparticles 
from 15% to ~34%. It was concluded that while a degree of control is possible, to 
obtain better stoichiometry in FePt NPs synthesized at room temperature, future 
investigations should first focus on overcoming the formation of hydrolytically 
unstable iron complexes, preferably by working in the absence of water. 
 
Based on the knowledge and experience learned from the FePt NPs synthesis in 
aqueous solution, a modified thermal decomposition method was developed for 
FePt NPs synthesis in Chapter 5. By using benzyl ether as a high-boiling organic 
solvent with Na2Fe(CO)4/Pt(acac)2 in the presence of oleic acid and oleylamine, 
uniform, well dispersed and close 1 to 1 iron to platinum ratio fcc-FePt NPs were 
obtained. The Fe2- precursor can act as a reducing agent for Pt(acac)2, through the 
reaction Fe2-+Pt2+→Fe + Pt, thus simultaneous generation of iron and platinum can 
be expected. In addition, the potential of ionic liquids (ILs), as novel solvents for 
FePt NPs synthesis was explored. ILs are low-melting organic salts, many of which 
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are liquid over a wide range of temperature, and can be used as solvents for 
numerous inorganic and organic materials.7-11 The results indicate that ILs can not 
only be used as a solvent for high temperature synthesis of FePt NPs, but also can 
provide an exciting alternative pathway to direct synthesis fct-FePt NPs. Extension 
of this work will need to focus on gaining further insight into fct-FePt formation 
mechanism in ILs, reduce NPs aggregation and control the polydispersity of 
fct-FePt NPs.  
 
In Chapter 6, the bioapplication of FePt NPs as MRI contrast agents was 
investigated. A family of FePt NPs including cysteamine coated fcc, fct FePt NPs 
and silica coated fcc FePt were specifically designed as model NPs to determine 
their toxicity parameters and assess the criteria needed to optimise the nano MRI 
contrast agent architecture. The reduction of magnetic properties observed with 
fct-FePt-A NPs prepared via annealing of silica coated NPs was attributed to the 
formation of silicides. Although widely used, this approach can be extremely 
detrimental to the targeted biomedical applications as shown in this work. Thus, 
research should focus on both direct fct-FePt synthesis and buffer layers 
engineering to prevent atomic diffusion. In contrast with previous reports, this work 
demonstrated that FePt NPs could be made non-toxic at the NP concentration as 
high as 30 µg/mL. TEM revealed that positively charged FePt NPs can efficiently 
enter tumour cells without requiring any external mediation. The cellular uptake by 
non-phagocytic tumour cells occurs via an apparent macropinocytosis mechanism. 
The 7.1 T MRI studies, in-vitro and in-vivo, confirmed that both fcc-FePt-A and 
fcc-FePt-silica-A NPs are stronger T2 contrast agents than commercial Feridex, 
with fcc-FePt-A T2 relaxivity (r2) being more than six times larger. The superior 
chemical stability and capability of MRI contrast enhancement of FePt NPs makes 
them an ideal platform for the design of diagnostic and therapeutic agents for 
image-guided magnetic drug delivery and hyperthermic tumour ablation. 
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In summary, different synthetic approaches for FePt NPs synthesis have been 
investigated. Whereas the aqueous media pathway is compromised by the 
hydrolysis of the iron precursor, the thermal decomposition method appears to be 
more promising to synthesize FePt NPs with controlled stoichiometry. In parallel, 
ILs have been demonstrated can not only be used as solvents for FePt NPs 
synthesis, but also can provide an exciting alternative pathway to synthesize 
fct-FePt NPs directly. As often when identifying new potentials for a chemical 
pathway, more work is needed to better understand the fct-FePt formation 
mechanism in ILs. For bioapplications of FePt NPs, it was demonstrated that FePt 
NPs could be made non-toxic at concentration used in the clinical environment. 
FePt NPs showed 6 times stronger MRI T2 contrast effect than Feridex, which 
makes them an ideal platform for the development of multifunctional diagnostic 
and therapeutic nano-tools in biomedicine.  
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Appendix 
 
 
Appx. I. Experimental Methods for Chapter 4 
 
Appx. I.1. Materials 
 
All chemical reagents, unless otherwise stated, were purchased from Sigma 
(Poole, UK). All chemicals were degassed before use. Iron (III) chloride (FeCl3,, 
reagent grade, 97%), iron (II) chloride (FeCl2, anhydrous, beads, 99.9% trace 
metals basis), iron (II) acetate (Fe(CO2CH3)2, 99.995% trace metals basis), 
Iron(III) nitrate nonahydrate (Fe(NO3)3.9H2O, ACS reagent, ≥  98%),  
potassium tetrachloroplatinate (II) (K2PtCl4, 98%), sodium hexachloroplatinate 
(IV) hexahydrate (Na2PtCl6.6H2O, 98%), hydrazine monohydrate (N2H4 • H2O, 
reagent grade, 98%), sodium borohydride (NaBH4, ReagentPlus®, 99%), 
polyethylene glycol hexadecyl ether, Brij52 (C16H33(OCH2CH2)2OH, average Mn 
~330 kD), 1-dodecane thiol (CH3(CH2)11SH, ≥98%), isooctane (ACS reagent, 
≥ 99.0%), hexane (ACS reagent, 99.0%), ethanol (ACS reagent, ≥ 99.5%), 
methanol (ACS reagent, ≥99.8%), HCl (Trace SELECT®, ≥ 37%) and HNO3 
(Trace SELECT®, ≥ 69.0%). 
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Appx. I.2. FePt Nanoparticles Synthesis 
 
In a typical synthesis, a surfactant (Brij52) solution (0.3 mol/L) was prepared by 
mixing isooctane (20 mL), Brij52 (1.98 g) and butanol (110 µL) in a surfactant to 
alcohol molar ratio of 5:1. Dissolution was obtained after 15 min sonication. 
K2PtCl4 (277 mmol/L) and FeCl3 (277 mmol/L) aqueous stock solutions were 
added to the amphiphilic system to obtain equal [Pt2+] and [Fe3+] concentration 
(2.5 mmol/L). 30 min sonication was then applied, followed by injection of 
N2H4.H2O to reach a molar ratio of [N2H4.H2O] / [Fe+Pt] = 40.  
 
The hydration, w, is the molar ratio of water to surfactant molecules, 
 
w = [H2O] / [Brij52]           eq.(1) 
 
and the final w is reached 4 after addition of hydrazine monohydrate. The system 
was stirred at 30 ºC for 3 h. Dodecane thiol was then injected and the solution 
aged for further 15 min. The NPs were then precipitated by adding alcohol, and 
collected by centrifugation. This extraction step was repeated several times. 
A similar protocol was followed when the syntheses were completed with 
different iron and platinum precursors and a different reducing agent. 
 
Appx. I.3. Characterization Techniques 
 
Impedance spectroscopy was used to quantify the electrical conductivity of the 
amphiphilic solutions. All samples had a surfactant concentration of [Brij52] = 0.3 
mol/L, and a surfactant to co-surfactant ratio of [Brij52] / [butanol] = 5. Water 
content, w, was varied from 1 to 6. The investigation of electrochemical properties 
of non-ionic amphiphilic systems is notoriously difficult due to the lack of charge 
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carriers. Therefore a dilute salt solution (10-3 mol/L NaCl in this work) is typically 
used instead of water to provide sufficient charge carriers to allow a detectable 
signal to be obtained while making sure the chemical phase behavior is not 
affected.1 The electrochemical test cell consisted of two disk-shaped electrodes 
within a thermally regulated cylindrical container. The test sample was placed 
between these electrodes and the height of the upper electrode was adjusted to 
bring it into contact with the upper surface of the solution to be tested. The 
temperature was controlled at 30 ± 1 ºC using a closed loop circulating water 
heating system. 
 
Impedance can be expressed as the sum of a real ( 'Z ) and an imaginary ( ''Z ) 
component. 
 
'jZ'Z'Z +=              eq.(2) 
 
'Z  relates to the resistive properties of a sample while ''Z  is related to the 
reactive elements, that is capacitances and inductances. Impedance spectra are 
obtained by sweeping the frequency over a wide range, so causing variations in 
the values of 'Z  , ''Z  and Z .2 Such spectra are conveniently presented as 
so-called Nquist plots in which ''Z  is plotted against 'Z . Such impedance 
spectra were obtained using a Solartron 1260 Frequency Response Analyser 
operating in two-electrode mode and run using ZPlot software. An a.c. potential of 
amplitude 400 mV was applied over a frequency range of 0.5 Hz to 1 MHz. The 
resulting Nyquist spectra contained approximately semicircular features which 
can be fitted to an equivalent electronic circuit model consisting of a resistance, R, 
and a capacitance, C, connected in parallel. The distance between the two 
intercepts of the semicircular arc with the 'Z  axis gives the value of R. C is 
related to the value of signal frequency, f (Hz), at the maximum height of the arc 
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where: 2-3 
 
Rf2π
1C =               eq.(3) 
 
Values of R and C were extracted from the impedance data using this fitting 
procedure in the ZView software package. The conductivity k (S/cm) of the 
solutions were calculated according to the following equation:3 
 
AR
dk =               eq.(4) 
 
where d (cm) is the distance between the electrodes and A (cm2) the effective area 
of the electrodes. In this experiment, the electrode radii were 1 cm and the 
distance between the electrodes was set to 0.3 cm. Standard deviation values of 
the conductivity were obtained by repeating each impedance measurement 3 times 
and fitting each resulting spectrum separately. 
 
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) 
measurements were completed with a Perkin Elmer Optima 5300 DV 
spectrometer. FePt NPs were dissolved overnight at room temperature by addition 
of hydrochloric acid (Trace SELECT®, ≥37%) and nitric acid (Trace SELECT®, 
≥ 69.0%) mixed in 3:1 volume ratio (aqua regia). After full dissolution of the 
NPs, the solutions were further diluted with deionised water. 
 
Wide-angle powder X-ray diffraction (XRD) spectra were collected on a Stoe 
STADI/P powder diffractometer operating in transmission mode and with a small 
angle position sensitive detector. The peaks were fitted by Lorentzians with 
STOEwinXpow and Kaleida-Graph software to determine the peak positions and 
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width. The crystalline grain size equivalent to the “average” dimension of the 
crystallites, DXRD, of the FePt NPs was calculated according to Scherrer’s formula: 
4 
 
DXRD = 0.9λ/(B cosθ)           eq.(5) 
 
where λ =1.936 Å corresponding to the wavelength of the incident X-ray radiation 
generated using a FeKα1 source, B is the full width at half maximum of the peak 
intensity (FWHM), θ is the glancing angle.4 DXRD is determined based on (111), 
(200) and (220) peaks.  
 
The composition of FexPt1-x NPs was deduced from the published variation of the 
fcc-FePt lattice constant with the alloy composition (Appx.Fig. 1).5 
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Appx.Fig. 1 FePt lattice constant (a) analyzed by XRD vs. composition curve. Data were extracted 
from ref.5 (Reprinted with permission from (6). Copyright 2010 American Chemical Society.) 
 
Appx.Fig. 1 leads to the following equations: 
 
x%Fe < 40% a = - 0.0014 x%Fe + 3.929      eq.(6) 
x%Fe > 40% a = - 0.0041 x%Fe + 4.039      eq.(7) 
 
It is noticeable that the alloys used by Bonakdarkpour et al were prepared by 
sputtering of Fe and Pt sources. Ideally nanoparticles and not films would have 
been used for us to compare with. However, at the moment, there is not a 
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consistent set of data available in the literature covering size, composition and 
surface chemistry of colloidal FePt NPs. At the current stage of development of 
FePt alloy NPs controlling the size and composition is already a challenge, as 
illustrated by our report, and using vacuum depositing films of FexPt100-x provides 
the most reliable reference to compare our material with.  
 
In our study, a was determined based on (111), (200) and (220) peaks to reduce 
potential risks of systematic error compared to a single peak analysis. A Rietveld 
approach could have been used as an alternative, however it would have been 
more time consuming without necessarily increasing the data precision.7 
 
Transmission electron microscopy (TEM) was conducted on an FEI Tecnai F20 
transmission electron microscope equipped with a field emission gun and 
operating at 200 kV.  
 
Nanometer scale scanning transmission electron microscopy and energy 
dispersive X-ray Energy dispersive X-Ray analysis was performed in both TEM 
and STEM modes using an EDAX spectrometer. Fe and Pt composition ratios 
were determined by comparing the intensity of Kα and Lα EDX peaks from a thin 
film FePt sample of known stoichiometry. Appx.Fig. 2A and B shows respectively 
the bright/dark field image  of a well-characterised fct-FePt - 1:1 Fe:Pt ratio - 
grown by molecular beam epitaxy (MBE) on MgO substrate.8 The red box in 
Appx.Fig. 2B indicates the area from where the nanoSTEM-EDX spectrum was 
obtained. The reference spectrum was shown in Appx.Fig. 2C, the ratio of Fe Kα 
at 6.398 keV and Pt Lα at 9.441 keV is about 0.8 ± 0.1 and was used as a reference 
to determine the composition of FePt NPs samples at a nanometer scale. 
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Appx.Fig. 2 Bright field STEM picture (A), corresponding high angle annular dark field (HAADF) 
STEM image with red squares indicating areas analyzed by nanoSTEM-EDX (B) and EDX spectra 
(C) of a 1:1 Fe:Pt ratio MBE-grown FePt(L10)/MgO sample. 
 
False-coloured energy filtered TEM (EF-TEM) images were obtained by using 
the Pt-M4,5 and Fe-L2,3 EELS edges, respectively, to map and overlap Pt and Fe 
rich areas. 
 
A superconducting quantum interference device (SQUID) magnetometer 
(MPMS XLTM from Quantum Design) was used to characterize the NPs 
magnetic properties. Zero-Field Cooled and Field Cooled (ZFC/FC) 
measurements were completed as follows: the sample was first cooled from room 
temperature to 5 K without applying any external field, then a small field of 100 
Oe was applied and the magnetization of NPs was recorded as the temperature 
was slowly increased to 275 K. The FC curve was obtained by cooling the sample 
back to 5 K while the same external field of 100 Oe was applied. The 
magnetization was then measured as the temperature was slowly increased to 275 
K. Hysteresis measurements were completed at temperatures of 5 K and 300 K 
with an external field sweep from -5 to 5 Tesla. 
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Appx. II. Experimental Methods for Chapter 5  
 
Appx. II.1. Materials  
 
All chemical reagents, unless otherwise stated, were purchased from Sigma, used 
without further purification but degassed before use: disodium 
tetracarbonylferrate-dioxane complex (Na2Fe(CO)4•1.5 C4H8O2), platinum(II) 
acetylacetonate (Pt(acac)2, 97%), oleylamine (70%), oleic acid (90%). When it is 
available, ACS grade was chosen to select the solvents: dibenzyl ether (≥ 98.0%), 
hexane (99.0%), ethanol (≥ 99.5%) and chloroform (≥ 99%, anhydrous).  
 
Appx. II.2. Synthesis 
 
Ionic liquids (ILs were provided by Dr. Mark Muldoon and Dr Kris Anderson from 
University of Belfast): Trihexyl(tetradecyl)phosphonium bis{(trifluoromethyl) 
sulfonyl}. amide ([P66614][NTf2]) was prepared by mixing trihexyl 
(tetradecyl)phosphonium chloride ([P66614]Cl) (supplied by Cytec) with  a slight 
excess (5 mol%) of Li[NTf2] which had been dissolved in de-ionized water. After 
stirring for 3 hours the hydrophobic [P66614][NTf2] was washed with portions of 
de-ionized water to remove LiCl and excess Li[NTf2]. After the aqueous washings 
were found to be chloride free by testing with silver nitrate (AgNO3), the IL was 
washed a further twice. The resulting IL was then dried, first using a rotary 
evaporator, followed by further drying under high vacuum while heating at 70 oC. 
The water content of the dried IL was found to be less than 400 ppm, and its 
structure was confirmed by 1H NMR and 13C NMR.  
 
FePt NPs: All the syntheses were completed under inert atmosphere. In a typical 
reaction, Na2Fe(CO4) (0.2 mmol) and a mixture of Pt(acac)2 (0.2 mmol), oleyl 
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amine (1.6 mmol) and oleic acid (0.8 mmol) were dissolved in separate jars 
containing 2 mL of [P6 6 6 14][NTf2] used as a solvent. After stirring at 100 °C for 1 h, 
the two solutions were mixed together and the temperature rose up to 150 °C for 1 h. 
To initiate the reaction, the temperature of the solution was further increased up to 
300-340°C with a heating rate of 15 °C/min. After reaction, the solution was cooled 
down to room temperature. NPs were then precipitated by ethanol addition and 
centrifugation. The supernatant was discarded, while the sediment was dispersed in 
hexane, and precipitated two more times with ethanol and centrifugation.  
 
For reaction time investigation experiments: aliquot NPs solutions were extracted 
to monitor the NPs growth mechanism at different reaction temperature and time. 
The reaction was quenched by mixing sample solution with ethanol immediately 
once taken from the reaction system.  
 
Additional precursor injection protocol: synthesis was started  with 4 mL of 0.025 
M Na2Fe(CO)4 and Pt(acac)2, [oleylamine]/[Pt(acac)2] = 16, [oleic 
acid]/[Na2Fe(CO)4] = 8, heating rate = 5 °C/min. After heating the main solution to 
300 ºC for 0.5 h, additional Fe and Pt precursor solution was injected drop wise for 
a period of 0.5 h. The additional Fe and Pt precursors solution were injected 
according to following sequence: Na2Fe(CO)4 was added into 1 mL ionic liquid, 
[Na2Fe(CO)4] = 1 M. In another separate jar, Pt precursor and surfactants were 
added into 1 mL ionic liquid as well, [Pt(acac)2] = 1 M, [oleylamine] / [Pt(acac)2] = 
8, [oleic acid] / [ Na2Fe(CO)4] = 4. Both mixtures were kept at 100 ºC for 0.5 h for 
dissolving purposes, mixed and stirred for 3 min before injection. After the slow 
injection of additional precursors, the final [Na2Fe(CO)4] = [Pt(acac)2] = 0.05 M. 
The reaction solution was kept at 300 ºC for another 0.5 h.  
 
Appx. III. Experimental Methods for Chapter 6 
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Appx. III.1. FePt Nanoparticles Preparation 
 
Materials: All chemical reagents, unless otherwise stated, were purchased from 
Sigma, used without further purification but degassed before use: disodium 
tetracarbonylferrate-dioxane complex (Na2Fe(CO)4•1.5 C4H8O2), platinum(II) 
acetylacetonate (Pt(acac)2, 97%), oleylamine (70%), oleic acid (90%), cysteamine 
(CA, HSCH2CH2NH2, BioChemika, ≥ 98.0%), tetraethylorthosilicate (TEOS, 
Si(OC2H5)4, GC, ≥ 99.0%), (3-Aminopropyl)triethoxysilane (APTES, 
H2N(CH2)3Si(OC2H5)3, ≥ 98%), IGEPAL® CO-520 (NP-5, (C2H4O)n•C15H24O, n 
~5). When it is available, ACS grade was chosen to select the solvents: dibenzyl 
ether (≥ 98.0%), hexane (99.0%), ethanol (≥ 99.5%), chloroform (≥ 99%, 
anhydrous), methanol (≥ 99.8%), cyclo-hexane (GC, ≥ 98.0%), ammonium 
hydroxide aqueous solution (NH4OH, 28.0 - 30.0%). 
 
fcc-FePt NPs synthesis: All the syntheses were carried out inside a glove box. A 
mixture of Pt(acac)2 (1 mmol), oleyl amine (8 mmol) and oleic acid (4 mmol) in 10 
mL of dibenzyl ether was placed in a 50 mL round bottom flask connected to a 
condenser. Under stirring, the mixture was heated up to 100 °C for 1 h to remove 
oxygen and moisture, then Na2Fe(CO)4 (1 mmol) in 10 mL dibenzyl ether mixture 
was added and heated up to 150 °C for 1h. The mixture was further heated up to 
reflux ~300 °C to for 3 h. The dark solution was cooled down to room temperature 
and after washing with hexane and ethanol, the NPs were collected by 
centrifugation. 9 
 
fcc-FePt-A preparation: Ligand exchange experiments were carried out in a glove 
box according to a modified protocol based on the literature.10 For a typical 
experiment, 30 mL hexane was added into 3 mL (13.5 mg/mL) of as-synthesized 
oleic acid/ oleylamine coated fcc-FePt hexane solution. To remove the excess of 
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ligands, the NPs were precipitated by addition of 60 mL ethanol and collected by 
centrifugation. The NPs were redispersed in 15 mL of chloroform assisted with 
sonication. 15 mL of cysteamine in methanol solution (0.5 M) was added dropwise 
to the FePt NPs/CHCl3 mixture under vigorous stirring. The final solution was left 
under stirring for 48 h to complete the ligand exchange. To extract the NPs, they 
were redispersed in 10 mL ethanol and sonicated, 20 mL hexane was added and the 
solution was centrifuged. This process was repeated twice to remove CHCl3, 
methanol and the excess of ligands. The NPs were then redispersed in 10 mL 
ethanol and 20 mL deionized water mixture, sonicated and collected by 
centrifugation. This step was repeated 6 times to obtain positively charged NPs 
stable in deionized water for more than 8 months.  
 
fcc-FePt-silica-A NPs preparation: The fcc-FePt-silica-A NPs were prepared by 
hydrolysis of tetraethylorthosilicate (TEOS) and the silica shell surface was further 
functionalized with (3-aminopropyl) triethoxysilane.11 Reverse microemulsions 
were prepared by mixing under vigorous stirring 10 mL cyclohexane, 1.3 mL NP-5 
and 50 µL DI H2O. 2 mg (~3-4 nmol) of FePt NPs were then dispersed in 1 mL 
cyclohexane and added dropwise into the reverse microemulsion. After 15 min, 80 
µL TEOS was added dropwise. After another 15 min, 150 µL NH4.H2O (28-30%) 
was added dropwise. The solution was kept under constant stirring at 250 rpm for 
72 h. To form amine functionalized FePt-silica NPs, 100 µL of APTES was added 
after 48 h and kept stirring for another 24 h. The NPs were precipitated by 
centrifugation after addition of 3 mL of ethanol and 2 mL of methanol. The NPs 
were redispersed in 5 mL of ethanol and precipitated by centrifugation after 
addition of 10 mL of hexane. This step was repeated up to 6 times to completely 
remove the surfactant. FePt-silica NPs were stable both in ethanol and DI water, 
while FePt-silica-A NPs were stable in deionized water. 
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fct-FePt-A NPs preparation:  16 mL 4 M NaOH water solution contains 1.2 g of 
cysteamine was added into fine milled 170 mg fct FePt-silica NPs. The mixture was 
kept under vigorous stirring for 48 h to dissolve the silica shell as well as to 
functionalize the NP surface with cystamine.  After addition of 10 mL ethanol, the 
NPs were collected by centrifugation. NPs were extracted by centrifugation after 
further washing with 10 mL DI H2O, 20 mL of ethanol. 
 
Appx. III.2. FePt Nanoparticles Characterization 
 
TEM: TEM images were recorded using a Gatan CCD camera on a JEOL 
JEM-2011 electron microscope operating at 200 kV. The chemical composition of 
FePt NPs was examined with energy-dispersive X-ray spectroscopy (EDX) using 
an Oxford Link system installed in the JEM-2011 microscope. 
 
XRD: fct ordering parameter after annealing can be calculated with intensity ratio 
of (110) and (111) peaks, based on the eq. (8),12 
 
{ }
{ }
bulk(111)(110)
obs(111)(110)2
/II
/II
S =             eq. (8) 
 
where S is chemical ordering parameter widely used to characterized the fcc to fct 
phase transition, varies from fcc (S = 0.0) to fct (S = 1.0). I is intensity of XRD 
diffraction peaks, {I(110)/I(111)}obs is the ratio of observed intensity ratio of (110) 
and (111) peaks, which is about 0.12. And {I(110)/I(111)}bulk is about 0.27 obtained 
based on PDF library card 03-065-9121. 
 
SQUID: The NPs were dispersed in polyvinylpyrrolidone (PVP) matrix 
(VPolymer/VNPs = 20) to prevent interaction between the NPs while the resulting 
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sample was loaded into a low background gelatin capsule. Zero-Field Cooled and 
Field Cooled (ZFC/FC) measurements were completed as follow: the sample was 
first cooled from room temperature to 2 K without any external field, next a small 
field 100 Oe was applied and the NPs magnetization was recorded as the 
temperature was increased up 275 K. The FC curve was obtained by cooling the 
sample back to 2 K under a 100 Oe magnetic field. The magnetization was then 
measured while the temperature was increased up to 275 K. Hysteresis 
measurements were completed at temperatures of 2 K and 300 K. The 
magnetization of the gelatine capsules and the PVP matrix was subsequently 
subtracted. 
 
ICP-OES (Perkin Elmer Optima 5300 DV): FePt NPs were dissolved by addition 
of hydrochloric acid (Trace SELECT®, ≥37%) and nitric acid (Trace SELECT®, 
≥ 69.0%) mixed in 3:1 as volume ratio and left overnight at room temperature. 
After full dissolution of the NPs, the solution was further diluted with DI water 
for ICP-OES measurements.  
 
The conversion of the weight concentration of FePt metal core into Fe molar 
concentration was completed according to the following equation:  
 
Fe-w
FeFePt
M
RC
[Fe] =              eq. (9) 
 
where [Fe] (mM) is the molar concentration of iron, CFePt (µg/mL) is the FePt core 
concentration, Mw-Fe the molecular weight of the iron atom and RFe is the mass 
ratio of Fe in FePt metal core. The x in FexPt1-x NPs was found to be ~ 0.43 by 
XRD/ICP-OES, which implies that the mass ratio of Fe in the NP core is ~ 0.18 as 
obtained from the equation below: 
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( ) Ptw-Few-
Few-
Fe Mx1xM
xMR −+=           eq. (10) 
 
A similar approach was used for fcc-FePt-silica-A NPs as described by eq. (11):  
 
Few-
FeA-silicaFePt
M
R'C
[Fe] −=             eq. (11) 
 
where [Fe] (mM) is the molar concentration of iron, CFePt-silica-A is the 
concentration of FePt-silica-A in µg/mL, Fe'R is the mass ratio of Fe in 
FePt-silica-A NPs which is ~ 0.01 according to eq. (12),  
 
FeFe yRR =′               eq. (12) 
 
where y is the mass ratio of FePt in FePt-silica-A NPs, i.e. [FexPt1-x]y[silica-A]1-y, 
which was found to be ~ 0.052 by ICP-OES. According to eq.(11) and (12), the 
weight concentration of FePt-silica-A NPs at 100 µg/mL corresponds then to ~ 
0.02 mM of Fe in molar concentration. 
 
Appx. III.3. Cell culture 
 
Materials: Human breast adenocarcinoma cell line MCF7 (ATCC; Cat# HTB-22), 
human osteosarcoma cell line U2OS (ATCC; Cat# HTB-96) were grown in 
Dulbecco’s Modified Eagle Medium (DMEM; GIBCO, Invitrogen, Paisley, UK). 
Human malignant melanoma cell line A-375M was kindly provided by Dr Daniele 
Bergamaschi (Institute of Cell and Molecular Science, Barts and The London, 
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Queen Mary’s School of Medicine and Dentistry) and was grown in RPMI-1640 
medium (GIBCO, Invitrogen). All media were supplemented with 10% fetal calf 
serum, 2 mM glutamine, 100 IU/mL penicillin, and 100 µg/mL streptomycin. 
Cells were grown under standard cell culture conditions in 5% CO2 at 37 °C to 
reach confluence of 60-70% before subjected to any further treatments. 
 
Cellular labeling/uptake of FePt NPs and TEM: Cell culture media were 
removed and replaced with the media containing FePt-A (30 µg/mL). For control 
experiments, media without FePt NPs was used. After 12-16 h of culture, cells 
were washed and fixed with 4% (w/v) paraformaldehyde/2.5% (v/v) 
glutaraldehyde buffered in 0.2 mol/L PIPES as a standard buffer solution. After 30 
min in fixative the cells were scraped off the flasks in1 mL of fixative, transferred 
to Eppendorf tubes and cetrifuged at 14000 g for 20 min. Pellets were washed in 
0.2M PIPES and post fixed in 1% aqueous osmium tetraoxide for 1 h, washed in 
water, and dehydrated in graded ethanol and propylene oxide before embedding in 
Durcupan resin (Sigma) and polymerisation at 60 °C for 24 h. 70 nm sections 
were cut on a Leica UCT ultramicrotome, mounted on Pioloform coated 100 mesh 
copper grids, stained with uranyl acetate and lead citrate before being examined in 
a Tecnai 12 electron microscope. Images were recorded in Digital Imaging Plates 
and scanned in a Ditabis Micron scanner (Pforzheim, Germany). 
 
Cell viability study by MTS assay: The MTS CellTitre 96 AQueous One 
Solution Cell Proliferation Assay (Promega, Southampton, UK) was used to 
determine cell viability in control and FePt NPs treated cells. This colorimetric 
assay is based on the conversion of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy 
methoxy-phenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) compound to a colored, 
soluble formazan product in metabolically active cells. Cells were seeded at 
densities 1,250-10,000 cells/well in 96-well plates depending on the duration of 
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incubation time and cultured overnight. Cell culture media were then removed and 
replaced with the media containing the FePt NPs at various concentrations with 
the iron content being determined by XRD and ICP-OES. For control experiments, 
media without FePt NPs was used. MTS assay was performed at specific time 
intervals by addition of CellTiter 96® AQueous One Solution reagent to each well, 
in triplicate, and further incubation of cells with the reagent for 3 h at 37 °C in 5% 
CO2. The colour development, i.e. absorbance, was read at 490 nm using a 
plate-reader (E-Max; Molecular Devices, CA, USA) and absorbance values of 
both labelled and control cells were subtracted by that of blank wells. Cell 
viability in labelled cells was expressed as percentage of that from the 
corresponding control cells. 
 
Fe release experiment: 3.6 mg (~ 0.6 mg Fe) of FePt fcc-FePt-A NPs in aqueous 
solution was dispersed in a dialysis tubing (MWCO 1000, Spectrum Laboratories, 
Inc.) which was further immersed into a 30 mL PBS (pH 4.8) or RPMI-1640 (20 
mM sodium citrate, pH 4.8) bath held at a constant temperature of 37 °C.7-8 
Aliquot buffer solution was then sampled at 6, 12, 24, 48, 72, 148 h, and it 
composition was subsequently analyzed with ICP-OES. 
 
Prussian blue staining and light microscopy analysis: To gain insight in 
intracellular iron ions distribution, cells grown on glass coverslips or cytospun on 
glass slides were washed with PBS to remove the excess of ferumoxides and then 
fixed with 4% para-formaldehyde for 30 min. They were then washed with double 
distilled water (ddH2O) and incubated for 30 min with 2.5% potassium 
ferrocyanide in 2.5% HCl to produce Fe(III) ferrocyanide (Prussian blue). 
Samples were then counterstained with nuclear fast red for cell nuclei. Cells were 
examined using a Zeiss microscope Axiovert 200 (Zeiss, Oberkochen, Germany) 
at x20, x40 and x63 magnification and Axiovision 4.6 software (Zeiss). Cells were 
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considered Prussian blue positive if intracytoplasmic blue granules could be 
identified. 
 
Preparation of Agarose Gel Phantoms for MRI of FePt NPs and FePt 
NP-labeled Cells: In the gel MRI study, 1% (w/v) low melting point agarose was 
dissolved in deionized water at 60-70 °C. The desired amount of NPs, i.e. Fe 
concentration as determined by XRD and ICP-OES was then added to the solution 
to obtain the targeted concentrations (up to 0.25 mM) and mixed gently. For 
cellular MRI, FePt labelled melanoma A375M cells were washed three times with 
PBS and harvested, suspended in low melting point agarose gel (1% in PBS at 
densities of 104, 105, 106 cell/mL, respectively. Samples were then transferred into 
200 µL thin wall tubes. In both cases, samples were rapidly cooled on ice to form 
homogenous gel suspensions and kept at 4 °C until further experiments.  
 
Quail Eggs Preparation: Fertilized Japanese quail (Coturnix japonica) eggs were 
obtained from Rosedean, Huntingdon, Cambs. The eggs were then placed 
vertically with air sac uppermost in a humidified incubator with a temperature of 
38 °C, this was referred to as Day 0. On Day 4, the shell above the air sac was 
pierced and cut away to remove the inner shell membrane and expose the embryo. 
The Day 4 embryos typically lay on their sides, the upper eye is visible allowing 
the solution containing the NPs to be injected into it using syringe with thin glass 
capillary needle. The top of the eggs were re-sealed with adhesive tape and then 
imaged. fcc-FePt NPs coated with either cysteamine or silica were added to cell 
culture media at concentrations ranging from 1-100 µg/mL. A control medium 
without NPs was also used. 
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Appx. III.4. Micro-MRI 
 
Micro-MRI data were acquired on a Bruker Avance FT NMR spectrometer with a 
wide bore 7.1 Tesla magnet resonating at 300.15 MHz for 1H, fitted with Bruker 
micro-imaging magnetic field gradients. A birdcage radio frequency resonator 
with an internal diameter of 30 mm was used. MRI pulse sequences were taken 
from the Bruker Paravision® library. All acquisitions were made at 19 ºC. Two 
acquisition sequences were collected and averaged to improve the signal-to-noise 
ratio and reduce artefacts. 
 
Relaxation measurements were determined from 128 x 128 axial planes across the 
samples with field of view of 30 mm, in-plane resolution of 0.234 mm/pixel and 
image slice thickness of 1 mm. In a typical experiment, 9 tubes were studied 
simultaneously, gels with no contrast agent acted as a standard. A recycle time (TR) 
of 12 s was used to avoid saturation. T1 relaxation times were measured using an 
inversion recovery (180º-TI-90º) imaging pulse sequence; 8 different inversion 
times (TI) that ranged from 100 to 15000 ms were applied and the echo time (TE) 
was 4 ms. 
 
T2 relaxation times were measured using a CPMG (Carr Purcell Meiboom Gill) 
spin echo imaging pulse sequence; a train of 16 echoes was acquired and the delay 
(τ) between 180º pulses ranged from 8 to 15 ms depending on the samples. Single 
exponential relaxation times were calculated from experimental data. Each sample 
was studied three times and average Longitudinal and transverse relaxation rate 
calculated. 
 
ri is defined as longitudinal relaxivity (i=1) or transverse relaxivity (i=2), and 
calculated with the following equation: eq.(13) 13 
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ioi
i
11]CA[
TT
r −=             eq. (13) 
where [CA] is the concentration of contrast agent, 1/Ti (i=1 or 2) is the 
longitudinal or transverse relaxation rate with the presence of contrast agent, 1/Tio 
is the relaxation rate of the medium in the absence of contrast agent. 
 
The 128 x 128 x 128 three-dimensional RARE-8 (rapid acquisition with 
relaxation enhancement) experiments were acquired with TR of 250 ms and TE 
between 180º pulses of 25 ms. The field of view was 30 mm and in-plane 
resolution was 0.234 mm/pixel. The scanning time was 34 minutes.  
 
3D representation of the embryo eye and major blood vessels were produced 
using Amira® software (Visage Imaging, Inc. San Diego, CA USA). 
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